

- Coronado, B. E., 853, S3:14
 Cosyns, J.-P., 323
 Coulange, C., 984
 Cowan, P. A., 221
 Coyne, D. W., 1031
 Croker, B. P., 508
 Culleton, B. F., S3:56
 Curhan, G. C., 802

 D'Agati, V. D., 328, 508
 Dagogo-Jack, S., 1031
 Dahlstrom, L. R., 611
 Daimon, S., 309
 Danesh, F. R., 1091
 D'Angelo, A., 657
 Daudon, M., 392
 Davenport, A., 4:E3
 Decaux, G., 692
 Deeter, R. B., 295
 Deira, J., 575
 Deitrick, C. L., 64
 De la Torre, E., 376
 Delmez, J., S2:48
 De Rosa, G., 5:E3
 Detwiler, R. K., 820
 Diez, J. J., 454
 Di Landro, D., 164
 Dimaano, F., 1019
 Disney, A. P. S., 384
 Distler, A., 1063
 Domico, J. R., 278
 Douglas, J. G., S3:66
 Dror, Y., 825
 Dunea, G., 524
 Dunham, L. A., 611
 Dusso, A. S., S2:13
 Dussol, B., 984
 Dworacki, G., 80
 Dworkin, L. D., 1
 Dymock, R. B., 384

 Ebben, J., S4:133
 Ebeling, P. R., 6:E3
 Eberhardt, M. S., 992
 Ebihara, I., 544, 953
 Edelman, C. M., Jr., 176
 Ehrich, J. H. H., 752
 Eiam-Ong, S., 361
 Eknoyan, G., 853, S3:1, 6: FLAG
 El Menyawi, I., 642
 Emerson, S., 629
 Emmett, M., 47
 Endreffy, E., 1068
 Erbeck, K. M., 290
 Evanson, J. A., 731

 Fabbian, F., 164
 Falk, R. J., 179
 Fanceschini, N., 247
 Fein, P., 761
 Feintzeig, I. D., 401

 Feld, S. M., 230
 Fenton, S. S. A., S4:44
 Fernández-Reyes, M. J., 454
 Figueroa, P., 230
 Finch, J., S2:40
 Fine, P. L., 328
 Fink, J. C., 254
 Finkel, K. W., 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
 Finkelstein, F., 623
 First, M. R., 101
 Fishbane, S., 917, 1086, S4:152
 Fisher, R. K., 4:E4
 Flanigan, M. J., 1:E3
 Flechner, S. M., 4:E4
 Fogel, M. A., 401
 Fogo, A., 1:E1, 344, 2:E1, 3:E1, 4:E1, 848, 5:E1, 6:E1
 Foley, R. N., 853, S3:112, S3:184
 Fonck, C., 323
 Fordtran, J. S., 47
 Frankenfield, D. L., 1:E3
 Frederick, P. R., 1:E3, S1:1
 Friedlander, M., 761
 Frye, R. F., 410
 Fujii, S., 309
 Fujishima, M., 482
 Funtanilla, J., 2:E3

 Gaber, A. O., 221
 Gabow, P. A., 976
 Gadallah, M. E., 160
 Gadallah, M. F., 273
 Galacteros, F., 208
 Gambaro, G., 657
 Garred, L. J., 444
 Gaspari, F., 115
 Gault, M. H., 351
 Gavin, J. P., 401
 Geadah, D., 444
 Gehr, T., 761
 Gellens, M. E., S2:61
 Ghiggeri, G. M., 1059
 Gholoum, B., 698
 Gi, H., 426
 Giatras, I., 208
 Gillespie, B., S1:1
 Girot, R., 208
 Gitomer, J. J., 5:E2, 6:E2
 Glassock, R. J., 672
 Glicklich, D., 318
 Gluck, S. L., 1091
 Goldblat, M. V., S2:48
 Goldfarb, D. S., 519
 Goldman, R. S., S4:182
 Golper, T. A., 139, 265, 410
 Gómez-Pan, A., 454
 González, E. A., S2:61
 Gorban-Brennan, N., 623
 Goss, T. F., 770
 Goto, A., 419

 Graham, B. S., 848
 Greer, J. W., S1:1
 Gretch, D., 629
 Grosse-Siestrup, C., 752
 Grünfeld, J.-P., 208, 5:i
 Guillén, E. L., 2:E4
 Guiraudon, C., 698
 Gusmano, R., 1059
 Gutierrez, C., 970

 Hagen, T., 761
 Hakim, R. M., 338, 432, 731, S4:71
 Haley, W. E., 705, 5:E8
 Hamano, Y., 962
 Hamburger, R., 761
 Hamm, L. L., S2:61
 Hanakawa, H., 309
 Harris, A. A., 179
 Hartnett, M., 761
 Hasbargen, J. A., 415
 Hashimoto, M., 725
 Haszon, I., 1068
 Hathaway, D. K., 221
 Hattori, M., 962
 Haug, M., 4:E4
 Hayama, N., 725
 Hayashi, Y., 146
 Haynie, J. D., 1046, 6:E5
 Hefferton, D., 794
 Heishi, M., 464
 Held, P. J., 139, S1:1, S4:9, S4:34
 Henneberry, K. J., 611
 Herman, W. H., 992
 Hibbard, J. U., 661
 Himmelfarb, J., 132, 432, 731
 Hirakata, H., 482
 Hirata, Y., 419
 Hiromura, K., 593
 Hirschberg, R., 230
 Hirth, R., S1:1
 Hobbs, G., 278
 Höffken, B., 752
 Holbrook, D., 132
 Holley, J. L., 494, 567
 Horikoshi, S., 785
 Hörli, W. H., 642
 Hruska, K., 153
 Hsu, F. F., 153
 Hulbert-Shearon, T. E., 139, S1:1, S4:9
 Hull, A. R., S4:6
 Humes, H. D., 6: FLAG
 Hunt, W. A., 401
 Huraib, S., 1036

 Iaccarino, V., 3:E3
 Ibels, L. S., 215
 Iglesias, P., 454
 Igwemezie, B., 376
 Iino, Y., 725
 Ikizler, T. A., 731

- Imberti, B., 115
 Inoue, A., 238
 Iqbal, A., 1036
 Ishida, Y., 238
 Ito, K., 962
 Ito, S., 1:E4
 Iványi, B., 1068
 Iwama, H., 785
 Izumotani, T., 946
- Jaber, K., 984
 Jacobs, A. A., 290
 Jean, G., S4:63
 Jennette, C., 179, 820
 Jevnikar, A., 698
 Jofré, R., 93
 Johnson, R. J., 629
 Jones, B., 5:E4
 Jones, C. A., 32, 139, S1:1, 992
 Jones, C. P., 992
 Jones, M., 761
 Josephson, M. A., 661
 Jouanneau, C., 392
- Kaider, A., 52
 Kalmár, T., 1068
 Kaplan, A. A., 314, 5:E5
 Kasiske, B. L., 853, S3:142
 Kastan, B., 265
 Katholi, C. R., 64
 Katholi, R. E., 64
 Katlama, C., 392
 Kaufman, C., 499
 Kaufman, J. S., S4:147
 Kawaguchi, Y., 2:xlix
 Kaysen, G. A., S4:118
 Kayyas, Y., 160
 Kehn, M., 752
 Keshav, G., S2:48
 Khayat, R., 5:E6
 Kim, D., 426
 Kim, H., 426
 Kim, M., 946
 Kim, R. C., 401
 Kimmel, P. L., 557
 Kimura, K., 419
 King, B. F., 976
 Kirk, K. A., 32
 Kirkland, G. S., 384
 Kittur, D., 43
 Kiyomoto, H., 1000, 6:E6
 Klag, M. J., 853
 Klein, S., 1031
 Kletzmayer, J., 642
 Kliger, A. S., 623, S4:173
 Knight, T., 761
 Knights, S., 731
 Kobayashi, Y., 464
 Koda, Y., 338
 Kodish, E., 934
 Koene, R. A. P., 582
- Koide, H., 544, 953
 Komaba, Y., 725
 Komatsuda, A., 5:E7
 Koni, I., 309
 König, P., 1041
 Konno, Y., 419
 Kopple, J. D., S4:96, S4:97
 Kotzmann, H., 52
 Kovarik, J., 642
 Krämer, R., 752
 Kraus, A., Jr., 761
 Ku, S., 426
 Kubo, M., 482
 Kuhlik, A. B., 646
 Kundu, G. C., 1106
 Kunis, C. L., 328
 Kunitomi, M., 146
 Kurihara, I., 1:E4
 Kurihara, S., 238, 725
 Kurosawa, M., 593
 Kurtzman, N. A., 1080, S4:1
 Kusek, J. W., 992
- Lacour, B., 208, 392
 Lago, N. R., 5:E3
 Lai, M. M., 813
 Lam, K.-K., 1075
 Landt, M., 1031
 Latham, C. E., S4:93
 Lau, A., S2:48
 Laurent, G., S4:63
 Lavelle, O., 984
 Leblanc, M., 444, 1023
 Lechevallier, E., 984
 Lee, E., 426
 Leggat, J. E., Jr., 139
 Leibowitz, J., 1019
 Leonetti, F., 984
 Lerma, J. L., 575
 Leung, C. B., 813
 Leunissen, K. M. L., 125
 Levey, A. S., 853, S3:5, S3:14, S3:120
 Levin, N. W., S4:83
 Levine, D. M., 107
 Lew, N. L., S4:16
 Lewis, J. B., 524
 Lewis, M. J., 470
 Leyboldt, J. K., 295
 Lhotta, K., 1041
 Li, L., 1011
 Li, P. K. L., 813
 Light, P. D., 254
 Limwongse, C., 934
 Lindberg, J. S., S2:48, S2:61
 Lindheimer, M. D., 661
 Lindholm, B., 834
 Livni, N., 825
 Llach, F., 514, S2:1, S2:3, S2:48
 Lo, C. Y., 1011
 Lo, W. K., 1011
 Loos, E., S1:1
- López-Gómez, J. M., 93
 Loute, G., 323
 Lowrie, E. G., S4:16, S4:105
 Luccioni, A., 984
 Luger, A., 52
 Lui, C.-C., 1075
 Lui, S. F., 813
 Lüttgen, F. M., 752
- Ma, J. Z., S4:133
 Ma, K., 426
 McAdams, A. J., 56
 McAdams, J., 589
 McCann, W. P., 64
 McDonald, L., 761
 McLaughlin, K., 698
 McClellan, W. M., 551
 McMonagle, E., 132
 McQuillan, G. M., 992
 Macres, M. G., 470
 Madore, F., 802
 Maeda, K., 258
 Maesaka, J. K., 917
 Mahnensmith, R. L., 302
 Mailloux, L. U., 705, 853, 5:E8, S3:120
 Maker, T., 254
 Makino, H., 146
 Mancini, E., 739, 5:E9
 Mandal, A. K., 1106
 Manns, M., 185
 Manske, C. L., 853, S3:157
 Mansmann, U., 752
 Markowitz, G. S., 328, 508
 Marsick, R., 934
 Marston, W. A., 168, 172
 Martin, K. J., S2:61
 Martín, B., 575
 Martina, G., 115
 Martinez, F., 208
 Martínez-Ara, J., 454
 Martis, L., 761
 Marumo, F., 238
 Marx, M. A., 410
 Masilamani, S., 605
 Massry, S., 32
 Mathew, T. H., 384
 Matsell, D. G., 535
 Matsumoto, Y., 258
 Matsunobu, S., 725
 Matzke, G. R., 410
 Maurice-Estépa, L., 392
 Mayer, G., 52
 M'Bappé, P., 5:E6
 Mees, E. J. D., 664
 Meisels, I. S., 646
 Menè, P., 778
 Merabet, E., 1031
 Messiaen, T., 5:E6
 Meyer, K. B., 853
 Meyer-Stout, P. J., 808

- Michelson, A. D., 132
 Miguel, J. L., 454
 Milord, R., 1098
 Milstead, E. J., 221
 Minetti, L., 115
 Minutolo, R., 3:E3
 Miralles, M., 842
 Mise, N., 419
 Misra, M., 334
 Mitch, W., 551
 Miura, A. B., 5:E7
 Miwa, M., 258
 Miwa, T., 258
 Miyashita, K., 419
 Miyatake, N., 146
 Mizuno, Y., 309
 Modlin, C. S., 4:E4
 Molony, D. A., 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
 Monaghan, J., 567
 Moran, J., 761, S4:52
 Moreno, F., 93
 Morgan, S. L., 475
 Morita, H., 258
 Morita, K., 5:E7
 Morris, J. G., Jr., 254
 Mougenot, B., 5:E6
 Muirhead, N., 698
 Mukai, K., 309
 Mukherjee, A. B., 1106
 Murer, L., 1059
 Murphy, B. F., 384
 Murphy, S. W., 794, S3:184
 Myer, K. B., S3:14

 Nadal, M. A., 5:E3
 Nagaba, Y., 464
 Nagata, M., 962
 Nakai, S., 258
 Nakamoto, M., 482
 Nakamura, T., 544, 953
 Nakamura, Y., 258
 Nakhleh, R. E., 5:E4
 Nardellotto, A., 657
 Naruse, T., 593
 Nast, C. C., 230
 Näther, S., 752
 Nelson, S., 132
 Nerenstone, S., 5:E5
 Neylan, J. F., 770
 Niemir, Z. I., 80
 Nissenson, A. R., S4:131, S4:142
 Nolin, L., 444
 Nolph, K. D., 334
 Noris, M., 115
 Nussbaum, P. B., 401

 Oba, S., 419
 O'Dea, D. F., 794
 Offermann, G., 1063
 Offner, G., 752

 Oh, H. K., 5:E4
 Ohashi, Y., 238
 Ohtani, H., 5:E7
 Ohwada, K., 725
 Ojo, A. O., S1:1
 Oliver, J. A., 970
 Olivieri, L. E., 5:E3
 Omata, M., 419
 Ondracek, M., 80
 Onoda, N., 725
 Orzol, S. M., 139, S1:1, S4:34
 Osono, E., 725
 Osten, B., 752
 O'Sullivan, D. A., 976
 Ota, K., 146
 Otschi, T., 946
 Otsuki, N., 309
 Otto, H. E., 80
 Ouimet, D., 444
 Ouseph, R., 290
 Owada, A., 238
 Owen, W. F. Jr., S4:39
 Özerkan, F., 664

 Packham, D., 6:E3
 Paganini, E. P., 832, 1023
 Palanichamy, V., 5:E4
 Palmisano, J., 314, 5:E5
 Parker, T. F. III, S4:2, S4:5, S4:190
 Paolini, F., 739, 5:E9
 Parekh, R., S1:1
 Parfrey, P. S., 794, 853, S3:112, S3:184
 Park, I.-S., 1000, 6:E6
 Parker, R. A., 432
 Parker, T. S., 107
 Patrassi, G., 657
 Pattabiraman, N., 1106
 Patterson, P., 635
 Paulson, W. D., 273
 Pecci, G., 778
 Peddi, V. R., 101
 Perazella, M. A., 302
 Pereira, B. J. G., S4:2, S4:190
 Petermann, A., 1063
 Peterson, R. A., 557
 Petri, I. B., 1068
 Pfeffer, M. A., 853, S3:101
 Pichette, V., 444
 Pierratos, A., S4:76
 Pierri, T., 5:E3
 Pintar, T. J., 503
 Piraino, B., 761
 Pirson, Y., 323
 Pittarello, F., 657
 Pliskin, N. H., 749
 Polish, L., 254
 Pommer, W., 752
 Popovtzer, M., 600
 Port, F. K., 139, S1:1, S4:9, S4:34, S4:88

 Powell, T., 153
 Pressley, T. A., 1084
 Pricci, F., 778
 Propst, A., 1041
 Propst, T., 1041
 Prospert, F., 692
 Provenzano, R., 5:E4
 Prowant, B. F., 1:E3
 Pugliese, F., 778
 Pugliese, G., 778

 Qasawa, B., S2:55
 Quadri, K., 1036
 Quilici, N., 6:E4

 Raabe, R. D., 611
 Racusen, L. C., 43
 Rahman, M., S3:66
 Rajaraman, S., 2:E3
 Rao, P., 72
 Ratnaike, S., 6:E3
 Remmers, A., Jr., 2:E3
 Remuzzi, G., 115
 Renne, H. G., 1098
 Rice, S. I., 265
 Richart, C., 970
 Rida, C., 970
 Riedl, M., 52
 Ritter, C., S2:40
 Ritz, E., 80
 Roccatello, D., 115
 Rocco, M. V., 1:E3
 Rodicio, J. L., 1:xlili
 Roghmann, M.-C., 254
 Romeh, S. A., 1036
 Ronco, P., 5:E6
 Rosenkranz, A. R., 642
 Rosenmann, E., 825
 Ross, D., 761
 Rosser, J., 5:E6
 Rubin, A. L., 107
 Ruiz, A. M., 2:E4
 Russo, D., 3:E3

 Sadler, R., S2:48
 Saffarian, N., 5:E4
 Saga, T., 309
 St Peter, W. L., 470
 Saithoh, K., 962
 Saito, J., 1:E4
 Saito, T., 1:E4
 Sakai, K., 1023
 Sakurai, Y., 725
 Sakurauchi, Y., 258
 Salive, M., 992
 Sallee, C. W., 265
 Salvadori, R., 6:E4
 Sandroni, S., 761
 Sankarasubbaiyan, S., 494
 Santoro, A., 739, 5:E9
 Sanz-Guajardo, D., 93

- Sarnak, M. J., S3:112
 Sato, H., 1:E4
 Sato, M., 258
 Savin, V., 230
 Savino, F. A., 3:E3
 Sazdovitch, V., 392
 Schaefer, F., 752
 Schillinger-Pokorny, E., 752
 Schmaldienst, S., 52
 Schmidt, R. J., 278
 Schmitt, F., 208
 Schreiber, M., 761
 Schribner, B. H., 720
 Schulman, G., 731, S4:32, S4:86
 Schumann, E., 752
 Scott, G., 494
 Sebastian, C., 499
 Sehgal, A. R., 284
 Selgas, R., 454
 Serur, D., 107
 Sharma, A. M., 1063
 Sharma, M., 230
 Sharma, R., 230
 Sheikh-Hamad, D., 692
 Sheil, A. G. R., 215
 Shidler, N. R., 557
 Shimada, N., 544, 953
 Shin, G., 426
 Shin, S., 426
 Shinoda, T., 238
 Shinzato, T., 258
 Shirato, I., 785
 Shoji, H., 953
 Short, R. A., 611
 Shustlin, L., 600
 Shyr, Y., 731
 Sigler, M. H., 185
 Singh, H., 820
 Sitprija, V., 361
 Sivaram, C. A., 499
 Slakey, D., 43
 Slatopolsky, E., S2:1, S2:40, S2:48
 Sloan, R. S., 265
 Smith, B., 265
 Snyder, J. W., 415
 So, E., 1011
 Soltanek, C., S2:55
 Soma, J., 1:E4
 Sorino, P., 1059
 Sorkin, M. I., 278
 Soupart, A., 692
 Speizer, F. E., 802
 Spital, A., 676
 Stack, A., S1:1
 Stamatakis, M. K., 808
 Stampfer, M. J., 802
 Stehman-Breen, C. O., 629
 Stein, H., 80
 Steinhauer, H. B., 752
 Steinwald, B., 770
 Stemmer, C. L., 508
 Stenzel, K. H., 107
 Stillman, I. E., 646
 Stock, K. J., 848
 Stokes, M. B., 649
 Stoll, R., S2:55
 Strawderman, R. L., S1:1
 Sullivan, E. M., 770
 Suzuki, N., 419
 Swartz, R., 761
 Szenohradszky, P., 1068
 Szeto, C. C., 813
 Taberner, J. M., 575
 Takahashi, F., S2:40
 Takai, I., 258
 Takeda, K., 482
 Takeuchi, M., 725
 Tamura, T., 475
 Tang, S., 1011
 Tanimu, D., 1036
 Tarshish, P., 176
 Tayeb, J. S., 5:E4
 Taylor, G. J., 64
 Taylor, L., 1:E3
 Tazawa, H., 464
 Tedeschi, P. J., S1:1
 Teehan, B. P., 185
 Terrat, J.-C., S4:63
 Thalhammer, F., 642
 Thibodeau, S. N., 976
 Thirion, X., 984
 Tisher, C.C., S4:1
 To, K. T., 813
 Tobin, J. N., 176
 Todeschini, M., 115
 Tojo, A., 419
 Tokars, J. I., 521
 Tolkoff-Rubin, N., 432
 Tomino, Y., 785
 Tomizawa, T., 725
 Torres, V. E., 976
 Toto, R. D., 32
 Töz, H., 664
 Traunmüller, F., 642
 Troidle, L., 623
 Trompeter, R. S., 176
 Tsang, K., 813
 Tsukamoto, Y., 464
 Türi, S., 1068
 Turk, J., 153
 Tuttle, K. R., 611, 842
 Twardowski, Z. J., 1046, 6:E5
 Umans, J. G., 749
 Ünsal, A., 664
 Uribarri, J., 1019
 Vacher-Copomat, H., 984
 Valderrábano, F., 93
 Van der Sande, F. M., 125
 Van Kuijk, W. H. M., 125
 Van Lente, F., 32
 Van Stone, J. C., 1046, 6:E5
 Van Ypersele de Strihou, C., 3:1
 Vanel, T., S4:63
 Varela, M. P., 1121
 Veal, A. M., 970
 Verran, D. J., 215
 Vickers, B., 273
 Vogel, W., 1041
 Vonesh, E., 761
 Vyhytil, A., 52
 Wada, J., 146
 Wakeen, M., 488
 Wald, H., 600
 Waldhäusl, W., 52
 Waldherr, R., 80
 Walser, M., 23
 Ward, R. A., 265
 Watanabe, T., 962
 Weaver, M., 761
 Webb, R. L., S1:1
 Webber, J. T., 611
 Weir, M. R., 1
 Weiskittel, P. D., 101
 Welch, T. R., 589
 Wende, R., 752
 Wenger, N. K., 853, S3:80
 West, C. D., 56
 Westphale, H.-J., 752
 Wetzels, J. F. M., 582
 Wheeler, J. R., S1:1
 Whelton, P. K., 32
 White, W. L., 376
 Whiting, J., 101
 Wicks, M. N., 221
 Willett, W. C., 802
 Wilson, P. W. F., 853, S3:56, S3:89
 Wingard, R. L., 432, 731
 Winsett, R. P., 221
 Wish, J. B., S4:161, S4:165, S4:177
 Wolfe, R. A., S1:1, S4:9, S4:34, S4:88
 Wolfson, M., S4:126
 Womack, K. A., 64
 Wong, T. Y. H., 813
 Woods, W. T., Jr., 64
 Work, J., 273
 Wright, E. J., 1023
 Wright, J. T., Jr., 853, S3:66
 Xia, A., S4:133
 Xu, Y.-C., 1000, 6:E6
 Yagi, N., 1023
 Yamaguchi, A., 5:E7
 Yamamoto, T., 946
 Yano, S., 593
 Yasuhara, S., 309
 Yee, J., 669
 Yim, H., 426
 Yoneshima, H., 725

Young, E. W., S1:1, S4:157
 Yu, S., 813
 Yu, Z., 328
 Yuan, C.-J., 1106
 Yuen, J. Y., S4:118

Yudd, M., S2:3
 Yuen, M. C., 1011
 Yuenger, N. J., 265
 Zhang, X.-Z., 605

Zhang, Z., 1106
 Zhu, X., S4:16
 Zimmering, M., 752
 Zimmerman, S. W., 488, 503, 761
 Zucchelli, P., 739, 5:E9

SUBJECT INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number. Page references to Supplement 1 (August 1998), Supplement 2 (October 1998), Supplement 3 (November 1998), and Supplement 4 (December 1998) are preceded, respectively, by S1:, S2:, S3:, and S4:.

AA (amino acid) solution, 1.1%, for malnourished ESRD patients on PD, 761-769

Abbreviations

1998 USRDS ADR, S1:7-8
 NKF Task Force report, 904-905

ABO blood group, and renal transplantation for ESRD, S1:93

Abstracts citing USRDS data, S1:28

AC (acetaminophen), *see* Analgesic(s)

Acceptance into ESRD therapy, USRDS 1998 ADR on, S1:149-151

Access to renal transplantation, USRDS 1998 ADR on, S1:91-93

of pediatric patients, S1:104-105

race and, S1:16, S1:92-93, S1:105

Accreditation, role in quality activities in ESRD, S4:177-181

ACE (angiotensin-converting enzyme) gene, I/D polymorphism in intron 16 of, in LVH with ESRD, 725-730

ACE inhibitors, *see* Antihypertensive drugs

Acetaminophen, *see* Analgesic(s)

Acetate dialysate (AD)

effects of, on NO synthesis, dialysis hypotension and, 115-124

trends in HD treatment and survival, S4:34-38

Acetate-free biofiltration (AFB), effects of, on NO synthesis, dialysis hypotension and, 115-124

Acetylsalicylic acid (aspirin), *see* Analgesic(s); Antiplatelet therapy of CAD, NKF Task Force report on

Acidosis, hyperkalemic distal renal tubular, H⁺-ATPase in 1091-1097

Acquired immunodeficiency syndrome, *see* AIDS

ACTH (adrenocorticotropin; cortisol) test in ESRD patients on CAPD and/or HD, 52-55

Actin, α -smooth muscle, in periglomerular myofibroblasts, GN progression and, 419-425

Activated protein C (PC) clotting inhibitor, Budd-Chiari syndrome during NS relapse and resistance to, 657-660

Acute Epstein-Barr virus (EBV) infection associated with SLE, 825-828

Acute graft rejection

in long-term renal transplant survivors, 103-104
 posttransplantation ATN and, 984-991

Acute-phase responses

to inflammatory stimuli, hypoalbuminemia and hypocholesterolemia as negative, in ESRD patients on HD, 107-114

in *P falciparum* malaria, 367

Acute Physiology and Chronic Health Evaluation II (APACHE II) score in prognosis of ARF requiring HD, 432-443

Acute renal failure (ARF)

with AIDS, histoplasmosis-induced granulomatous IN and, 2:E3

carboplatin-related hematuria and, 5:E5

P falciparum malaria and, *see: Plasmodium falciparum* malaria

see also Acute renal failure, CRRTs for; Acute renal failure, HD for

Acute renal failure (ARF), CRRTs for

advantages of, 187-192

characteristics of, 186-187

drug dosage during, 193

hemodynamic stability and slow continuous ultrafiltration on, 188-189

heparin-induced thrombocytopenia during, management of, 4:E3

membranes used in, 194-196

metabolic control and Kt/V during, 187

new technology and techniques for, 197-198

ongoing anticoagulation with, 193-194

for poisoning, 192-193

protein catabolism and, 444-453

replacement fluid and dialysate in, 196-197

who should perform, 198

Acute renal failure (ARF), HD for

APACHE II score in prognosis of, 432-443

- in OHT recipients, CVVH and/or HD for, 290-294
- prescribed v delivered HD dose for, 731-738, 832-833
- Acute thrombosis, inferior vena cava and unilateral renal vein, rTPA for, 1075-1079
- Acute tubular necrosis (ATN)
 - ARF and, 735
 - down-regulated CHIF mRNA in, 600-604
 - posttransplantation, graft survival and, 984-991
- AD (acetate dialysate)
 - effects of, on NO synthesis, dialysis hypotension and, 115-124
 - trends in HD treatment and survival, S4:34-38
- Address of USRDS site on Internet World Wide Web, S1:25
- Adenoma, adrenal, reversible renin-aldosterone axis suppression after unilateral adrenalectomy for, 160-163
- Adenosine, contrast nephropathy and production of, 64-71
- Adenosine triphosphatase (ATPase), H^{+} -, in hyperkalemic DRTA, 1091-1097
- Adequacy of dialysis dose
 - changes in PD prescription in last decade, S4:44-51
 - delivered dose and membrane transport in PD, S4:58-62
 - effect of changes in PD on outcomes, S4:52-57
 - obstacles to achieving, S4:93-95
 - status of HD in US and improved survival, S4:39-43
- ADH (antidiuretic hormone), renal clearance of uric acid and, 692-697
- Adjusted death rates of ESRD patients, USRDS 1998 ADR on, S1:75-76, S1:153-154
- Adjustment
 - standard population for, in USRDS 1998 ADR, S1:11, S1:144
 - see also* Adjustment, rate, in USRDS 1998 ADR
- Adjustment (standardization), rate, in USRDS 1998 ADR, S1:151-153
 - adjusted death rates of ESRD patients, S1:75-76, S1:153-154
- Administration of CRRTs, arguments on, 198
- Admissions, *see* Hospitalization for ESRD, USRDS 1998 ADR on
- ADPKD, *see* Autosomal dominant polycystic kidney disease
- Adrenal adenoma, reversible renin-aldosterone axis suppression after unilateral adrenalectomy for, 160-163
- Adrenal function in ESRD patients on CAPD and/or HD, 52-55
- Adrenalectomy, unilateral, for adrenal adenoma, reversible renin-aldosterone axis suppression after, 160-163
- α - and β -Adrenergic blockers, *see* Antihypertensive drugs
- Adrenocorticotropin (ACTH; cortisol) test in ESRD patients on CAPD and/or HD, 52-55
- Advantages of CRRTs, 187-192
- Adverse effects
 - of antihypertensive drugs, S3:125
 - of falecalcitriol and alfacalcidol, 243
 - of glycemic control in diabetic CRD patients, S3:160
 - of nicotine on kidney, S3:173
 - of paricalcitol therapy, S2:52
 - of rhGH therapy, 459
 - see also* Nephrotoxicity
- AF (autonomic function) in patients awaiting renal transplantation, 221-229
- AFB (acetate-free biofiltration), effects of, on NO synthesis, dialysis hypotension and, 115-124
- African Americans, *see* Race
- AFS (annual facility survey), *see* Facilities for ESRD care, USRDS 1998 ADR on
- Age
 - of ADPKD patients, 971, 978
 - of ARF patients, 733, 735
 - of atherosclerotic ostial RAS patients, 613
 - of combined MN-IgAN patients, 650, 654
 - of coronary angiography patients, 66
 - of critically ill patients on CRRT, 1025, 1026
 - CVD and, in CRD, mortality and, 870, S3:7
 - of endotoxemic patients, 955
 - of ESRD patients, *see* Age of ESRD patients, USRDS 1998 ADR on; Age of ESRD patients on CAPD, HD, and/or PD
 - and exclusion from renal transplantation, 568, 570; *see also* Age of RTRs
 - of FSGS patients, 73, 232
 - of GN patients, 420, 594, 963
 - HTN management in older hypertensive patients in general population, S3:73-74
 - LVM and diastolic function in normotensive ADPKD young adults, 970-975
 - of nephrolithiasis patients, 804
 - NHANES III of serum creatinine levels by, 992-999
 - of NIDDM patients, plasma matrix MMP-9 levels and microalbuminuria and, 545
 - of OHT recipients, 291
 - race and, *see* Age, race and
 - of renal biopsy patients, 427, 429
 - as risk factor for CVD, S3:7
 - of SCA patients, 210
 - see also* Pediatric patients
- Age, race and
 - of HTN patients, 35
 - kidney donor's, impact of, on glomerular size, 43-46
- Age of ESRD patients, USRDS 1998 ADR on, S1:12
 - expected remaining years of life by, S1:79
 - first-year death rates and, S1:72
 - incidence and prevalence of treated ESRD by, S1:40, S1:42-43, S1:101
 - Medicare expenditures by, S1:127, S1:128
 - medication use by, S1:62
 - patient survival by, S1:54
 - use of RRT modalities by, S1:56-58
 - withdrawal of dialysis and, S1:86-87
- Age of ESRD patients on CAPD, HD, and/or PD
 - adrenal function and, 53
 - alfacalcidol effects on lymphocyte phenotyping and, 1037
 - anemia treatment algorithm and, 637
 - and antibody response to HBV vaccination, 1043
 - AVG thrombosis and, 305, 477
 - awaiting renal transplantation, 223
 - calciphylaxis and, 378
 - and L-carnitine supplementation effects on quality of life, 270
 - and catheter-related infections on PD, 755, 757, 758
 - cefazolin therapy and, 411
 - colonization with VRE and, 255, 256

- ER and, 279
 exercise training effects and, 1012
 with HIV infection, 630, 632
 and long-term CAPD effects on cardiac function, 483, 486
 with LVH, 726
 of malnourished patients on rhGH therapy, 455
 noncompliance and, 140, 141
 with peritonitis, 624
 PS, SEP and, 947
 quality of care ratings and, 286, 287
 with rHuEPO therapy, 472, 489
 with secondary HPT, *see* Age of ESRD patients on CAPD, HD, and/or PD with secondary HPT
 survival and, 110, 111
- Age of ESRD patients on CAPD, HD, and/or PD with secondary HPT
 on falcacitriol and alfacalcidol therapy, 240, 241
 on paricalcitol therapy, S2:50, S2:58
 VDR gene polymorphism and, 466, 467
- Age of RTRs
 and ATN-induced DGF, 986, 987
 and changes in quality of life, 96
 long-term survival and, 102, 103
 posttransplantation coagulation and fibrinolysis and, 576
 posttransplantation hospitalization with CsA and FK506 and, 772
 recurrent type I MPGN and, 583, 584
- Ageing kidney, pressure natriuresis in, renal nerves in, 605-610
- AIDS (acquired immunodeficiency syndrome)
 ARF with, histoplasmosis-induced granulomatous IN and, 2:E3
 nephrotoxicity of foscarnet therapy for CMV retinitis with AIDS, glomerular crystals due to, 392-400, 519-520
 as primary disease, colonization by VRE and, 255, 256
 urate excretion with, 922
- Albumin
 permeability of glomerular capillary, in steroid-resistant FSGS, 230-237
see also Albumin in ESRD patients on CAPD, HD, and/or PD; Hypoalbuminemia; Microalbuminuria in DM; Proteinuria
- Albumin in ESRD patients on CAPD, HD, and/or PD
 AVG thrombosis and stenosis and, 305
 L-carnitine supplementation effects on, during and between HD, 265-272
 exercise effects on, 1014
 factors influencing, S4:118-119
see also Albumin in malnourished ESRD patients on CAPD, HD, and/or PD; Serum albumin in ESRD patients on CAPD, HD, and/or PD
- Albumin in malnourished ESRD patients on CAPD, HD, and/or PD
 1.1% amino acid PD solution effects on, 765, 766
 rhGH therapy and, 455, 458
- Aldosterone
 serum, in hyperkalemia of ATN, 601
see also Renin-aldosterone axis; Renin-angiotensin-aldosterone axis
- Alfacalcidol [$1\alpha(\text{OH})\text{D}_3$] in ESRD patients on HD
 effects of IV, on lymphocyte phenotyping, 1036-1040
 falcacitriol versus, for PTH suppression in patients with secondary HPT, 238-246
- Alkaline phosphatase (ALP), serum, in ESRD patients with secondary HPT, 466, 467, S2:9, S2:63-65
- Allopurinol before coronary and left ventricular angiography, effects of, on free radical formation, 64-71
- ALP (alkaline phosphatase), serum, in ESRD patients with secondary HPT, 466, 467, S2:9, S2:63-65
- Alpha-adrenergic blockers, *see* Antihypertensive drugs
- Alpha (α_2)-antiplasmin ($\alpha_2\text{APL}$), posttransplantation coagulation and fibrinolysis and, 577-578
- Alpha (α)-smooth muscle actin ($\alpha\text{-SMA}$) in periglomerular myofibroblasts, GN progression and, 419-425
- Alpha (α) tocopherol (vitamin E), cardioprotective effects of, S3:59
- Alport's syndrome, as primary disease in familial ESRD, 796
- Alternative care, Medicare expenditures for, USRDS 1998 ADR on, S1:125-128
- Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis for ESRD
- Amino acid (AA) peritoneal dialysis (PD) solution, 1.1%, for malnourished ESRD patients, 761-769
- Amputations of diabetic ESRD patients on PD, rHuEPO, peripheral vascular disease and, 488-493
- Amyloidosis
 due to prednisone- and methotrexate-treated RA, remission of NS and, 5:E7
 polyclonal IgG deposition disease and, 328-333
- AN, *see* Analgesic nephropathy
- Analgesic(s)
 DMMS on use of, S1:66
see also Analgesic nephropathy
- Analgesic nephropathy (AN), 351-360
 diagnosis of, 356-357
 epidemiology and prevalence of, 352-353
 mechanisms of, 357
 nephrotoxicity of specific analgesics and, 353-356
- Analytical methods used in USRDS 1998 ADR, S1:19, S1:142-162
 and acceptance into ESRD therapy, S1:149-151
 adjustment rates in, *see* Adjustment, rate, in USRDS 1998 ADR
 on cost of ESRD care, S1:160-162
 to determine causes of mortality, S1:81-82, S1:143, S1:155-157
 on expected remaining years of life, S1:159
 geography and, S1:149
 on graft survival, S1:159-160
 on incidence and prevalence, S1:149-151, S1:155
 lost to follow-up methodology in, S1:148-149
 new data in, S1:142-144; *see also* Data, USRDS 1998 ADR
 on patient survival, S1:158-159
 reasons for changes in reported numbers and, S1:147-148
 on RRT modalities, S1:160
- ANCAs, *see* Anti-neutrophil cytoplasmic antibodies
- Anemia
 sickle cell, glomerular permselectivity in, 208-214

- see also Anemia of ESRD patients on HD and/or PD, treatment of; Anemia of LVH, NKF Task Force report on; Anemia of pre-ESRD and ESRD patients
- Anemia of ESRD patients on HD and/or PD, treatment of treatment algorithm for, 635-641
- see also Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
- Anemia of LVH, NKF Task Force report on correction of, 856, 895-896, S3:12, S3:190-191 research recommendations on, 903-904
- Anemia of pre-ESRD and ESRD patients acute-phase inflammatory process contributing to, S4:105-112
- dialysis dose, membrane type, and control of, S4:157-160
- iron treatment safety issues, S4:152-156
- optimal hematocrit in dialysis therapy, S4:142-146
- strategies for influencing outcomes in (special conference), S4:131-160
- subcutaneous erythropoietin therapy, S4:147-151
- trends in treatment of, S4:133-141
- Angina pectoris, DM-associated, in general population, S3:91
- Angiography
- left ventricular, effects of allopurinol before, on free radical formation, 64-71
- see also Coronary angiography
- Angioplasty (percutaneous transluminal coronary angioplasty), see Coronary artery revascularization
- Angiotensin-converting enzyme (ACE) gene, I/D polymorphism in intron 16 of, in LVH with ESRD, 725-730
- Angiotensin-converting enzyme inhibitors, see Antihypertensive drugs
- Annual Data Report of USRDS, see United States Renal Data System, 1993 ADR of; United States Renal Data System, 1997 ADR of; United States Renal Data System, 1998 ADR of
- Annual death rate with renal transplantation, S1:157-158
- Annual Facility Survey, see Facilities for ESRD care, USRDS 1998 ADR on
- Antibiotics, see specific antibiotics and specific conditions
- Antibodies
- circulating, to 58-kD TIN antigen, childhood MN with anti-tubular basement membrane nephritis and, 1068-1074
- response of, to ID, IM and SC HBV vaccination in ESRD patients on HD, compared, 1041-1045
- see also Anti-neutrophil cytoplasmic antibodies
- Anticoagulation
- need for ongoing, with CRRTs, 193-194
- see also Antiplatelet therapy of CAD, NKF Task Force report on
- Antidiuretic hormone (ADH; vasopressin), renal clearance of uric acid and, 692-697
- Antigens
- 58-kD TIN, childhood MN with anti-tubular basement membrane nephritis and circulating antibodies to, 1068-1074
- P. falciparum*, in *P. falciparum* malaria, 364-365
- Anti-glomerular basement membrane (GBM) disease
- ANCAs and, in MN, 646-648
- see also Anti-glomerular basement membrane glomerulonephritis
- Anti-glomerular basement membrane (GBM) glomerulonephritis (GN), 3:E1
- recurrent fulminant, in RTRs, 323-327
- Antihypertensive drugs, 711-712
- DMMS on use of, 1:63-64
- see also Antihypertensive drugs, renal protective actions of; Antihypertensive drugs in CRD, NKF Task Force report on; Antihypertensive drugs in general population, NKF Task Force report on
- Antihypertensive drugs, renal protective actions of, 1-22
- BP-dependent and -independent effects of drugs and, 16-18
- in diabetic nephropathy, 11-13
- dietary salt restriction and, 7, 13-16
- in essential HTN, 7-9
- experimental studies of, 2-6
- in nondiabetic chronic renal disease, 9-11
- Antihypertensive drugs in CRD, NKF Task Force report on, S3:12
- for CRI, 875-876, S3:123-125
- in ESRD patients on HD, S3:129-131
- in ESRD patients on PD, S3:132
- introduction to, 895-896
- for LVH, 895-896, S3:190-191
- research recommendations on, 904
- Antihypertensive drugs in general population, NKF Task Force report on, S3:67-68, S3:71-72
- with CAD, S3:104, S3:105
- Anti-myeloperoxidase (MPO) antibodies-anti-neutrophil cytoplasmic antibodies (ANCA) necrotizing glomerulonephritis (GN), rheumatoid arthritis and, 5:E6
- Anti-neutrophil cytoplasmic antibodies (ANCAs)
- anti-glomerular basement membrane disease and, in MN, 646-648
- anti-MPO-ANCA necrotizing GN, rheumatoid arthritis and, 5:E6
- test of, in pauci-immune vasculitides, 344-349
- α (α)₂-Antiplasmin (α ₂APL), posttransplantation coagulation and fibrinolysis and, 577-578
- Antiplatelet therapy of CAD, NKF Task Force report on
- in CRD patients, 892-893, S3:184-185
- in general population, S3:103-104
- Antithrombin III (AT-III)
- in hypercoagulable state of NS, 658
- posttransplantation coagulation and fibrinolysis and, 577
- Antithrombotics, DMMS on use of, S1:66
- Anti-tubular basement membrane nephritis, childhood MN with circulating antibodies to 58-kD TIN antigens and, 1068-1074
- Aortic valve involvement in calciphylaxis, 499-502
- APACHE II (Acute Physiology and Chronic Health Evaluation II) score in prognosis of ARF requiring HD, 432-443
- α ₂APL (α ₂-antiplasmin), posttransplantation coagulation and fibrinolysis and, 577-578
- ARF, see Acute renal failure
- Arterial pressure, see Blood pressure
- Arteriography, coronary, contrast nephropathy and, S3:187
- Arteriolohyalinosis, CsA-induced, effects of CsA withdrawal on, 247-253

- Arteriopathy
 calcific uremic, *see* Calciphylaxis, ESRD and
 CsA-induced, effects of CsA withdrawal on, 247-253
- Arteriovenous grafts (AVGs), HD, stenosis of
 of chronic HD grafts, Doppler ultrasound or fistulography
 in diagnosis of, compared, 273-277
 reduction of, with venous pressure-driven protocol, 302-308
- Arthritis, *see* Immunosuppression in RA
- ASA (acetylsalicylic acid; aspirin), *see* Analgesic(s); Antiplatelet therapy of CAD, NKF Report on
- Ascitic fluid, reinfusion and concentration of, in cirrhotic ESRD patient on HD, 164-167
- Aspirin, *see* Analgesic nephropathy; Antiplatelet therapy of CAD, NKF Task Force report on
- AT-III, *see* Antithrombin III
- Atherosclerosis
 in diabetic CRD patients, S3:157-160
see also Atherosclerotic cardiovascular disease; Atherosclerotic ostial renal artery stenosis
- Atherosclerotic cardiovascular disease (CVD) in ESRD, cytokines predisposing to hypoalbuminemia, malnutrition and, 836-838
- Atherosclerotic ostial renal artery stenosis (RAS), intravascular stent for, 611-622
- Atlas of renal pathology, 1:E1, 2:E1, 3:E1, 4:E1, 5:E1, 6:E1
- ATN, *see* Acute tubular necrosis
- ATPase (adenosine triphosphatase), H⁺, in hyperkalemic DRTA, 1091-1097
- Atrial fibrillation, DM-associated, S3:93
- Attention, mental processing speed and, of ESRD patients on HD, 749-751
- Autologous lymphocyte-activated killer (LAK) cells, therapy of high-grade PTLD with, 813-819
- Automated percutaneous renal biopsy, 426-431
- Automated peritoneal dialysis (PD), changes in prescription of in last decade, S4:44-51
- Autonomic function (AF) in patients awaiting renal transplantation, 221-229
- Autonomy, respect for, as ethical principle, 679-680
- Autosomal dominant polycystic kidney disease (ADPKD)
 CF and phenotypic expression of, 976-983, 1081-1083
 LVM and diastolic function in normotensive young adults with, 970-975
 as primary disease in ESRD, 1012
 progression to renal failure in, 5:i-iii
see also Autosomal dominant polycystic kidney disease, genetic testing for
- Autosomal dominant polycystic kidney disease (ADPKD), genetic testing for, 938-942
 known genetic defect in, 938
 and living related organ donation, 941-942
 positive testing for, 940
- Autosomal recessive nephronophthisis (NPH) with homozygous deletion of NPH1 gene locus, retinal dystrophy with, 1059-1062, 1084-1085
- Autotransplantation, renal, or radical renal neurectomy for LPHS, 215-220
- AVGs, *see* Arteriovenous grafts, HD, stenosis of; Thrombosis of HD AVGs
- Bardet-Biedl syndrome, as primary disease in familial ESRD, 796
- Bence-Jones cast nephropathy (BJCN), plasma cell dyscrasias and, 529-532
- Beneficence principle, 681
- Berger's disease, *see* IgA nephropathy
- Beta-adrenergic blockers, *see* Antihypertensive drugs
- Beta₂-microglobulin (β_2 -m), clearance of, with reused HD dialyzers, 298
- Bibliography used in NKF Task Force report, S3:26-55
- Bicarbonate (HCO₃) dialysate, effects of, on NO synthesis, dialysis hypotension and, 328-333
- Bilateral fibromuscular dysplasia (FMD) in identical twins, 6:E4
- Bilirubin
 paricalcitol effects on, S2:52, S2:53
 and posttransplantation coagulation and fibrinolysis, 576
- Bioartificial hemofilter, 6: FLAG:
- Bioartificial renal tubule, 6: FLAG:
- Biocompatible dialysis membranes, *see* High-flux hemodialysis membranes, effects of biocompatible
- Biofeedback, BV regulation during HD with, 740
- Biofiltration, acetate-free, effects of, on NO synthesis, dialysis hypotension and, 115-124
- Biological role and properties
 of calcitriol, S2:3-4
 of UG, 1110
- Biomedical Scientific Advisory Committee (B-SAC), USRDS, S1:5
- Biopsy, *see* Renal biopsy
- Biopsy gun, automated renal biopsies with, 426-431
- BJCN (Bence-Jones cast nephropathy), plasma cell dyscrasias and, 529-532
- Black Americans, *see* Race
- Blastokinin (uteroglobin), physiological role of, in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120
- Blood concentrations of cefazolin in HD patients, 410-414
- Blood glucose, fasting, in ESRD patients on CAPD, exercise effects on, 1014
- Blood group, ABO, and renal transplantation, S1:93
- Blood line temperature in critically ill patients on CRRT, 1023-1030
- Blood pressure (BP)
 BP-dependent and -independent renal protective actions of antihypertensive drugs, 16-18
 of critically ill patients on CRRT, 1026
 measurement of, in general population with normal renal function, S3:66-67
 in NIDDM, 545
 normotensive young adults with ADPKD, LVM and diastolic function in, 970-975
 in OHT recipients, 292
 renal biopsy and, 427, 429
 in RTRs, 248, 662
see also Blood pressure in ESRD patients on CAPD, HD, and/or PD; Goal blood pressure; Hypertension; Intradialytic blood pressure
- Blood pressure (BP) in ESRD patients on CAPD, HD, and/or PD
 with calciphylaxis, 378

- in diabetic patients, rHuEPO and, 489
- exercise effects on, 1013-1015
- goal, 712-714
- long-term CAPD effects on, 483, 486
- with LVH, 726
- measurement of, 876, S3:127
- trends in time on HD and, S4:63-70
- see also* Hypertensive end-stage renal disease, CAPD, HD, and/or PD for
- Blood urea nitrogen, *see* BUN
- Blood volume (BV) regulation during HD, 739-748, 5:E9
- BMI, *see* Body mass and body mass index
- Body mass and body mass index (BMI)
 - and ATN-induced DGF, 986, 987
 - of HTN patients, race and, 35
 - of nephrolithiasis patients, 804
 - see also* Body mass and body mass index of ESRD patients on CAPD, HD, and/or PD
- Body mass and body mass index (BMI) of ESRD patients on CAPD, HD, and/or PD
 - adrenal function and, 53
 - catheter-related infections on PD and, 755, 757
 - mortality and, 110, 111
- Body weight (BW)
 - AD, AFB, and HCO₃ dialysate effects on, 118
 - of ADPKD patients, 971, 978
 - of coronary angiography with contrast medium patients, 66
 - of CsA-induced arteriopathy subjects, 248
 - of ESRD patients, *see* Body weight of ESRD patients on CAPD, HD, and/or PD; Body weight of RTRs
 - of HTN patients, race and, 35
 - of SCA patients, 210
 - see also* Obesity
- Body weight (BW) of ESRD patients on CAPD, HD, and/or PD
 - with calciphylaxis, 376-383, 514-518
 - caloric intake and ideal, calculated from LBM, 1019-1022
 - cefazolin therapy and, 411
 - long-term CAPD effects on cardiac function and, 486
 - of malnourished patients on rhGH therapy, 455, 457
 - with rHuEPO therapy, 472
 - secondary HPT on paricalcitol therapy and, S2:50, S2:58
 - survival and, 111
 - see also* Dry body weight of ESRD patients on CAPD and/or HD
- Body weight (BW) of RTRs
 - and ATN-induced DGF, 986, 987
 - long-term renal function and CsA disposition in 500-pound transplant recipient, 4:E4
 - of pregnant RTRs, 662
- BOR (branchio-oto-renal) syndrome, 334-337
- BP, *see* Blood pressure
- Brain function, and optimal hematocrit in dialysis patients, S4:142-146
- Branchio-oto-renal (BOR) syndrome, 334-337
- Breast cancer, vitamin D analogues for, S2:26, S2:28-29
- B-SAC (Biomedical Scientific Advisory Committee), US-RDS, S1:5
- Budd-Chiari syndrome during NS relapse, resistance to activated PC clotting inhibitor and, 657-660
- BUN (blood urea nitrogen)
 - pre-HD, in ARF, 735
 - pre-OHT, 291
 - see also* BUN in ESRD patients on CAPD and/or HD
- BUN (blood urea nitrogen) in ESRD patients on CAPD and/or HD
 - in hyponatremic patients, CVVHD effects on, 830
 - and long-term CAPD effects on cardiac function, 483
 - in malnourished ESRD patients on rhGH therapy, 458
 - recirculation and, 1050
- BV (blood volume) regulation during HD, 739-748, 5:E9
- BW, *see* Body weight
- C1q (complement 1q) mesangial labeling in IgAN, 589-592
- C3 (complement 3) in MPGN types I and III, 56-63
- Ca, *see* Ca dialysate; Ca in ESRD patients on CAPD and/or HD; Dietary Ca; Hypercalcemia in secondary HPT; Hypocalcemia and entries beginning with element: Calc-
- Ca (calcium) channel blockers, *see* Antihypertensive drugs
- Ca (calcium) dialysate, effects of, on intradialytic BP in cardiac-compromised patients, 125-131
- Ca (calcium) in ESRD patients on CAPD and/or HD
 - DMMS on use of medications to maintain phosphorus and Ca balance, S1:65
 - in malnourished patients on rhGH therapy, 458
 - metabolism of, in calciphylaxis, 379-380
 - see also* Serum Ca in ESRD patients on CAPD and/or HD
- CABG (coronary artery bypass grafting), *see* entries beginning with terms: Coronary artery revascularization
- CAD, *see* Coronary artery disease
- Caffeine, nephrotoxicity of, 355-356
- Calcemic uremic arteriopathy, *see* Calciphylaxis, ESRD and
- Calcification, medial, and intimal hyperplasia, uremic small artery disease and, 499-502
- Calciphylaxis (calcemic uremic arteriopathy), ESRD and, 376-391, 514-518
 - aortic valve involvement in, 499-502
 - cryofibrinogenemia and, 494-498
 - cutaneous necrosis in, *see* Cutaneous necrosis in calciphylaxis
 - secondary HPT and, S2:7-9
- Calcipotriol, therapeutic uses of, S2:25, S2:26, S2:35
- Calcitonin, serum, in HD patients with secondary HPT, 242
- Calcitriol [1,25(OH)₂D₃; 1,25-dihydroxyvitamin D₃], S2:13-24
 - as cornerstone of secondary HPT therapy, S2:9
 - genomic actions of, *see* Genomic actions of calcitriol
 - nongenomic actions of, S2:18, S2:34-35
 - role of, in secondary HPT, S2:3-4; *see also* Secondary hyperparathyroidism in ESRD patients on HD
 - transcription factor for, *see* Vitamin D receptor
 - vitamin D bioactivation and control of homeostasis of, S2:14-16
 - see also* Vitamin D analogue(s)
- Calcium, *see* Ca dialysate; Ca in ESRD patients on CAPD and/or HD; Dietary Ca; Hypercalcemia in secondary HPT; Hypocalcemia and entries beginning with element: Calc-
- Calculi, *see* Nephrolithiasis

- Caloric intake, and ideal BW of PD patients calculated from LBM, 1019-1022
- Cancer, vitamin D analogues for, S2:26-29
- CAPD, *see* Continuous ambulatory peritoneal dialysis for ESRD
- Capillary albumin, permeability of glomerular, in steroid-resistant FSGS, 230-237
- Capillary hydraulic pressure, glomerular, antihypertensive drugs and control of, 2-3
- Carboplatin, *see* Cisplatin
- Cardiac disease, *see entries beginning with terms:* Cardiovascular disease
- Cardiac evaluation of renal transplant candidates, 567-574
- Cardiac failure
malnutrition in ESRD and, 836
see also Cardiac failure in general population, NKF Task Force report on; Congestive heart failure
- Cardiac failure in general population, NKF Task Force report on
epidemiology of, S3:61-62
in hypertensive general population, effects of, on antihypertensive drug selection, S3:72-73
- Cardiac function
autonomic, in patients awaiting renal transplantation, 221-229
effects of long-term CAPD and/or HD on, 482-487
- Cardiac output, OHT and, 292
- Cardiomyopathy
dilated uremic, in ESRD patients on HD, persistent ultrafiltration for, 664-668
DM and, in general population, S3:92-93
- Cardiovascular disease, *see* Cardiac failure; Cardiomyopathy; Risk factors for CVD and *entries beginning with terms:* Cardiovascular disease
- Cardiovascular disease (CVD) in CRD, NKF Task Force report on control of, 853-906
abbreviations used in, 904-905
background to, 857-868
clinical recommendations of, *see* Clinical recommendations of NKF Task Force on CVD
executive summary of, *see* Executive summary of NKF Task Force report
introduction to, S3:1-4
list of references reviewed by Task Force, S3:26-55
literature reviews and synthesis in, S3:14-26
research recommendations of, *see* Research, NKF Task Force recommendations on
Task Force members, 905-906
see also Chronic renal disease, and CVD, NKF Task Force report on; General population, evidence for CVD in, NKF Task Force report on
- Cardiovascular disease (CVD) in ESRD
Ca dialysate effects on intradialytic BP in cardiac-compromised patients, 125-131
malnutrition, mortality and, 834-841
medications for, DMMS on use of, S1:64-65
- Cardiovascular (CV) function, and optimal hematocrit in dialysis patients, S4:142-146
- Cardiovascular (CV) system
AD, AFB, and HCO₃ dialysate effects on stability of, 118
see also entries beginning with term: Heart and elements: Card-, Vascul-
- L-Carnitine (γ -trimethyl-ammonium- β -hydroxybutyrate) supplementation for ESRD patients on HD, 258-272
effects of, on muscular symptoms, 258-264
role of, on quality of life during and between HD, 265-272
- Caroli syndrome, as primary disease in familial ESRD, 796
- Carpal tunnel syndrome (CTS) in ESRD patients on HD, effects of high-flux biocompatible membranes on, 338-343
- Case Mix Adequacy Study (CMAS), S1:30, S1:33
on CD-ROM, S1:32
- Case Mix Severity Study, USRDS, S1:29, S1:33
- Catheters
flush-tip and staggered-tip, recirculation with, 1046-1058, 6:E5
infections due to, on PD, silver ring device in prevention of, 752-760
- Cavernoma, portal, NS and, 657-660
- CC (Coordinating Center) University of Michigan, USRDS, S1:4-5
- CCPD, *see* Continuous cycling peritoneal dialysis for ESRD
- cDNA (complementary deoxyribonucleic acid), UG, cloning of, 1108
- CD-ROM(s), core SAF, S1:28-35
- CD-ROM drive needed to use SAFs, S1:32
- Cefazolin in ESRD patients on HD
as alternative to vancomycin in chronic HD patients, 401-409, 521-523
as empiric therapy, 401-414
- Cell-surface receptors, nongenomic activity of vitamin D analogues mediated by S2:34-35
- Cell therapy, tissue engineering and, for RRT, 6: FLAG:
- Cellulose acetate hemodialyzers, ofloxacin clearance with, 642-645
- Census
of ESRD networks, S1:146
population, as base for computing incidence and prevalence of treated ESRD, S1:150-151
- Cephalin kaolin time, posttransplantation coagulation and fibrinolysis and, 576
- Cerebral salt wasting, and hypouricemia, 925-926
- Certification of ESRD care facilities, S1:133-134
- CF (cystic fibrosis), and phenotypic expression of ADPKD, 976-983, 1081-1083
- CFTR (cystic fibrosis transmembrane conductance regulator) protein, ADPKD and, 976-983, 1081-1084
- CG (collapsing glomerulopathy), phenotypic features of hyperplastic epithelial cells in, 962-969
- CGN, *see* Crescentic glomerulonephritis
- Charcot-Marie-Tooth (CMT) syndrome
FGN and, 5:E3
as primary disease in familial ESRD, 796
- CHD, *see* Coronary heart disease in general population
- CHF, *see* Congestive heart failure
- CHIF mRNA (messenger ribonucleic acid), down-regulated, in hyperkalemia of ATN, 600-604
- Children, *see* Pediatric patients
- Chinese herbs nephropathy (CHNP), 3:I-1ii
- "Ma-Huang" nephrolithiasis, 153-159
- Chloride, *see* Cl

- CHNP, *see* Chinese herbs nephropathy
- Cholesterol
 serum, in posttransplantation de novo minimal change disease, 511
see also Cholesterol in ESRD patients on CAPD, HD, and/or PD; Hypocholesterolemia and entries beginning with term: Hyperlipidemia
- Cholesterol in ESRD patients on CAPD, HD, and/or PD with catheter-related infections on PD, 755
 in diabetic patients, rHuEPO therapy and, 489
 in malnourished patients on rhGH therapy, 455
 total, *see* Total cholesterol in ESRD patients on CAPD
- Chronic glomerulonephritis (GN), as primary disease in ESRD
 ER and, 279
 exercise training effects and, 1012
 and long-term CAPD effects on cardiac function, 483, 486
 and secondary HPT, 240
- Chronic hemodialysis (HD) for ESRD
 AVG stenosis on, Doppler ultrasound or fistulography in diagnosis of, compared, 273-277
 VRE on, *see* Vancomycin-resistant enterococci in ESRD patients on chronic HD
- Chronic interstitial nephritis (IN), and secondary HPT in ESRD patients on HD, 240
- Chronic nephrotoxicity due CsA, arteriopathy and, 247-253
- Chronic renal disease (CRD)
 nondiabetic, renoprotective effects of antihypertensive drugs in, 9-11
see also Chronic renal disease, and CVD, NKF Task Force report on and specific conditions
- Chronic renal disease (CRD), and CVD, NKF Task Force report on
 extrapolation of evidence from general population to, 862-865, S3:17-18
see also Cardiovascular disease in CRD, NKF Task Force report on control of; Coronary artery disease in CRD, NKF Task Force report on; Diabetes mellitus, and CVD in CRD, NKF Task Force report on; Epidemiology of CVD in CRD, NKF Task Force report on; Homocysteine, and CVD in CRD, NKF Task Force report on; Hyperlipidemia, and CVD in CRD, NKF Task Force report on; Hypertension, and CVD in CRD, NKF Task Force report on; Left ventricular hypertrophy in CRD, NKF Task Force report on; Menopause, and CVD in CRD, NKF Task Force report on; Physical inactivity, and CVD in CRD, NKF Task Force report on; Tobacco use, and CVD in CRD, NKF Task Force report on
- Chronic renal failure (CRF)
 CrCl measurement of renal function in, 23-31
 effectiveness of nutrition interventions in, S4:126-130
see also End-stage renal disease and entries beginning with term: Uremic
- Chronic renal insufficiency (CRI)
 FSGS with, 74, 75
 quality of life and psychosocial relationships with, 557-566
see also Chronic renal insufficiency, CVD and, NKF Task Force report on
- Chronic renal insufficiency (CRI), CVD and, NKF Task Force report on
 with DM, glycemic control in, 886, S3:165-166
 epidemiology of, 869, S3:112-114
 HTN and, 874-876, S3:121-125
 hyperlipidemia in, 881-882, S3:143-148
 menopause and, S3:180
 research recommendations on, 899
- Chronic transplant glomerulopathy (CTG), recurrent, differences between recurrent posttransplantation MPGN type I and, 582-588
- Cimetidine, GFR in CRF assessed with, 23-31
- Circulating antibodies to 58-kD tubular interstitial nephritis (TIN) antigen, childhood MN with anti-tubular basement membrane nephritis and, 1068-1074
- Circulating nephritic factor (NF)-stabilized convertase, glomerular deposits with, in MPGN types I and III, 56-63
- Cirrhosis, ESRD patients on HD with, reinfusion and concentration of ascitic fluid in, 164-167
- Cisplatin (carboplatin)
 hematuria induced by, ARF and, S:E5
 HUS induced by, TPE for, 314-317
- CIT (cold ischemia time), as risk factor for ATN-induced DGF, 984-991
- Cl (chloride)
 in hyponatremic ESRD patients, CVVHD effects on, 830
 Na, *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension; Salt wasting, and hypouricemia
- Claims records, paid HCFA, S1:145-146, S1:160
- Clara cell 10-kD protein (uteroglobin), physiological role of, in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120
- Classification
 NKF Task Force study, S3:19, S3:21-22
 PAN, 505
- Clinical course, *see* Course
- Clinical features and presentation
 of childhood MN with anti-tubular basement membrane nephritis, 1072
 of *P falciparum* malaria, 362, 363
 of RAS, 844
 of secondary HPT, S2:6-9
see also specific conditions
- Clinical practice guidelines, and performance measures in ESRD, S4:173-176
- Clinical recommendations of NKF Task Force on CVD
 on evidence of CVD in general population, 862, S3:7-9
 executive summary of, 854-856, S3:10-12
 format for, 867-868
see also Cardiovascular disease in CRD, NKF Task Force report on control of and specific risk factors; for example: Hyperlipidemia, and CVD in CRD, NKF Task Force report on
- Clinical trials, NKF Task Force research recommendations on CVD, 856-857, 901-904, S3:12
 DM, S3:167
 homocysteine level, 903, S3:182
 HTN, 901, S3:134
 hyperlipidemia, 902, S3:152

- menopause, 903, S3:180
 physical inactivity, 903, S3:178
 screening for CAD and LVH, 904, S3:194-195
 thrombogenic factors, 903
 tobacco use, 902, S3:174
- Clotting, *see* Coagulation
- CMAS, *see* Case Mix Adequacy Study
- CME (continuing medical education) exercises, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
- CMT, *see* Charcot-Marie-Tooth syndrome
- CMV, *see* Cytomegalovirus
- Coagulation
 activated PC inhibitor of, Budd-Chiari syndrome during NS relapse and resistance to, 657-660
 in diabetic ESRD patients on PD and rHuEPO therapy, peripheral vascular disease and, 488-493
 postransplantation fibrinolysis and, with OKT3 or CsA induction therapy, 575-581
 see also Antiplatelet therapy of CAD, NKF Task Force report on; Platelet(s) and entries beginning with element: Thromb-
- Cognitive function, and optimal hematocrit in dialysis patients, S4:142-146
- Cold ischemia time (CIT), as risk factor for ATN-induced DGF, 984-991
- Collagen type III, deposition of mesangial, in IgAN, 146-152
- Collapsing glomerulopathy (CG), phenotypic features of hyperplastic epithelial cells in, 962-969
- Colonization with VRE in chronic HD for ESRD, 254-257
- Combined acetaminophen (AC) and acetylsalicylic acid (ASA), nephrotoxicity of, 353-354
- Committees, USRDS, S1:5-6, S1:22
- Comorbidity
 effects of, on antihypertensive drug selection for general population, S3:71-72
 with HTN, 874
 and quality of life changes following renal transplantation, 94
 see also specific conditions
- Complement, *see* C1q; C3; Hypocomplementemia
- Compliance
 by CRI patients, relationship between psychological and social measures and, 560-561
 noncompliance with HD for ESRD, 139-145
 obstacle to achieving adequate dialysis dose, S4:93-95
- Computer needed to use SAFs, S1:32
- Conduction disorders in DM, S3:93
- Congestive heart failure (CHF)
 in general population, DM and, S3:92-93; *see also* Diabetes mellitus, and CHD in general population
 slow continuous ultrafiltration on CRRTs and, 192
- Consent, informed, in genetic testing for renal diseases, 939-940, 943
- Contacts, USRDS, S1:21
- Contents and address of USRDS site on Internet World Wide Web, S1:25
- Continuing medical education (CME) exercises, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD
 adrenal function and, 52-55
 beneficial effects of exercise for patients on, 1011-1018
 caloric intake by patients on, 1019-1022
 changes in demographics and prescription of in last decade, S4:44-51
 in Japan, 2:xlix-lxiii
 long-term, effects of, on cardiac function, 482-487
 with LVH, I/D polymorphism in intron 16 of ACE gene in, 725-730
 morphology of mesothelial cells in CAPD effluent, 946-952
 peritonitis on, *see* Peritonitis on CAPD
 and rhGH therapy for malnourished patients, 454-463
 see also Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1998 ADR on; Diabetic end-stage renal disease, CAPD, HD, and/or PD for; Hemodialysis for ESRD; Hypertensive end-stage renal disease, CAPD, HD and/or PD for; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD, USRDS 1998 ADR on
 hospitalization of patients on, S1:113
 Medicare expenditures for, S1:119, S1:120, S1:126, S1:128
 as option, S1:51-52
 patient survival on, S1:54, S1:105-106
 for pediatric ESRD, S1:104
 trends in utilization of, S1:52-55
 utilization of, by age, sex, race, and primary disease, S1:56-58
- Continuous Ambulatory Peritoneal Dialysis (CAPD) and Peritonitis Rates Study, USRDS, S1:29-30, S1:33
- Continuous cycling peritoneal dialysis (CCPD) for ESRD
 caloric intake by patients on, ideal BW and, 1019-1022
 see also Continuous cycling peritoneal dialysis for ESRD, USRDS 1998 ADR on
- Continuous cycling peritoneal dialysis (CCPD) for ESRD, USRDS 1998 ADR on, S1:51-58
 hospitalization of patients on, S1:113
 Medicare expenditures for, S1:119, S1:126, S1:128
 as option, S1:51-52
 patient survival on, S1:54
 for pediatric ESRD, S1:104
 trends in utilization of, S1:52-55
 utilization of, by age, sex, race, and primary disease, S1:56-58
- Continuous hemodiafiltration, *see* Acute renal failure, CRRTs for
- Continuous hemofiltration, *see* Acute renal failure, CRRTs for; Continuous venovenous hemofiltration
- Continuous quality improvement (CQI) in ESRD
 clinical practice guidelines and performance measures for, S4:173-176
 role of networks, USRDS, and facility-specific reports, S4:182-189
 see also Quality improvement
- Continuous renal replacement therapy(ies) (CRRTs)
 of critically ill patients, cooling effect of, 1023-1030
 see also Acute renal failure, CRRTs for; Continuous venovenous hemodialysis; Continuous venovenous hemofiltration; Slow continuous ultrafiltration

- Continuous venovenous hemodialysis (CVVHD), severe hyponatremia treated with, 829-831
- Continuous venovenous hemofiltration (CVVH), post-OHT, 290-294
- Contrast nephropathy
and coronary arteriography, S3:187
free radicals and, 64-71
- Convertase, circulating NF-stabilized, glomerular deposits with, in MPGN types I and III, 56-63
- Cooling effect of CRRT in critically ill patients, 1023-1030
- Coordinating Center (CC) University of Michigan, USRDS, S1:4-5
- Core Indicators Project, for continuous quality improvement in ESRD, S4:182-189
- Core Standard Analysis File (SAF) CD-ROMs, S1:28-35
- Coronary angiography
effects of allopurinol before, on free radical formation, 64-71
see also Coronary angiography in general population
- Coronary angiography in general population
in CAD diagnosis, S3:102
with DM, risks of, S3:92
- Coronary arteriography, contrast nephropathy and, S3:187
- Coronary artery bypass grafting, *see entries beginning with terms: Coronary artery revascularization*
- Coronary artery disease (CAD)
as CVD risk factor in atherosclerotic ostial RAS, 614; *see also* Coronary artery disease in CRD, NKF Task Force report on
as primary disease in ESRD, colonization with VRE on chronic HD and, 255, 256
see also Coronary artery disease in general population, NKF Task Force report on
- Coronary artery disease (CAD) in CRD, NKF Task Force report on, 892-895, S3:184-199
antiplatelet therapy of, 892-893, S3:184-185
in CRI, 869, S3:113
in ESRD patients on HD, 871, S3:116
in ESRD patients on PD, 872, S3:116
research recommendations on, 904, S3:194-195
revascularization for, 856, 893-895, S3:11, S3:186-190
in RTRs, S3:117
screening for, 856, 896-898, 904, S3:12, S3:191-195
- Coronary artery disease (CAD) in general population, NKF Task Force report on, S3:101-111
antiplatelet therapy of, S3:103-104
diagnosis of, S3:101-102
revascularization for, S3:92, S3:93, S3:105-110
- Coronary artery revascularization
in CRD patients, 856, 893-895, S3:11, S3:186-190
in general population, S3:92, S3:93, S3:105-110
- Coronary heart disease (CHD) in general population
in hypertensive general population, effects of, on antihypertensive drug selection, S3:72-73
see also Diabetes mellitus, and CHD in general population
- Coronary risk factor(s) in general population, reduction of, S3:80-88
with hormone replacement therapy, S3:85-87
- hyperlipidemia as, S3:81-83
physical inactivity as, S3:83-85
- Cortisol (adrenocorticotropin) test in ESRD patients on CAPD and/or HD, 52-55
- Costs
of cefazolin, vancomycin, and gentamicin administration, 406
frequency and, of posttransplantation hospitalization with FK506 and CsA, compared, 770-777
of microalbuminuria tests in DM, 524-528
of renal transplantation candidate evaluation, 567-574
of SAFs, S1:32-34
see also Costs, ESRD care
- Costs, ESRD care
ER and, 278-283
see also Costs of ESRD care, USRDS 1998 ADR on
- Costs of ESRD care, USRDS 1998 ADR on, S1:18
analytical methods applied to, S1:160-162
Facility Cost Report, S1:29, S1:33, S1:146
see also Medicare expenditures for ESRD, USRDS 1998 ADR on
- Counseling, genetic, and genetic testing for renal diseases, 942-943
- Course
of CGN, 181
early, of childhood MCNS, outcome and, 176-178
see also Progression and specific conditions
- C-peptide in malnourished ESRD patients on CAPD and/or HD and rhGH therapy, 460
- Cr and CrCl, *see* Creatinine and creatinine clearance
- CRD, *see* Chronic renal disease
- C-reactive protein, acute-phase inflammatory process and uremia, S4:105-112
- Creatinine (Cr) and creatinine clearance (CrCl)
in ADPKD with CF, 982
in ARF patients on CRRT, as basis for estimation of protein catabolism, 449-453
in atherosclerotic ostial RAS, 613
in CG, 963
in combined MN-IgAN, 650, 654
in contrast nephropathy, 64-71
in ESRD, *see* Creatinine and creatinine clearance in ESRD on CAPD, HD, and/or PD
in FSGS, 73-74, 232
pre-OHT, 291
in RTRs with CsA-induced arteriopathy, 249
serum, *see* Serum creatinine
see also Creatinine and creatinine clearance, GFR assessment with
- Creatinine (Cr) and creatinine clearance (CrCl), GFR assessment with, 23-42
in CRF, 23-31
in HTN, 32-42
- Creatinine (Cr) and creatinine clearance (CrCl) in ESRD on CAPD, HD, and/or PD
AD, AFB, and HCO₃ dialysate effects on, 118
catheter-related infections on PD and, 755, 757
exercise effects on, 1014
in malnourished patients on rhGH therapy, 458
mortality and, 110

- PS, SEP and, 947
recirculation and, 1050
see also Serum creatinine in ESRD patients on CAPD and/or HD
- Credentialing, role in quality activities in ESRD, S4:177-181
- Crescentic glomerulonephritis (CGN)
CMV-induced necrotizing and, in RTRs, 820-824
infective endocarditis-induced, effects of plasmapheresis on, 309-313
pauci-immune, ANCA test in, 344-349
renal biopsy in glomerular Ig localization in, 179-184
- CRF, *see* Chronic renal failure
- CRI, *see* Chronic renal insufficiency
- Critically ill patients, cooling effect of CRRT in, 1023-1030
- CRRTs, *see* Continuous renal replacement therapy(ies)
- Cryofibrinogenemia, calciphylaxis and, 494-498
- CsA, *see* Cyclosporine
- CTG (chronic transplant glomerulopathy), recurrent, differences between recurrent posttransplantation MPGN type I and, 582-588
- CTS (carpal tunnel syndrome) in ESRD patients on HD, effects of high-flux biocompatible membranes on, 338-343
- CUA (calcemic uremic arteriopathy), *see* Calciphylaxis, ESRD and
- Cutaneous necrosis in calciphylaxis, 379, 384-391, 514-518
digital, 499-502
- CV system, *see* Cardiovascular system
- CVD (cardiovascular disease), *see* Cardiac failure; Cardiomyopathy; Risk factors for CVD and entries beginning with terms: Cardiovascular disease
- CVVH, *see* Continuous venovenous hemofiltration
- CVVHD, *see* Continuous venovenous hemodialysis
- Cycling peritoneal dialysis for ESRD, *see* Continuous cycling peritoneal dialysis for ESRD
- Cyclophosphamide, IV, MMF for lupus nephritis refractory to, 318-322
- Cyclosporine (CyA; CsA)
effects of withdrawal of, on CsA-induced arteriopathy, 247-253
frequency and cost of posttransplantation hospitalization with FK506 and, compared, 770-777
induction therapy with OKT3 or, coagulation and fibrinolysis following, 575-581
long-term renal function and disposition of, in 500-pound transplant recipient, 4:E4
- Cystic fibrosis (CF), and phenotypic expression of ADPKD, 976-983, 1081-1083
- Cystic fibrosis transmembrane conductance regulator (CFTR) protein, ADPKD and, 976-983, 1081-1084
- Cytokines
as factors predisposing to atherosclerotic CVD, hypoalbuminemia, and malnutrition in ESRD, 836-838
in *P. falciparum* malaria, 365-366
see also specific cytokines
- Cytomegalovirus (CMV)
foscarnet therapy of CMV retinitis with AIDS, glomerular crystals due to nephrotoxicity of, 392-400, 519-520
necrotizing and crescentic GN induced by, in RTRs, 820-824
- Daily hemodialysis (HD)
long or short, S4:83-85
renewed interest in, S4:76-82
- Data, USRDS
abstracts citing, S1:28
release of, S1:35, S1:36-37
requests for, S1:25-26
see also Data, USRDS 1998 ADR
- Data, USRDS 1998 ADR
changes in, S1:10-11
collection of, for DMMS on medication use, S1:61
on international RRTs, S1:136-137
on Medicare expenditures, S1:31-32
new, analytical methods and, S1:142-144; *see also* Analytical methods used in USRDS 1998 ADR
on RRT modalities, S1:52
sources of, for database, S1:144-147
UNOS, S1:143, S1:146
see also Database, USRDS 1998 ADR and specific data sources
- Data abstraction forms used by NKF Task Force, S3:19-21
- Data Request Review Committee (DRRC), USRDS, S1:6, S1:22
- Database, USRDS 1998 ADR, S1:22-23
sources of data for, S1:144-147; *see also* Data, USRDS 1998 ADR
see also Analytical methods used in USRDS 1998 ADR
- Data management, to understand ESRD trends and outcomes, S4:165-172
- DBP (diastolic blood pressure), *see* Blood pressure
- Deafness, renal failure and, in BOR syndrome, 334-337
- Death Notification Form (Form 2746), S1:82, S1:145
- Death rates, USRDS 1998 ADR on, S1:70-75
annual, with renal transplantation, S1:157-158
national, S1:74-75, S1:79
see also Death rates of ESRD patients, USRDS 1998 ADR on
- Death rates of ESRD patients, USRDS 1998 ADR on
adjusted, S1:75-76, S1:153-154
first-year, S1:70-74
see also Mortality of ESRD patients, USRDS 1998 ADR on
- Deemed status, role in quality activities in ESRD, S4:177-181
- Delayed graft function (DGF), posttransplantation ATN and, 984-991
- Delivered dialysis dose
improving outcomes in PD patients, S4:58-62
v prescribed dialysis dose for ARF, 731-738, 832-833
see also K_t/V ; K_t/V_{urea}
- Demographics, changes in PD during last decade, S4:44-51
- De novo minimal change disease (minimal change nephrotic syndrome), posttransplantation, 508-513
- Deoxyribonucleic acid, *see* DNA
- Department of Veterans Affairs (DVA), ESRD care facilities of, S1:135
- Deposition disease
polyclonal IgG, HCDD and, 328-333
see also Light chain deposition disease
- Depression in CRI patients, 557-566
- Detection, *see* Diagnosis

- Dextran, clearance of, in SCA, 210-211
- DGF (delayed graft function), posttransplantation ATN and, 984-991
- Diabetes mellitus (DM)
- costs versus accuracy of microalbuminuria tests in, 524-528
 - see also* Diabetes mellitus, and CHD in general population; Diabetes mellitus, and CVD in CRD, NKF Task Force report on; Insulin-dependent diabetes mellitus, CRD with; Non-insulin-dependent diabetes mellitus and entries beginning with term: Diabetic
- Diabetes mellitus (DM), and CHD in general population, S3:89-100
- angina pectoris and myocardial ischemia associated with, S3:91
 - angiography in, S3:92
 - CHF, cardiomyopathy and, S3:92-93
 - conduction disorders, atrial fibrillation, and heart rate variability with, S3:93
 - coronary artery revascularization with, S3:92, S3:93, S3:105-110
 - effects of, on selection of antihypertensive drugs, S3:71-72
 - epidemiology of, S3:58-59
 - glycemic control of, S3:93-94
 - hyperlipidemia and, S3:94-96
 - MI and, S3:91-92
 - mortality due to, S3:90-91
 - prevalence of, S3:89-90
 - renal disease, HTN, microalbuminuria and, S3:94
- Diabetic end-stage renal disease (ESRD), and CVD in CRD, NKF Task Force report on, 855, S3:157-171
- atherosclerosis and, S3:157-160
 - glycemic control of, *see* Glycemic control in CRD patients
 - introduction to, 884-886, S3:157
 - research recommendations on, 902, S3:167
- Diabetic end-stage renal disease (ESRD), CAPD, HD, and/or PD for
- and ATN-induced DGF, 986, 987
 - with calciphylaxis, 378, 386
 - and L-carnitine supplementation effects on quality of life in, 267, 270
 - catheter-related infections on PD and, 755, 757
 - colonization by VRE in, 255, 256
 - ER and, 279
 - familial, 796, 797
 - glycemic control of, S3:166
 - with LVH, 726
 - and long-term CAPD and/or HD effects on cardiac function, 482-487
 - malnutrition and, 764
 - mortality with, 110
 - noncompliance by patients with, 140, 141
 - quality of care ratings and, 286, 287
 - see also* Diabetic end-stage renal disease, CAPD, HD, and/or PD for, with rHuEPO therapy
- Diabetic end-stage renal disease (ESRD), CAPD, HD, and/or PD for, with rHuEPO therapy
- and pain with single-dose and multidose rHuEPO, 472
 - peripheral vascular disease and, 488-493
- Diabetic end-stage renal disease (ESRD), renal transplantation for, S1:91, S1:93
- AF in patients with, awaiting, 221-229
 - and exclusion from renal transplantation, 568, 570
- Diabetic end-stage renal disease (ESRD), USRDS 1998 ADR on
- incidence of, S1:44, S1:46
 - Medicare expenditures for, S1:126, S1:128
 - medication use by patients with, S1:67
 - mortality and, S1:71, S1:84, S1:86, S1:87
 - pediatric, S1:101, S1:102
 - renal transplantation for, S1:91, S1:93
 - withdrawal from dialysis and, S1:86, S1:87
- Diabetic nephropathy
- renoprotective effects of antihypertensive drugs in, 11-13
 - see also* entries beginning with terms: Diabetic end-stage renal disease
- Diabetic renal hypertrophy, early, IGFBP mRNA in, 1000-1010, 6:E6
- Diagnosis
- of AN, 356-357
 - CAD, S3:101-102
 - DM, 884, S3:90
 - EBV, 785-793
 - see also* Diagnosis of ESRD, USRDS 1998 ADR on; Screening specific diagnostic techniques and specific conditions
- Diagnosis of ESRD, USRDS 1998 ADR on
- mortality by year since, S1:76-77
 - see also* Primary disease in ESRD, USRDS 1998 ADR on
- Dialysate
- effects of AD and HCO₃⁻, on NO synthesis, dialysis hypotension and, 115-124
 - used on CRRTs, 196-197
- Dialysis dose
- changes in, for PD, effect on outcomes, S4:52-57
 - consensus report on quantity and time, S4:86-87
 - delivered dose and membrane transport in PD, S4:58-62
 - membrane type, anemia control, and, S4:157-160
 - obstacles to achieving adequate, S4:93-95
 - outcome-based measures of, S4:16-31
 - see also* Adequacy of dialysis dose, Delivered dialysis dose, and Dose
- Dialysis facilities
- facility-specific reports in continuous quality improvement, S4:182-189
 - role of external oversight for quality activities at, S4:177-181
- Dialysis hypotension, *see* Intradialytic hypotension
- Dialysis membranes
- dialysis dose, anemia control, and, S4:157-160
 - influence on outcome of ESRD patients, S4:71-75
 - on CRRTs, 194-196
 - see also* Dialysis membranes on HD
- Dialysis membranes on HD
- and trends in treatment and survival, S4:34-38
 - USRDS 1998 ADR on, S1:55-56
 - see also* High-flux hemodialysis membranes, effects of biocompatible
- Dialysis Morbidity and Mortality Study (DMMS), S1:30, S1:32, S1:33

- on CD-ROM, S1:32
- see also* Medication use, DMMS data on
- Dialysis and transplant centers for ESRD, S1:133
- Dialysis patients
 - acute-phase inflammatory process and uremia in, S4:105-112
 - factors influencing serum albumin in, S4:118-125
 - global trends in outcomes in morbidity and mortality of, S4:5-31
- Dialysis quantity, *see* Dialysis dose and Quantity of dialysis
- Dialyzers, *see* Hemodialyzers
- Diastolic blood pressure, *see* Blood pressure
- Diastolic function, LVM and, in normotensive young adults with ADPKD, 970-975
- Diet
 - and CVD, S3:59-60
 - see also* Nutrition and entries beginning with term: Dietary
- Dietary Ca (calcium)
 - effects of calcitriol and, on VDR in secondary HPT, S2:3-4; *see also* Hypercalcemia in secondary HPT
 - nephrolithiasis and, 804
- Dietary K (potassium), nephrolithiasis and, 804
- Dietary management
 - of HTN, *see* Dietary management of HTN with NaCl restriction
 - of hyperlipidemia, 879-883, S3:146-148, S3:150, S3:151
 - of type 2 DM, S3:160-161
 - see also* L-Carnitine supplementation in ESRD patients on HD and specific vitamins
- Dietary management of HTN with NaCl restriction, 875-878, S3:120
 - in CRI, 875-876, S3:124
 - in ESRD patients on HD, 877, S3:128
 - in ESRD patients on PD, 877, S3:132
 - in general population, S3:69
 - and renal protective effects of antihypertensives, 7, 13-16
 - in RTRs, 878
- Dietary Mg (magnesium), nephrolithiasis and, 804
- Dietary Na (sodium), nephrolithiasis and, 804
- Dietary protein, and energy requirements in ESRD, S4:97-104
- Digital necrosis in calciphylaxis, 499-502
- Digitalis-like substance, endogenous, HTN in ESRD and, 708-709
- 2,8 Dihydroxyadenine disease, as primary disease in familial ESRD, 796
- 1,25-Dihydroxyvitamin D₃, *see* Calcitriol
- Dilated uremic cardiomyopathy in ESRD patients on HD, persistent ultrafiltration for, 664-668
- Direct patient care, Medicare expenditures for, S1:122-125
- Discontinuity in USRDS 1993 ADR, S1:148
- Disease states
 - urate transport in, 921-923
 - see also* specific conditions
- Disk storage needed to use SAFs, S1:32
- Distal renal tubular acidosis (DRTA), hyperkalemic, H⁺-ATPase in 1091-1097
- DM, *see* Diabetes mellitus
- DMMS, *see* Dialysis Morbidity and Mortality Study
- DNA (deoxyribonucleic acid)
 - RXR-VDR binding to VDR, S2:17-18, S2:20
 - UG complementary, cloning of, 1108
- Documentation, USRDS, S1:33-35
- Donors
 - race of, and glomerular size, 43-46
 - see also* Living organ donations, ethical issues in; Living related organ donations
- Doppler ultrasound, fistulography or, in diagnosis of chronic HD AVG stenosis, compared, 273-277
- Dose
 - drug, during CRRTs, 193
 - of falcacalcitriol and alfacalcidol, 242
 - HD, for ESRD, USRDS 1998 ADR on, S1:54-55; *see also* Delivered dialysis dose
 - IV infusion of total iron, in PD patients, 1086-1090
 - see also* Adequacy of dialysis dose, Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD, dose of
- Down-regulated CHIF mRNA (messenger ribonucleic acid) in hyperkalemia of ATN, 600-604
- Drop-out from CAPD, peritonitis and, 623-628
- DRRC (Data Request Review Committee), USRDS, S1:6, S1:22
- DRTA (distal renal tubular acidosis), hyperkalemic, H⁺-ATPase in 1091-1097
- Drug(s), *see* Medication use, DMMS data on and specific drugs; for example: Antihypertensive drugs; Lipid-lowering agents
- Dry body weight (BW) of ESRD patients on CAPD and/or HD
 - BV regulation during HD and, 746
 - dry-weight method of HTN control, 710-711, 720, 722, S3:124, S3:128
 - exercise effects on, 1014
- Duplicate records, elimination of, in USRDS 1998 ADR, S1:10, S1:143
- DVA (Department of Veterans Affairs), ESRD care facilities of, S1:135
- Dyscrasias, plasma cell, renal biopsy of, 529-532
- Dysplasia
 - bilateral fibromuscular, in identical twins, 6:E4
 - see also* Renal dysplasia
- Dystrophy, *see* Renal osteodystrophy; Retinal dystrophy
- Early referral (ER) for ESRD, impact of, on dialysis, health care costs, and outcome, 278-283
- EB1089, therapeutic uses of, S2:26, S2:29, S2:33
- EBV, *see* Epstein-Barr virus infection
- EC (Executive Committee), USRDS, S1:5, S1:22
- ECG, *see* Electrocardiogram in general population
- Echocardiography of ESRD patients
 - of cardiac function in patients on long-term CAPD and/or HD, 482-487
 - with hypertensive ESRD, 714
 - transesophageal, of patients with calciphylaxis, 499-502
- ECM (extracellular matrix), plasma matrix MMP-9 and microalbuminuria in NIDDM, 544-550, 669-671
- Economic Scientific Advisory Committee (E-SAC), USRDS, S1:5-6
- ECV, *see* Extracellular volume

- ED-71 [2-(3-hydroxypropyl)-1,25(OH)₂D₃], therapeutic uses of, S2:26, S2:30, S2:33, S2:45
- EDB (Enrollment Database) of Medicare, S1:145
- Education
 continuing medical, exercises on, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
 see also Educational status of CAPD and/or HD patients
- Educational status
 noncompliance and, 140, 141
 obstacle to achieving adequate dialysis dose, S4:93-95
 quality of ESRD care ratings and, 286, 287
- Eicosanoids, synthesis of, in peripheral blood monocytes, as marker of disease activity in lupus nephritis, 778-784
- Electrocardiogram (ECG) in general population
 in CAD diagnosis, S3:101-102
 as predictor of LVH, S3:60
- Electrolytes
 CRRTs and avoidance of fluctuation in, 187-188
 see also specific electrolytes
- Electron microscopy (EM)
 of de novo minimal change disease, 509
 of lesions in calciphylaxis, 387
 of recurrent posttransplantation MPGN type I and CTG, 582-588
 see also specific conditions
- Eligibility of ESRD patients for hospitalization, S1:110
- EM, *see* Electron microscopy
- Empiric therapy, cefazolin as, of HD-related infections, 401-414
- Encapsulating peritonitis, sclerosing, and CAPD for ESRD, 946-952
- Endocarditis, infective, effects of plasmapheresis on CGN due to, 309-313
- Endocrine/hormonal agents, DMMS on use of, S1:67
- Endogenous digitalis-like substance, HTN in ESRD and, 708-709
- Endoperoxide synthetase, prostaglandin, as marker of disease activity of lupus nephritis, 778-784
- Endothelial cells, AFB, AD, and HCO₃ dialysate effects on IL-1 β concentrations in, 114-124
- Endothelin-1 (ET-1), plasma, and PB monocyte ET-1 mRNA in sepsis, effects of hemoperfusion with PMX-F on, 953-961
- Endothelium-derived factors, HTN in ESRD and, 709
- Endotoxemia, *see* Sepsis
- Endovascular management of thrombosed vascular access grafts, 172-175
- End-stage renal disease (ESRD)
 analgesic nephropathy and, *see* Analgesic nephropathy
 family history of, as risk factor for ESRD in first-degree relatives, 794-801
 nephrology manpower and patterns of care for, 551-556, 672-675
 strategies for influencing outcomes in (special conference), S4:1-193
 see also Calciphylaxis, ESRD and; Chronic renal failure; Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Hemodialysis for ESRD; Hypertensive end-stage renal disease, CAPD, HD and/or PD for; Hyperphosphatemia in ESRD patients on HD; Malnutrition in ESRD patients; Outcomes in pre-ESRD and ESRD patients; Peritoneal dialysis for ESRD; Renal transplantation for ESRD; United States Renal Data System, 1998 ADR of and entries beginning with terms: Diabetic end-stage renal disease
- Energy balance and requirements of PD patients, caloric intake and, 1019-1022
- Energy requirements, dietary, in ESRD patients, S4:97-104
- Enrollment Database (EDB) of Medicare, S1:145
- Enterococci, *see* Vancomycin-resistant enterococci in ESRD patients on chronic HD
- Ephedrine ("Ma-Huang") nephrolithiasis, 153-159
- 20-Epi-1,25(OH)₂D₃, therapeutic uses of, S2:33, S2:34
- Epidemiology
 of AN, 352-353
 of atherosclerosis in diabetic CRD patients, S3:157-158
 of nephrolithiasis with HTN, 802-807
 see also Epidemiology of CVD in CRD, NKF Task Force report on; Epidemiology of CVD in general population, NKF Task Force report on; Incidence; Prevalence and specific conditions
- Epidemiology of CVD in CRD, NKF Task Force report on, 854, S3:10-12, S3:112-119
 in CRI, 869, S3:112-114
 in ESRD patients on HD, 869-871, S3:114-116
 in ESRD patients on PD, 871-872, S3:116
 research recommendations on, 900-901, S3:117-118
 in RTRs, 872, S3:116-117
- Epidemiology of CVD in general population, NKF Task Force report on, S3:56-65
 cardiac failure and, S3:61-62
 DM and, S3:58-59
 homocysteine level and, S3:59
 HTN and, S3:58
 hyperlipidemia and, S3:57-58
 lifestyle and, S3:59-60
 LVH and, S3:60-61
 post-MI risk factors and, S3:61
 preventive implications of, S3:61
- Epithelial cells, hyperplastic, in CG, phenotypic features of, 962-969
- Epithelium, transitional urinary bladder, carboplatin toxicity to, 5:E5
- EPO, *see* Erythropoietin cell therapy; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
- Epstein-Barr virus (EBV) infection
 acute, associated with SLE, 825-828
 in glomerular mesangial injury, 785-793
 PTLD and, 813-819
- ER (early referral) for ESRD, impact of, on dialysis, health care costs, and outcome, 278-283
- Erythrocytes, parasitized, in *P falciparum* malaria, 362-364
- Erythropoietin, *see* Erythropoietin cell therapy; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
- Erythropoietin (EPO) cell therapy, 6: FLAG:
- E-SAC (Economic Scientific Advisory Committee), US-RDS, S1:5-6

- ESRD, *see* End-stage renal disease
- Essential hypertension (HTN)
- renoprotective effects of antihypertensive drugs in, 7-9
 - see also* Hypertension
- Estrogen replacement therapy, *see* Hormone replacement therapy
- ET-1 (endothelin-1), plasma, in sepsis, effects of hemoperfusion with PMX-F on, 953-961
- Ethical considerations
- on genetic testing for renal diseases, 939-941
 - see also* Living organ donations, ethical issues in
- Ethnicity, *see* Race
- Evidence-based medicine, clinical practice guidelines and performance measures in ESRD, S4:173-176
- Evidence for primary and secondary prevention of CVD, NKF Task Force report on
- grading of, based on clinical studies, 862; *see also* Clinical trials, NKF Task Force research recommendations on CVD
 - see also* General population, evidence for CVD in, NKF Task Force report on
- Exclusion, S1:142-144
- from renal transplantation, pre-transplant evaluation of candidates and, 567-574
 - see also* Exclusion from analytical methods
- Exclusion from analytical methods
- patients with insufficient Medicare-paid dialysis, S1:143-144
 - patients with minimal data, S1:142-143
- Executive Committee (EC), USRDS, S1:5, S1:22
- Executive summary
- of 1998 USRDS ADR, S1:9-19
 - see also* Executive summary of NKF Task Force report
- Executive summary of NKF Task Force report, 853-857, S3:5-13
- of clinical recommendations, 854-856, S3:10-12; *see also* Clinical recommendations of NKF Task Force on CVD
 - of research recommendations, 856-857, S3:12; *see* Research, NKF Task Force recommendations on
 - Task Force goal, S3:5; *see also* entries beginning with terms: Primary and secondary prevention
- Exercise(s), CME, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
- Exercise capacity, and optimal hematocrit in dialysis patients, S4:142-146
- Exercise training
- for ESRD patients on CAPD, beneficial effects of, 1011-1018
 - see also* entries beginning with terms: Physical inactivity
- Expected remaining years of life of ESRD patients, USRDS 1998 ADR on, S1:78-79, S1:159
- Extracellular matrix (ECM), plasma matrix MMP-9 and microalbuminuria in NIDDM, 544-550, 669-671
- Extracellular volume (ECV)
- effects of changes in, on urate transport, 920-921
 - see also* Extracellular volume in HTN
- Extracellular volume (ECV) in HTN
- of CRI, 875, 876, S3:124, S3:132
 - see also* Extracellular volume in hypertensive ESRD patients on HD and/or PD
- Extracellular volume (ECV) in hypertensive ESRD patients on HD and/or PD, 877, S3:126-129
- at dry weight, 722
 - Na balance and balance of, 708, 710
- Extrarenal disease, procainamide-induced lupus nephritis in absence of, 698-702
- Facilities for ESRD care, USRDS 1998 ADR on, S1:18, S1:52, S1:132-135
- as data source, S1:146
 - described, S1:134
 - of DVA, S1:135
 - ESRD patients by type and location of, S1:132-134
 - Facility Cost Report, S1:29, S1:33, S1:146
 - number and location of, S1:132
 - number of treatments administered by, S1:134
 - role of reports by, in continuous quality improvement, S4:182-189
 - SHR and SMR by, S1:24-25
 - see also* Dialysis facilities
- Facility Cost Report, S1:29, S1:33, S1:146
- Falecalcitriol, alfacalcidol versus, for PTH suppression in HD patients with secondary HPT, 238-246
- Familial end-stage renal disease (ESRD), as risk factor for ESRD in first-degree relatives, 794-801
- Familial hemolytic-uremic syndrome (HUS), 1063-1067
- Fanconi syndrome, severe osteomalacia and, due to lambda light chain nephropathy, 6:E3
- Fasting blood glucose in ESRD patients on CAPD, exercise effects on, 1014
- Fe, *see* Iron
- Fever, rash, and myalgias with SLE, renal biopsy of, 848-852
- FGN, *see* Fibrillary glomerulonephritis
- Fibrillary glomerulonephritis (FGN; immunotactoid glomerulonephritis)
- CMT syndrome and, 5:E3
 - with hypocomplementemia, steroid pulse therapy for, 1:E4
 - in renal allograft, 5:E4
- Fibrinogen
- and EBV in glomerular mesangial injury, 785-783
 - in hypercoagulable state of NS, 658
 - in posttransplantation coagulation and fibrinolysis, 576
- Fibrinolysis, posttransplantation coagulation and, OKT3 or CsA induction therapy and, 575-581
- Fibromuscular dysplasia (FMD), bilateral, in identical twins, 6:E4
- Fibronectin (Fn), role of UG in preventing glomerulopathy due to deposition of, 1084-1086, 1106-1120
- Fibrosis
- cystic, and phenotypic expression of ADPKD, 976-983, 1081-1083
 - peritoneal, and CAPD for ESRD, 946-952
 - tubulointerstitial, due to mast cell infiltration in GN, 593-599
- 58-kD tubulointerstitial nephritis (TIN) antigen, childhood MN with anti-tubular basement membrane nephritis and circulating antibodies to, 1068-1074
- File media and formats, USRDS, S1:32
- First-degree relatives of ESRD patients, risk factor for ESRD in, 794-801

- First renal transplantation in analytical methods, S1:144, S1:157, S1:159
- First service date (FSD), S1:147
- First-year death rates of ESRD patients, USRDS 1998 ADR on, S1:70-74
- Fistulography, Doppler ultrasound or, of chronic HD AVG stenosis, compared, 273-277
- FK506 (tacrolimus), frequency and cost of posttransplantation hospitalization with CsA and, compared, 770-777
- Fludrocortisone, effects of, on TTKG, urinary K/Na ratio, and fractional excretion of K, 47-51
- Fluid balance on CRRTs, 189-190
- Flush-tip catheters, recirculation with, 1046-1058, 6:E5
- FMD (fibromuscular dysplasia), bilateral, in identical twins, 6:E4
- Fn (fibronectin) deposition, role of UG in preventing glomerulopathy due to, 1084-1086, 1106-1120
- Focal segmental glomerulosclerosis (FSGS)
CG as variant of, 962-969
in children and adults, long-term outcome of, 72-79
EBV detection in, 785-793
plasmapheresis for steroid-resistant, 230-237
as primary disease in ESRD with calciphylaxis, 386
SCA-associated, 208-214
- Folate, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
- Follow-up
on combined MN-IgAN, 650, 652
see also Outcome
- Form 2728 (Medical Evidence Form), S1:28-29, S1:143-145
- Form 2746 (Death Notification Form), S1:82, S1:145
- Formalin, reuse of dialyzers and clinical outcome, S4:88-92
- Foscarnet therapy for CMV retinitis with AIDS, glomerular crystals due to nephrotoxicity of, 392-400, 519-520
- Fournier transform infrared microscopy, glomerular crystals due to foscarnet therapy of CMV retinitis in AIDS identified with, 392-400
- Fractional excretion of K, mineralocorticoid effects on, 47-51
- Free radicals, contrast nephropathy and, 64-71
- Free thyroxine (FT4) in malnourished ESRD patients on CAPD and/or HD and rhGH therapy, 455, 460
- Freestanding (independent) units for ESRD care, S1:132
- Frequency, cost and, of posttransplantation hospitalization with FK506 and CsA, compared, 770-777
- FSD (first service date), S1:147
- FSGS, *see* Focal segmental glomerulosclerosis
- FT4 (free thyroxine) in malnourished ESRD patients on CAPD and/or HD and rhGH therapy, 455, 460
- Fulminant anti-glomerular basement membrane (GBM) glomerulonephritis (GN), recurrent, in RTRs, 323-327
- Functional renal transplant, changes in quality of life with, 94-96
- Gamma-trimethyl-ammonium- β -hydroxybutyrate, *see* L-Carnitine supplementation for ESRD patients on HD
- Gas chromatography/mass spectrometry (GC/MS) of ephedrine nephrolithiasis, 153-159
- Gastrointestinal (GI) drugs, DMMS on use of, S1:66
- Gastrointestinal (GI) pH, influence of, on phosphate binder disintegration, 808-812
- GBM (glomerular basement membrane), *see* Anti-glomerular basement membrane disease
- GC/MS (gas chromatography/mass spectrometry) of ephedrine nephrolithiasis, 153-159
- Gene knockout, UG, physiological role of UG in normal glomerular function uncovered by, 1084-1086, 1106-1120
- General population
expected remaining years of life of, S1:78-79
NKF Task Force report on CVD in, *see* Coronary artery disease in general population, NKF Task Force report on; Coronary risk factor(s) in general population, reduction of; Diabetes mellitus, and CHD in general population; Epidemiology of CVD in general population, NKF Task Force report on; General population, evidence for CVD in, NKF Task Force report on; Hyperlipidemia, and CVD in general population; Hypertension, and CVD in general population, NKF Task Force report on; Primary and secondary prevention of CVD in general population, NKF Task Force report on
serum creatinine levels in, NHANES III of, 992-999
- General population, evidence for CVD in, NKF Task Force report on, 860-866, S3:16-24
defined, S3:16-17
evidence evaluation, 866, S3:18-19
evidence retrieval, 865-866, S3:19-22
extrapolation from, to CRD patients, 862-865, S3:17-18
for interventions, *see* Interventions for CVD in CRD, NKF Task Force report on
recommendations on, 862, S3:7-9
risk assessment and, 861-862, S3:6-7
synthesis of, 866, S3:22-24
- General renal community, USRDS products available for, *see* Standard Analysis Files, USRDS
- Genetic counseling, and genetic testing for renal diseases, 942-943
- Genetic privacy, legislation on, 941
- Genetic testing for renal diseases, 934-945
for ADPKD, *see* Autosomal dominant polycystic kidney disease, genetic testing for
ethical considerations on, 939-941
genetic counseling issues and, 942-943
with a known genetic defect, 935-936
legislation on genetic privacy, 941
medical considerations in use of, 937-939
methods of, 936-937
- Genetics, *see* DNA; Gene knockout; Genetic testing for renal diseases; Genomic actions of calcitriol; mRNA: Phenotype; Polymorphism; Twins and entries beginning with terms: Autosomal, Familial
- Genomic actions of calcitriol, S2:16-20
regulation of, S2:18-20
- Gentamicin, and cefazolin for ESRD patients on chronic HD, 401-409
- Geography
geographic variation in incidence and prevalence of treated ESRD, S1:48-49

- location of ESRD care facilities, S1:132-134
see also Residence of ESRD patients
- GFR, *see* Glomerular filtration rate
- GH (growth hormone), recombinant human, for malnourished ESRD patients on CAPD and/or HD, 454-463
- GI (gastrointestinal) drugs, DMMS on use of, S1:66
- GI (gastrointestinal) pH, influence of, on phosphate binder disintegration, 808-812
- Global trends
 in outcomes in morbidity and mortality in dialysis patients, S4:5-31
- Glomerular basement membrane, *see* Anti-glomerular basement membrane disease
- Glomerular capillary albumin permeability in steroid-resistant FSGS, 230-237
- Glomerular capillary hydraulic pressure (P_{GC}), antihypertensive drugs and control of, 2-3
- Glomerular crystals due to foscarnet therapy of CMV retinitis with AIDS, 392-400, 519-520
- Glomerular deposits with circulating NF-stabilized convertase in MPGN types I and III, 56-63
- Glomerular filtration rate (GFR)
 in ADPKD, 978
 glomerular permselectivity and, in SCA, 210-211
 and pressure natriuresis in aging kidney, 605-610
see also Creatinine and creatinine clearance, GFR assessment with
- Glomerular function
 normal, physiological role of UG in, gene knockout technique and discovery of, 1084-1086, 1106-1120
see also specific conditions
- Glomerular Ig (immunoglobulin) in CGN, renal biopsy in localization of, 179-184
- Glomerular injury
 glomerular pressure and, 2-6
 mesangial, EBV detection in, 785-793
see also specific conditions
- Glomerular permselectivity in SCA, 208-214
- Glomerular pressure, glomerular injury and, 2-6
- Glomerular size, impact of kidney donor's race on, 43-46
- Glomerulonephritis (GN)
 IL-10 and TNF- α expression in, disease activity and, 80-92
P falciparum malaria and, *see: Plasmodium falciparum* malaria
 periglomerular myofibroblast α -SMA and progression of, 419-425
 tubulointerstitial mast cell infiltration in, 593-599
see also Glomerulonephritis, as primary disease in ESRD and specific types of glomerulonephritis
- Glomerulonephritis (GN), as primary disease in ESRD
 alfalcidol effects on lymphocyte phenotyping and, 1037
 and ATN-induced DGF, 986
 calciphylaxis and, 386
 catheter-related infections on PD and, 755
 chronic, *see* Chronic glomerulonephritis, as primary disease in ESRD
 and exclusion from renal transplantation, 568
 in familial ESRD, 796, 797
 and mortality, 110
 quality of care ratings and, 286
 VRE and, 255, 256
- Glomerulopathy
 due to fibronectin deposition, UG preventing, 1084-1086, 1106-1120
 recurrent chronic transplant, differences between recurrent posttransplantation MPGN type I and, 582-588
see also specific glomerular conditions
- Glomerulosclerosis (GS)
 periglomerular myofibroblast α -SMA and progression of, 419-425
see also Focal segmental glomerulosclerosis
- Glucose
 plasma, and early diabetic renal hypertrophy, 1002
see also Glucose in ESRD patients on CAPD and/or HD
- Glucose in ESRD patients on CAPD and/or HD
 fasting blood, exercise effects on, 1014
 in malnourished ESRD patients, rhGH therapy and, 455, 458
 metabolism of, *see* Diabetes mellitus
- Glycated Hb (hemoglobin) in NIDDM, 545
- Glycemic control
 in general population, S3:93-94
see also Glycemic control in CRD patients
- Glycemic control in CRD patients, S3:160-167
 with CRI, 886, S3:165-166
 in ESRD patients on HD and PD, 887, S3:166
 research recommendations on, S3:167
 in RTRs, 887-888, S3:166-167
 in type 1 DM, S3:164
 in type 2 DM, S3:160-164
- Glycocalicin, plasma, ristocetin-induced platelet agglutination and, in ESRD patients on HD, 132-138
- Glycoprotein (GP) Ib/IX, role of, in platelet agglutination, 132-138
- GN, *see* Glomerulonephritis
- Goal blood pressure (BP)
 in CRD patients, S3:123
 in ESRD patient, 712-714
 in general population, S3:66-67
- GP (glycoprotein) Ib/IX, role of, in platelet agglutination, 132-138
- Graft function, delayed, posttransplantation ATN and, 984-991
- Graft rejection, *see* Acute graft rejection
- Graft survival
 long-term, 102, S1:95-96
 posttransplantation ATN, 984-991
see also Graft survival, USRDS 1998 ADR on
- Graft survival, USRDS 1998 ADR on, S1:89-90, S1:94-96
 analytical method applied to, S1:159-160
 long-term, S1:95-96
 pediatric, S1:106
 short-term, S1:94-95
- Gram-positive and gram-negative peritonitis on CAPD, outcome of, 623-628
- Granulomatosis, *see* Wegener's granulomatosis
- Granulomatous interstitial nephritis (IN), histoplasmosis-induced, ARF with AIDS and, 2:E3

- Gross hematuria
in GN, 82
nutcracker syndrome and, 3:E3
- Growth and Development Study of pediatric ESRD patients, S1:30, S1:33
- Growth hormone (GH), recombinant human, for malnourished ESRD patients on CAPD and/or HD, 454-463
- GS, *see* Glomerulosclerosis
- H⁺-ATPase (hydrogen-adenosine triphosphatase) in hyperkalemic DRTA, 1091-1097
- Hb (hemoglobin)
glycated, in NIDDM, 545
renal biopsy and, 427-429
in RTRs, 576, 662
see also Hb in ESRD patients on CAPD, HD, and/or PD
- Hb (hemoglobin) in ESRD patients on CAPD, HD, and/or PD
with catheter-related infections on PD, 755
with LVH, 726
and rhGH therapy in malnourished ESRD patients, 455
with secondary HPT, effects of paricalcitol therapy on, S2:52, S2:53
- HbA1c (hemoglobin A1c) in malnourished ESRD patients on HD and/or CAPD with rhGH therapy, 455
- HBV (hepatitis B) vaccination, ID, of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045
- HCDD (heavy chain deposition disease), polyclonal IgG deposition disease and, 328-333
- HCFA, *see* Health Care Financing Administration
- HCO₃ (bicarbonate) dialysate, effects of, on NO synthesis, dialysis hypotension and, 115-124
- Hct, *see* Hematocrit
- HCV (hepatitis C virus) infection in ESRD patients on HD and/or PD, mortality and, 629-634
- HD, *see* Hemodialysis
- HDLs (high-density lipoproteins), exercise effects on, in CAPD patients, 1014
- Health Care Financing Administration (HCFA), S1:4
Death Notification Form of, S1:82, S1:145
Medical Evidence Form of, S1:28-29, S1:143-145
paid claims records of, S1:145-146, S1:160
PMMIS and REBUS database of, S1:144
see also Medicare
- Health insurance status of ESRD patients
ER and, 281
quality of care ratings and, 286, 287
see also Medicare
- Health policy issues, NKF Task Force report on, 857, S3:12
- Heart, *see* Coronary heart disease in general population; Endocarditis; Heart rate variability; Heart transplantation *entries beginning with terms:* Left ventricular, Mitral, Myocardial and element: Card-
- Heart failure, *see* Cardiac failure
- Heart rate (HR)
of critically ill patients on CRRT, 1026
see also Heart rate variability
- Heart rate (HR) variability
in DM, S3:93
in patients awaiting renal transplantation, 221-229
- Heart transplantation, orthotopic, CVVH and HD after, 290-294
- Heavy chain deposition disease (HCDD), polyclonal IgG deposition disease and, 328-333
- Hematocrit (Hct)
AD, AFB, and HCO₃ dialysate effects on, 118
in pregnant RTRs, 662
renal biopsy and, 428, 429
in SCA, 210
see also Anemia and Hematocrit in ESRD patients on CAPD, HD, and/or PD
- Hematocrit (Hct) in ESRD patients on CAPD, HD, and/or PD
AVG thrombosis and stenosis and, 305
in diabetic patients, rHuEPO and peripheral vascular disease and, 489
effects of IV infusion of total Fe dose on, 1089
and long-term CAPD effects on cardiac function, 483
with LVH, 726
in malnourished ESRD patients on rhGH therapy, 455
mortality and, 110
optimal, S4:142-146
- Hematoma, *see* Perirenal hematoma
- Hematuria
carboplatin-related, ARF and, 5:E5
in CG, 963
in combined MN-IgAN, 650, 654
in FSGS, 73
gross, *see* Gross hematuria
loin pain/hematuria syndrome, renal autotransplantation or radical renal neurectomy for, 215-220
persistent microscopic, renal biopsy of NS with, 1098-1105
- Hemodiafiltration, continuous, *see* Acute renal failure, CRRTs for
- Hemodialysis (HD)
for ARF, *see* Acute renal failure, HD for
continuous venovenous, *see* Continuous venovenous hemodialysis
post-OHT, 290-294
see also Hemodialysis for ESRD
- Hemodialysis (HD) for ESRD, 132-145
adequacy of in US, improved survival and, S4:39-43
adrenal function and, 52-55
alfacalcidol in, *see* Alfacalcidol in ESRD patients on HD
attention and mental processing speed in patients on, 749-751
BV regulation during, 739-748, 5:E9
calciphylaxis and, *see* Calciphylaxis, ESRD and cefazolin therapy and, *see* Cefazolin in ESRD patients on HD
chronic, *see* Chronic hemodialysis for ESRD
in cirrhotic patients, reinfusion and concentration of ascitic fluid in, 164-167
daily, renewed interest in, S4:76-82
diabetic, *see* Diabetic end-stage renal disease, CAPD, HD, and/or PD for
dilated uremic cardiomyopathy on, persistent ultrafiltration for, 664-668
hemodialyzers used on, *see* Hemodialyzers

- hypertensive, *see* Hypertensive end-stage renal disease, CAPD, HD, and/or PD for
- iron treatment in, safety issues, S4:152-156
- long-term, effects of, on cardiac function, 482-487
- mortality and, *see* Mortality of ESRD patients on HD and/or PD
- noncompliance with, 139-145
- patient ratings of, 284-289
- patterns of care on, 551-556, 672-675
- plasma glycoalbumin and ristocetin-induced platelet agglutination in, 132-138
- quality of life and psychosocial relationships of patients on, 557-566
- reinforced ID HBV vaccination of, antibody response to IM and SC vaccination compared with, 1041-1045
- renal osteodystrophy and, and secondary HPT, S2:3, S2:48; *see also* Secondary hyperparathyroidism in ESRD patients on HD
- and rhGH for malnourished ESRD patients, 454-463
- subcutaneous rHuEPO therapy for, efficacy and economic implications, S4:147-151
- treatment algorithm for anemia of, 635-641; *see also* Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
- trends in time on, from 1989 to 1998, S4:63-70
- trends in treatment and survival in US, S4:9-15, S4:34-38
- see also* L-Carnitine supplementation for ESRD patients on HD; Hemodialysis for ESRD, CVD and, NKF Task Force report on; Hemodialysis for ESRD, US-RDS 1998 ADR on; Secondary hyperparathyroidism in ESRD patients on HD; Vascular access
- Hemodialysis (HD) for ESRD, CVD and, NKF Task Force report on**
- CAD and LVH in, 871, S3:116, S3:192, S3:193
- epidemiology of CVD, 869-871, S3:114-116
- for diabetic ESRD, glycemic control of, 887, S3:166
- homocysteine level and, S3:180, S3:181
- hyperlipidemia and, 882-883, S3:148-149
- for hypertensive ESRD, 876-877, S3:125-129
- physical inactivity and, S3:174-176
- research recommendations, 899, S3:117-118
- tobacco use and, S3:172
- Hemodialysis (HD) for ESRD, USRDS 1998 ADR on**
- causes of mortality on, S1:82-85
- data for analysis of, S1:52
- described, S1:51
- and DMMS data on medication use, S1:62
- dose of, S1:54-55
- by facilities, S1:134
- history of, S1:50
- international use of, S1:138-139
- membranes used, S1:55-56
- patient survival on, S1:54
- trends in utilization of, S1:52-55
- utilization of, by age, sex, race, and primary disease, S1:56-58
- see also* Hemodialysis for pediatric ESRD, USRDS 1998 ADR on
- Hemodialysis (HD) for pediatric ESRD, USRDS 1998 ADR on, S1:103-106**
- patient survival with, S1:105-106
- Hemodialyzers**
- cellulose acetate and polysulfone, ofloxacin clearance with, 642-645
- reuse of, dissociation between small and large solute clearances and, 295-301
- reuse of and clinical outcomes, S4:88-92
- see also* Dialysis membranes on HD
- Hemodynamics**
- in critically ill patients, CRRT effects on, 1023-1030
- see* Renal hemodynamics; Systemic hemodynamics
- Hemofilter, bioartificial, 6: FLAG:**
- Hemofiltration, *see* Continuous venovenous hemofiltration**
- Hemoglobin, *see* Hb**
- Hemolytic uremic syndrome (HUS)**
- cisplatin-induced, TPE for, 314-317
- familial, 1063-1067
- Hemoperfusion with PMX-F, effects of, on plasma ET-1 and PB monocyte ET-1 mRNA in sepsis, 953-961**
- Hemorrhagic urethritis, carboplatin-related, 5:E5**
- Heparin**
- low molecular weight, calciphylaxis and, 384-391
- thrombocytopenia during CRRT induced by, management of, 4:E3
- Hepatitis B (HBV) vaccination, reinforced ID, of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045**
- Hepatitis C virus (HCV) infection in ESRD patients on HD and/or PD, mortality and, 629-634**
- Heredity, *see* DNA; Gene knockout; Genetic testing for renal diseases; Genomic actions of calcitriol; mRNA: Phenotype; Polymorphism; Twins and entries beginning with terms: Autosomal, Familial**
- Heterodimerization, *see* RXR-VDR heterodimerization**
- High-density lipoproteins (HDLs), exercise effects on, in CAPD patients, 1014**
- High-flux hemodialysis (HD) membranes, effects of biocompatible**
- on CTS and mortality in ESRD, 338-343
- on plasma leptin concentrations, 1031-1035
- High-grade posttransplantation lymphoproliferative disorder (PTLD), autologous LAK cell therapy of, 813-819**
- Hispanic Americans, *see* Race**
- Histology and histopathology**
- of calciphylaxis, 386
- of GN, 421
- of steroid-resistant FSGS, 232, 233
- see also* Renal biopsy
- Histoplasmosis-induced granulomatous interstitial nephritis (IN), ARF with AIDS and, 2:E3**
- HLA class I (and II) antigens, childhood MN and, 1068-1074**
- HLA matching, and long-term survival with renal transplantation, 103**
- Home hemodialysis, renewed interest in, S4:76-82**
- Homeostasis, vitamin D bioactivation and control of calcitriol, S2:14-16**
- Homocysteine, and CVD in CRD, NKF Task Force report on, 855-856, S3:11, S3:180-182**
- research recommendations on, 903, S3:182

- vitamin B₁₂, vitamin B₆, and folate effects on, 891-892, S3:180
- Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and and CVD in CRD, 891-892, S3:180
- and CVD in general population, S3:59
- and HD AVG thrombosis, 475-481
- 22(S)-24-Homo-26,27-hexafluoro-1,22,25(OH)₃D₃, therapeutic uses of, S2:29
- Homozygous deletion of NPH1 gene locus in autosomal recessive NPH with retinal dystrophy, 1059-1062, 1084-1085
- Hormonal/endocrine agents, DMMS on use of, S1:67
- Hormone replacement therapy
- DMMS on use of, S1:67
- see also Hormone replacement therapy, NKF Task Force report on
- Hormone replacement therapy, NKF Task Force report on
- for CRD patients, 890-891, S3:178-180
- for hyperlipidemic general population, S3:85-87
- Hospital centers and facilities for ESRD care, S1:132
- Hospital Standard Analysis File (SAF), S1:31
- Hospitalization
- posttransplantation, frequency and cost of, with CsA and FK506, compared, 770-777
- see also Hospitalization for ESRD, USRDS 1998 ADR on
- Hospitalization for ESRD, USRDS 1998 ADR on, S1:10, S1:109-117
- analytical methods applied to, S1:143, S1:155-157
- eligibility for, S1:110
- Hospital SAF, S1:31
- of pediatric patients, S1:106-107
- rates of, based on total admissions, S1:111-114
- SHR, see Standard Hospitalization Ratio
- trends in, S1:110-111, S1:116-117
- HPT, see Hyperparathyroidism
- HR, see Heart rate
- HTN, see Hypertension
- Human erythropoietin, see Erythropoietin cell therapy; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
- Human growth hormone (GH), recombinant, for malnourished ESRD patients on CAPD and/or HD, 454-463
- Humoral factors in *P. falciparum* malaria, 366-367
- HUS, see Hemolytic uremic syndrome
- Hydraulic pressure, glomerular capillary, antihypertensive drugs and control of, 2-3
- Hydrogen-adenosine triphosphatase (H⁺-ATPase) in hyperkalemic DRTA, 1091-1097
- Hydronephrosis, and carboplatin toxicity, 5:E5
- 24-Hydroxylase
- in calcitriol degradation, S2:15-16
- in metabolism of vitamin D analogues, S2:33-34
- 2-(3-Hydroxypropyl)-1,25(OH)₂D₃ (ED-71), therapeutic uses of, S2:26, S2:30, S2:33, S2:45
- 1 α -Hydroxyvitamin D₂ [1 α (OH)D₂], therapeutic uses of, S2:26-27
- 1 α -Hydroxyvitamin D₃ [1 α (OH)D₃], therapeutic uses of, S2:26-29
- Hypercalcemia in secondary HPT, S2:6-7
- calcitriol and, S2:9, S2:55
- and lack of hypercalcemic effects of paricalcitol, S2:40-47, S2:55, S2:61-66
- Hypercoagulable state in NS, 657-660
- Hyperglycemia, see Diabetes mellitus
- Hyperkalemia
- of ATN, down-regulated CHIF mRNA in, 600-604
- with *P. falciparum* malaria, 362
- reversible renin-aldosterone axis suppression after unilateral adrenalectomy for adrenal adenoma and, 160-163
- Hyperkalemic distal renal tubular acidosis (DRTA), H⁺-ATPase in 1091-1097
- Hyperlipidemia, and CVD in CRD, NKF Task Force report on, 855, S3:142-156
- in CRI, 881-882, S3:143-148
- in diabetic patients, S3:158-160
- in ESRD patients on HD, 882-883, S3:148-149
- in ESRD patients on PD, 883, S3:149-150
- introduction to, 879-881, S3:142-143
- research recommendations on, 902, S3:151-152
- in RTRs, 883-884, S3:150-151
- Hyperlipidemia, and CVD in general population, S3:80-88
- beneficial effects of physical activity on, S3:83-85
- with DM, S3:94-96
- epidemiology of, S3:57-58
- with HTN, effects of, on antihypertensive drug selection, S3:72
- postmenopausal hormone therapy in, S3:85-87
- Hypernatremia with *P. falciparum* malaria, 362
- Hyperparathyroidism (HPT)
- in ESRD, HTN and, 709
- see also Secondary hyperparathyroidism in ESRD patients on HD
- Hyperphosphatemia in ESRD patients on HD
- GI pH effects on phosphate binder disintegration in, 808-812
- see also Hyperphosphatemia in ESRD patients on HD with secondary HPT
- Hyperphosphatemia in ESRD patients on HD with secondary HPT, S2:4-7
- calcitriol and, S2:9, S2:55
- and lack of hypercalcemic effects of paricalcitol therapy, S2:40-47, S2:55, S2:61-66
- Hyperplasia
- of epithelial cells in CG, phenotypic features of, 962-969
- intimal, and medial calcification, uremic small artery disease and, 499-502
- Hyperreninemic hypertension (HTN) secondary to subcapsular perinephric hematoma in PAN, 503-507
- Hypertension (HTN)
- in atherosclerotic ostial RAS, 611-622
- in combined MN-IgAN, 650, 654
- in GN, 420
- hyperreninemic, secondary to subcapsular perinephric hematoma in PAN, 503-507
- in long-term renal transplant survivors, 103, 104
- nephrolithiasis as risk for, sex and, 802-807
- race and, CrCl measurement of GFR in, 32-42
- salt-sensitive, and blunted pressure natriuresis in aging kidney, 605-610

- Spanish Society and League Against, history of, 1:xliv-xlv
 see also Hypertension, and CVD in CRD, NKF Task Force report on; Hypertension, and CVD in general population, NKF Task Force report on; Hypertensive end-stage renal disease, CAPD, HD, and/or PD for
- Hypertension (HTN), and CVD in CRD, NKF Task Force report on, 855, 872-878, S3:10-11, S3:120-141
 introduction to, 873-874, S3:120-121
 in CRI, 874-876, S3:121-125
 in ESRD patients on HD, 876-877, S3:125-129
 in ESRD patients on PD, 877-878, S3:129, S3:131-132
 research recommendations on, 901, S3:133-134
 in RTRs, 878, S3:132-133
- Hypertension (HTN), and CVD in general population, NKF Task Force report on
 and CVD prevention, see Hypertension in general population with normal renal function, CVD prevention in with DM, S3:94
 epidemiology of, S3:58
- Hypertension (HTN) in general population with normal renal function, CVD prevention in, S3:66-79
 with antihypertensives, see Antihypertensive drugs in general population, NKF Task Force report on
 BP goals, BP measurement, and risk assessment in, S3:66-67
 lifestyle modification in, S3:68-70
 in minorities, S3:74-75
 in older patients, S3:73-74
- Hypertensive end-stage renal disease (ESRD), CAPD, HD, and/or PD for, 705-724
 and ATN-induced DGF, 986, 987
 background to, 706-708
 bibliography on, 5:E8
 and L-carnitine supplementation effects on quality of life, 267
 and colonization by VRE, 255, 256
 conclusions on, 713-714
 ER and, 279
 and exclusion from renal transplantation, 568
 for familial ESRD, 796, 797
 future direction and suggested studies on, 714
 mortality and, 110
 pathology of, 708-709, 722
 quality of care ratings and, 286
 and rhGH for malnutrition on, 455
 see also Hypertensive end-stage renal disease, CAPD, HD, and/or PD for, and HTN control
- Hypertensive end-stage renal disease (ESRD), CAPD, HD, and/or PD for, and HTN control, 709-714, 720-724
 with antihypertensives, see Antihypertensive drugs
 dry-weight method of, 710-711, 720, 722, S3:124, S3:128
 ECV in, see Extracellular volume in hypertensive ESRD patients on HD and/or PD
 history of, 720
 lag phenomenon and, 720-722
 with Na balance control, 708, 710
 see also Hypertensive end-stage renal disease, CAPD, HD, and/or PD for, HTN control in CVD prevention in
- Hypertensive end-stage renal disease (ESRD), CAPD, HD, and/or PD for, HTN control in CVD prevention in
 in HD patients, 876-877, S3:125-129
 in PD patients, 877-878, S3:129, S3:131-132
- Hypertrophy
 early diabetic renal, IGFBP mRNA in, 1000-1010, 6:E6
 left ventricular, see Left ventricular hypertrophy in CRD, NKF Task Force report on; Left ventricular hypertrophy in ESRD patients on CAPD, HD, and/or PD
- Hyperuricemia, 927-929
- Hypoalbuminemia
 factors influencing, in dialysis patients, S4:118-125
 IL-6 as predictor of hypocholesterolemia, mortality and, in ESRD patients on HD, 107-114
 malnutrition and, and CVD in ESRD, 836-838
 systemic inflammatory response syndrome and, in ESRD, S4:113-117
- Hypocalcemia with *P falciparum* malaria, 362
- Hypocholesterolemia, IL-6 as predictor of hypoalbuminemia, mortality and, in ESRD patients on HD, 107-114
- Hypocomplementemia, immunotactoid glomerulopathy with, steroid pulse therapy for, 1:E4
- Hypokalemia
 and hyperreninemic HTN secondary to subcapsular perinephric hematoma in PAN, 503-507
 with *P falciparum* malaria, 362
- Hypomagnesemia, and contrast nephropathy, 64-71
- Hyponatremia
 with *P falciparum* malaria, 362
 severe, CVVHD in treatment of, 829-831
- Hypophosphatemia
 in lambda light chain nephropathy, 6:E4
 with *P falciparum* malaria, 362
- Hypotension, see Intradialytic hypotension
- Hypothermia, and CRRT in critically ill patients, 1023-1030
- Hypouricemia, 922-926
- Hypovolemia, and intradialytic hypotension, BV regulation during HD and, 739-748
- I/D (insertion/deletion) polymorphism in intron 16 of ACE gene in LVH with ESRD, 725-730
- ID HBV (intradermal hepatitis B) vaccination, reinforced, of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045
- IDDM, see Insulin-dependent diabetes mellitus, CRD with
- Ideal body weight (BW) of PD patients calculated from LBM, caloric intake and, 1019-1022
- Identical twins, bilateral fibromuscular dysplasia in, 6:E4
- IF, see Immunofluorescence
- Ig (immunoglobulin), glomerular, in CGN, renal biopsy in localization of, 179-184
- IgA nephropathy (IgAN; Berger's disease)
 EBV in, 785-793
 IgM and C1q mesangial labeling in, 589-592
 mesangial type III collagen deposition in, 146-152
 MN with, 649-656
 as primary disease in ESRD, 279, 386
- IgAN, see IgA nephropathy
- IGF-1, see Insulin-like growth factor-1 in malnourished ESRD patients

- IGFBP (insulin-like growth factor-binding protein) mRNA (messenger ribonucleic acid) in early diabetic renal hypertrophy, 1000-1010, 6:E6
- IgG (immunoglobulin G) deposition disease, polyclonal, 328-333
- IgM (immunoglobulin M) mesangial labeling in IgAN, 589-592
- IL-1 β , *see* Interleukin-1 β
- IL-6 (interleukin-6), as predictor of hypoalbuminemia, hypocholesterolemia, and mortality in ESRD patients on HD, 107-114
- IL-10 (interleukin-10), expression of TNF- α and, in GN, disease activity and, 80-92
- IM HBV (intramuscular hepatitis B) vaccination of ESRD patients on HD, antibody response to ID vaccination compared with, 1041-1045
- Immune complex glomerulonephritis (GN), 649-656
- Immunocytochemistry of hyperkalemic DRTA, 1093-1094
- Immunofluorescence (IF)
- of de novo minimal change disease, 509
 - of recurrent posttransplantation MPGN type I and CTG, 582-588
 - see also specific conditions*
- Immunoglobulin, *see* entries beginning with acronym: Ig
- Immunohistochemistry
- of C1q and IgM, 590
 - of periglomerular myofibroblasts in GN, 421
- Immunologic disorders, vitamin D analogues for, S2:29-30
- Immunosuppression in RA
- anti-MPO-ANCA necrotizing GN and, 5:E6
 - with prednisone and methotrexate, remission of NS in renal amyloidosis due to, 5:E7
- Immunosuppression in renal transplantation
- long-term survival and, 102, 103
 - nonimmunosuppression in pregnant transplant recipients, 661-663
 - see also specific immunosuppressive agents*
- Immunotactoid glomerulopathy, *see* Fibrillary glomerulonephritis
- Immunotherapy of PTLD with autologous LAK cells, 813-819
- IN, *see* Interstitial nephritis
- Incidence
- of perirenal hematoma with renal biopsy, 428
 - see also* Epidemiology; Incidence and prevalence of treated ESRD, USRDS 1998 ADR on
- Incidence and prevalence of treated ESRD, USRDS 1998 ADR on, S1:10, S1:13, S1:38-49
- analytical methods applied to, S1:149-151, S1:155
 - geographic variation in, S1:48-49
 - international, S1:137-139
 - measuring, S1:38-39
 - overall, S1:39-42
 - by patients' characteristics, S1:40, S1:42-47
 - of pediatric ESRD, S1:98-99, S1:101
- Independent (freestanding) units for ESRD care, S1:132
- Independently supported research, USRDS 1998 ADR on, S1:27
- Induction immunosuppression with OKT3 or CsA for renal transplantation, coagulation and fibrinolysis follow-up, 575-581
- Infections
- ARF and, 735
 - catheter-related, on PD, silver ring device in prevention of, 752-760
 - in long-term renal transplant survivors, 104
 - see also* Sepsis and specific infections
- Infective endocarditis, effects of plasmapheresis on CGN due to, 309-313
- Inferior vena cava, acute thrombosis of, rTPA for, 1075-1079
- Inflammation
- acute-phase process leading to uremia in dialysis patients, S4:105-112
 - and development of atherosclerotic CVD, 836-838
 - factors influencing serum albumin in dialysis patients, S4:118-125
 - systemic inflammatory response syndrome in ESRD, S4:113-117
- Informed consent, and genetic testing for renal diseases, 939-940, 943
- Infrared microscopy, Fournier transform, in identification of glomerular crystals due to foscarnet therapy of CMV retinitis in AIDS, 392-400
- Injury, *see* Glomerular injury; Tubulointerstitial injury
- Insertion/deletion (I/D) polymorphism in intron 16 of ACE gene in LVH with ESRD, 725-730
- Insulin in malnourished ESRD patients on rhGH therapy, 460
- Insulin-dependent diabetes mellitus (type 1 diabetes mellitus; IDDM), CRD with
- glycemic control in, S3:164
 - tobacco use and, S3:173
 - see also* Diabetes mellitus
- Insulin-like growth factor-1 (IGF-1) in malnourished ESRD patients
- 1.1% amino acid PD solution effects on, 765, 766
 - rhGH therapy and, 455, 460
- Insulin-like growth factor-binding protein (IGFBP) mRNA (messenger ribonucleic acid) in early diabetic renal hypertrophy, 1000-1010, 6:E6
- Insulin resistance, medications increasing, S3:161
- Insurance status, *see* Health insurance status of ESRD patients
- Intent-to-treat analysis of Medicare expenditures for ESRD, S1:119-121, S1:126-128, S1:160-162
- Interleukin-1 β (IL-1 β)
- effects of hemoperfusion with PMX-F on, 953-961
 - epithelial cell concentrations of, AFB, AD, and HCO₃ dialysate effects on, 114-124
- Interleukin-6 (IL-6), as predictor of hypoalbuminemia, hypocholesterolemia, and mortality in ESRD patients on HD, 107-114
- Interleukin-10 (IL-10), expression of TNF- α and, in GN, disease activity and, 80-92
- Interleukins (IL), in systemic inflammatory response syndrome in ESRD, S4:113-117
- International renal replacement therapy (RRT) modality(ies) for ESRD, USRDS 1998 ADR on
- data on, S1:136-137
 - HD and PD, S1:138-139
 - incidence and prevalence, S1:137-139

- patient survival and, S1:140-141
 renal transplantation, S1:139-140
 summary on, S1:18-19
 Internet World Wide Web, 1998 USRDS products on, S1:23, S1:25
 Interstitial collagen in IgAN, 146-152
 Interstitial nephritis (IN)
 histoplasmosis-induced granulomatous, ARF with AIDS and, 2:E3
 see also Interstitial nephritis, as primary disease in ESRD
 Interstitial nephritis (IN), as primary disease in ESRD and ATN-induced DGF, 986
 catheter-related infections and, 755
 chronic, and secondary HPT in HD patients, 240
 and exclusion from renal transplantation, 568
 in familial ESRD, 796, 797
 Interventions for CVD in CRD, NKF Task Force report on current status of care, 867-868
 defined, 859-860, S3:15-16
 see also entries beginning with terms: Primary and secondary prevention specific conditions and specific interventions; for example: Antihypertensive drugs; Dietary management
 Intimal hyperplasia, medial calcification and, in uremic small artery disease, 499-502
 Intracranial pressure on CRRTs, 191
 Intradermal hepatitis B (ID HBV) vaccination, reinforced, of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045
 Intradialytic blood pressure (BP)
 in cardiac-compromised patients, Ca dialysate effects on, 125-131
 see also Intradialytic hypotension
 Intradialytic disequilibrium, flawed recirculation measurements due to recirculation at low flow or, 1046-1058, 6:E5
 Intradialytic hypotension
 BV regulation during HD and, 739-748
 effects of AFB, AD and HCO₃ dialysates on NO synthesis and, 115-124
 with reinfusion and concentration of ascitic fluid in cirrhotic patients, 164-167
 Intramuscular hepatitis B (IM HBV) vaccination of ESRD patients on HD, antibody response to ID vaccination compared with, 1041-1045
 Intravascular stent for atherosclerotic ostial RAS, 611-622
 Intravenous (IV) alfacalcidol [1 α (OH)D₃], effects of, on lymphocyte phenotyping in ESRD patients on HD, 1036-1040
 Intravenous (IV) cyclophosphamide, MMF for lupus nephritis refractory to, 318-322
 Intravenous iron (IV Fe) infusion, total dose, in PD patients, 1086-1090
 Intron 16 of ACE gene, I/D polymorphism in, in LVH with ESRD, 725-730
 Investigator-initiated research, policy on data release for, USRDS 1998 ADR on, S1:33-35
¹²⁵I-iothalamate, CrCl and, measuring GFR in black hypertensive patients, 35, 37
 Iron (Fe)
 administration of, in anemia treatment algorithm, 635-641
 DMMS on use of, S1:65-66
 IV infusion of total dose, in PD patients, 1086-1090
 safety issues, in anemia treatment, S4:152-156
 Ischemia, myocardial DM-associated, in general population, S3:91
 Ischemia time, cold, as risk factor for ATN-induced DGF, 984-991
 Ischemic tissue necrosis in calciphylaxis, 384-391
 IV (intravenous) alfacalcidol [1 α (OH)D₃], effects of, on lymphocyte phenotyping in ESRD patients on HD, 1036-1040
 IV (intravenous) cyclophosphamide, MMF for lupus nephritis refractory to, 318-322
 IV (intravenous) iron (Fe) infusion, total dose, in PD patients, 1086-1090
 Justice principle, 681
 K (potassium)
 AD, AFB, and HCO₃ dialysate effects on, 118
 dietary, nephrolithiasis and, 804
 mineralocorticoid effects on TTKG, urinary K/Na ratio, and fractional excretion of, 47-51
 see also Hyperkalemia; Hyperkalemic distal renal tubular acidosis; Hypokalemia; K in ESRD patients; Serum K
 K (potassium) in ESRD patients
 hyponatremic, CVVHD effects on, 830
 malnourished, on rhGH therapy, 455
 KH1049, therapeutic uses of, S2:28
 KH1060, therapeutic uses of, S2:26, S2:28, S2:30
 Kidney
 adverse effects of nicotine on, S3:173
 aging, renal nerves and pressure natriuresis in, 605-610
 see also entries beginning with term: Perirenal and elements: Nephro-, Ren-
 Kinetics
 Cr, and protein catabolism in ARF patients on CRRT, 444-453
 see also Kinetics, urea; Pharmacokinetics
 Kinetics, urea
 and protein catabolism in ARF patients on CRRT, 444-453
 see also Kt/V
 Kt/V
 as outcome-based measure of dialysis dose, S4:16-31
 during CRRTs, 187
 exercise effects on, in CAPD patients, 1014
 prescribed v delivered dialysis dose for ARF and, 731-738, 832-833
 rhGH therapy effects on, 459-460
 see also Kt/V_{urea}
 Kt/V_{urea}
 and L-carnitine supplementation effects on quality of life, 269-270
 in malnourished ESRD patients on rhGH therapy, 455
 LAK (lymphocyte-activated killer) cells, therapy of high-grade PTLN with autologous, 813-819
 Lambda (λ) light chain nephropathy, Fanconi syndrome and severe osteomalacia due to, 6:E3
 LBM (lean body mass), ideal BW of PD patients calculated from, caloric intake and, 1019-1022

- LCDD, *see* Light chain deposition disease
- LDLs (low-density lipoproteins), exercise effects on, in CAPD patients, 1014
- Lean body mass (LBM), ideal BW of PD patients calculated from, caloric intake and, 1019-1022
- Left ventricular angiography, effects of allopurinol on free radical formation before, 64-71
- Left ventricular hypertrophy (LVH)
- NKF Task Force report on epidemiology of, in general population, S3:60-61
 - see also* Left ventricular hypertrophy in CRD, NKF Task Force report on; Left ventricular hypertrophy in ESRD patients on CAPD, HD, and/or PD
- Left ventricular hypertrophy (LVH) in CRD, NKF Task Force report on
- anemia, *see* Anemia of LVH, NKF Task Force report on
 - antihypertensives for, 895-896, S3:190-191
 - in CRI, 869, 871, 872, 895-896, S3:113
 - defined, S3:14-15
 - in ESRD patients on HD and on PD, 871, S3:116
 - research recommendations on, 903-904, S3:194-195
 - in RTRs, S3:117
 - screening for, 856, 898, S3:12, S3:193-195
- Left ventricular hypertrophy (LVH) in ESRD patients on CAPD, HD, and/or PD, 871, S3:116
- I/D polymorphism in intron 16 of ACE gene in, 725-730
 - on long-term CAPD and/or HD, 482-487
 - persistent ultrafiltration for, 664-668
- Left ventricular mass (LVM), diastolic function and, in normotensive young adults with ADPKD, 970-975
- Left ventricular wall thickness in LVH, 725-730
- Legislation, genetic privacy, 941
- Leptin, plasma, effects of high-flux HD on concentrations of, 1031-1035
- Leukemia, vitamin D analogues for, S2:26, S2:29
- Licensure, role in quality activities in ESRD, S4:177-181
- Lifestyle modification
- in HTN management, 873, S3:68-70
 - role of, in epidemiology of CVD, S3:59-60
 - see also specific aspects of lifestyle; for example:* Diet; Physical inactivity, and CVD in CRD, NKF Task Force report on
- Ligand binding by VDR, S2:17
- control of, S2:19
 - vitamin D analogues altering, S2:30-31
- Light chain deposition disease (LCDD), 6:E1
- plasma cell dyscrasias and, 529-532
 - polyclonal IgG deposition disease and, 328-333
- λ (lambda) Light chain nephropathy, Fanconi syndrome and severe osteomalacia due to, 6:E3
- Light microscopy of posttransplantation de novo minimal change disease, 509
- Lipid(s)
- exercise effects on, in CAPD patients, 1014
 - see also* Lipid-lowering agents; Triglycerides in ESRD patients on CAPD, HD, and/or PD and entries beginning with term: Hyperlipidemia
- Lipid-lowering agents
- in CRI, 882, S3:145-148
 - in ESRD patients on HD, 883, S3:148
 - in ESRD patients on PD, 883, S3:149
 - in general population, S3:104-105
 - in RTRs, 883-884, S3:151
- Literature reviews and synthesis by NKF Task Force, S3:14-26
- Lithiasis, *see* Nephrolithiasis
- Living organ donations, ethical issues in, 676-691
- case history of, 676-677, 684-685
 - ethical principles involved, 678-681
 - historical overview of, 677
 - in living related organ donations, 677-678, 681-682
 - need for, 678
 - paternalism in, 682-683
 - questions and answers on, 685-689
 - in unconventional donations, 682-684
- Living related organ donations
- ethical issues in, 677-678, 681-682
 - and genetic testing for ADPKD, 941-942
- Location of ESRD care facilities, USRDS 1998 ADR on, 1:132-134
- Loin pain/hematuria syndrome (LPHS), renal autotransplantation or radical renal neurectomy for, 215-220
- Long-term continuous ambulatory peritoneal dialysis (CAPD) and/or hemodialysis (HD) for ESRD, effects of, on cardiac function, 482-487
- Long-term outcome
- of adult and childhood FSGS, 72-79
 - see also* Long-term outcome of renal transplantation
- Long-term outcome of renal transplantation, 101-106
- long-term renal function and CsA disposition in 500-pound transplant recipient, 4:E4
- Long-term survival
- of ESRD patients, S1:74-75
 - renal graft, 102, S1:95-96
 - of RTRs, 101-106
- Longevity, expected ESRD patients', USRDS 1998 ADR on, S1:78-79, S1:159
- Lost to follow-up methodology in USRDS 1998 ADR, S1:148-149
- Low-density lipoproteins (LDLs), exercise effects on, in CAPD patients, 1014
- Low flow, recirculation at, flawed recirculation measurements due to intradialytic disequilibrium or, 1046-1058, 6:E5
- Low molecular weight heparin, calciphylaxis and, 384-391
- LPHS (loin pain/hematuria syndrome), renal autotransplantation or radical renal neurectomy for, 215-220
- Lupus nephritis
- disease activity in, eicosanoid synthesis in peripheral blood monocytes as marker of, 778-784
 - mesangial and membranous, 1:E1
 - procainamide-induced, in absence of extrarenal disease, 698-702
 - refractory to IV cyclophosphamide, MMF for, 318-322
- LVH, *see* Left ventricular hypertrophy
- LVM (left ventricular mass), diastolic function and, in normotensive young adults with ADPKD, 970-975
- Lymphocyte-activated killer (LAK) cells, therapy of high-grade PTLN with autologous, 813-819
- Lymphocyte phenotyping, effects of IV alfacalcidol on, in ESRD patients on HD, 1036-1040

- β_2 -m (β_2 -microglobulin), clearance of, with reused HD dialyzers, 298
- Magnesium (Mg), dietary, nephrolithiasis and, 804
- "Ma-Huang" (ephedrine) nephrolithiasis, 153-159
- Maintenance dialysis
effectiveness of nutrition interventions in, S4:126-130
see also Continuous ambulatory peritoneal dialysis, Hemodialysis, and Peritoneal dialysis
- Malaria, *see: Plasmodium falciparum* malaria
- Malnutrition in ESRD patients
acute-phase inflammatory process contributing to, S4:105-112
CVD, mortality and, 834-841
on HD, rhGH for, 454-463
on PD, 1.1% amino acid PD solution for, 761-769
systemic inflammatory response syndrome and, S4:113-117
- Managed care alternatives, Medicare expenditures for, USRDS 1998 ADR on, S1:125-128
- Manpower in nephrology, and patterns of ESRD care, 551-556, 672-675
- Manual percutaneous renal biopsy, 426-431
- MAP (mean arterial pressure), *see* Blood pressure
- Mass spectrometry/gas chromatography of ephedrine nephrolithiasis, 153-159
- Mast cells, tubulointerstitial infiltration of, in GN, 593-599
- Matrix metalloproteinase-9 (MMP-9), plasma, and microalbuminuria in NIDDM, 544-550, 669-671
- Maximal planar area (MPA) of glomerular tuft, donor's race and, 43-46
- MC1288, therapeutic uses of, S2:30
- MCNS (minimal change nephrotic syndrome), *see* Minimal change disease
- Mean arterial pressure, *see* Blood pressure
- Medial calcification, and intimal hyperplasia, uremic small artery disease and, 499-502
- Medical considerations in genetic testing for renal diseases, 937-939
- Medical education, exercises on continuing, 1:E2, 2:E2, 3:E2, 4:E2, 5:E2, 6:E2
- Medical Evidence Form (Form 2728), S1:28-29, S1:143-145
- Medical suppliers, Medicare expenditures by type of, S1:128-131
- Medicare
quality of care ratings by ESRD patients on, 286, 287
see also Medicare expenditures for ESRD, USRDS 1998 ADR on
- Medicare expenditures for ESRD, USRDS 1998 ADR on, S1:18, S1:118-131, S1:143-144
data on, S1:31-32
for direct patient care, S1:122-125
EDB of, S1:145
intent-to-treat analysis of, S1:119-121, S1:126-128, S1:160-162
for managed care alternatives, S1:125-128
Medicare payment data SAF, S1:31
paid Medicare claims, S1:145-146, S1:160
by physician specialty and supplier type, S1:128-131
see also Medicare expenditures for ESRD by modality, USRDS 1998 ADR on
- Medicare expenditures for ESRD by modality, USRDS 1998 ADR on
for CAPD, S1:119, S1:120, S1:126, S1:128
for CCPD, S1:119, S1:126, S1:128
for renal transplantation, S1:120-122, S1:126, S1:128
- Medicare payment data Standard Analysis File (SAF), S1:31
- Medication use, DMMS data on, S1:11, S1:14, S1:60-68
analysis of, S1:61-62
of antihypertensives, S1:63-64
of CV medications, S1:64-65
data collection for, S1:61
of endocrine/hormonal agents, S1:67
of EPO and iron, S1:65-66
of gastrointestinal agents, analgesics, and antithrombotics, S1:66
for maintenance of Ca and phosphorus balance, S1:65
overview of, S1:62-63
patient selection, S1:60-61
of psychiatric medications, S1:67-68
of vitamin D analogues, S1:65
of vitamins, S1:68
- Membranes, *see* Dialysis membranes
- Membrane transport, improving outcomes in PD patients, S4:58-62
- Membranoproliferative glomerulonephritis (MPGN) type I and FGN in renal allograft, 5:E4
glomerular deposits with circulating NF-stabilized convertase in, 56-63
recurrent posttransplantation, differences between recurrent CTG and, 582-588
- Membranoproliferative glomerulonephritis (MPGN) type III, glomerular deposits with circulating NF-stabilized convertase in, 56-63
- Membranous lupus nephritis, 1:E1
- Membranous nephropathy (MN), 646-656
anti-glomerular basement membrane disease and ANCA in, 646-648
childhood, anti-tubular basement membrane nephritis and circulating antibodies to 58-kD TIN antigen in, 1068-1074
EBV detection in, 785-793
IgAN with, 649-656
- Menopause, and CVD in CRD, NKF Task Force report on, 855, S3:11
research recommendations on, 903, S3:180
see also Hormone replacement therapy, NKF Task Force report on
- Mental processing speed, attention and, in ESRD patients on HD, 749-751
- Mesangial injury, glomerular, EBV detection in, in, 785-793
- Mesangial labeling, C1q and IgM, in IgAN, 589-592
- Mesangial lupus nephritis, 1:E1
- Mesangial type III collagen deposition in IgAN, 146-152
- Mesothelial cells, morphology of, in CAPD effluent in ESRD patients, 946-952
- Messenger ribonucleic acid, *see* mRNA
- Metabolic control achieved with CRTs, 187
- Metalloproteinase-9 (MMP-9), plasma matrix, and microalbuminuria in NIDDM, 544-550, 669-671
- Methicillin-resistant *Staphylococcus aureus* infections, *see* Cefazolin in ESRD patients on HD

- Methodological issues in NKF Task Force report, 856, S3:12
- Methotrexate, amyloidosis due to RA treated with prednisone and, remission of NS due to, 5:E7
- 5,10-Methylenetetrahydrofolate reductase, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
- Mg (magnesium), dietary, nephrolithiasis and, 804
- MI, *see* Myocardial infarction in general population
- Microalbuminuria, *see* Microalbuminuria in DM; Proteinuria
- Microalbuminuria in DM
- in general population, S3:94
 - importance of accurate determination of, test costs and, 524-528
 - in NIDDM, plasma matrix MMP-9 and, 544-550, 669-671
- β₂ (beta₂)-Microglobulin (β₂-m), clearance of, with reused hemodialyzers, 298
- Microscopic hematuria, NS with persistent, renal biopsy of, 1098-1105
- Microscopic polyangiitis, ANCA test in, 344-349
- Microscopy, *see* Fournier transform infrared microscopy; Electron microscopy; Light microscopy and specific conditions
- Mineralocorticoids, effects of, on TTKG, urinary K/Na ratio, and fractional excretion of K, 47-51
- Minimal change disease (minimal change nephrotic syndrome; MCNS)
- in children, outcome and early course of, 176-178
 - de novo posttransplantation, 508-513
- Minimum aggregation size in analytical methods, S1:144
- Minorities, *see* Race
- Mitral regurgitation in ESRD patients on HD, 664-668
- MMF (mycophenolate mofetil) for lupus nephritis refractory to IV cyclophosphamide, 318-322
- MMP-9 (metalloproteinase-9), plasma matrix, and microalbuminuria in NIDDM, 544-550, 669-671
- MN, *see* Membranous nephropathy
- Modality Sequence (Treatment History) Standard Analysis File (SAF), S1:28, S1:33, S1:160
- Molecular control of nephrogenesis, renal dysplasia and, 538-539
- Monocytes/macrophages
- in GN, 87-88
 - see also* Peripheral blood monocytes
- Mononuclear cells, *see* Monocytes/macrophages
- Morbidity
- in dialysis patients, global trends in, S4:5-31
 - with ESRD, impact of ER on, 278-283
 - see also* Comorbidity and specific conditions
- Morbidity and Mortality Meeting (Dallas, 1989), progress since, S4:6-8
- Morphology of mesothelial cells in CAPD effluent in ESRD patients, 946-952
- Mortality
- with CVVH and/or HD after OHT, 290-294
 - due to CABG, S3:188
 - due to DM in general population, S3:90-91
 - of FSGS, 75
 - and national death rates, S1:74-75, S1:79
 - and posttransplantation ATN, 988
 - see also* Mortality of dialysis patients, global trends in outcomes; Mortality of ESRD patients, USRDS 1998 ADR on; Mortality of ESRD patients on HD and/or PD
- Mortality, cause(s) of ESRD patients', USRDS 1998 ADR on, S1:15-16, S1:81-88, S1:155-156
- analytical methods used to determine, S1:81-82, S1:143, S1:155-157
 - among HD and PD patients, S1:82-85
 - in pediatric patients, S1:107
 - among RTRs, S1:85-86
 - withdrawal from dialysis as, S1:86-87
- Mortality of dialysis patients, global trends in outcomes, S4:5-31
- compared with 1989 meeting, S4:6-8
 - introduction, S5
 - measures of dialysis dose and, S4:16-31
- Mortality of ESRD patients, USRDS 1998 ADR on, S1:10, S1:14-15, S1:69-80
- adjusted death rates, S1:75-76, S1:153-154
 - first-year death rates, S1:70-74
 - hospitalization and, S1:143, S1:155-157
 - of pediatric patients, S1:107
 - SMR and, *see* Standard Mortality Ratio
 - by year since diagnosis, S1:76-77
 - see also* Death rates of ESRD patients, USRDS 1998 ADR on; Mortality, cause(s) of ESRD patients', USRDS 1998 ADR on
- Mortality of ESRD patients on HD and/or PD
- effects of high-flux biocompatible membranes on, 338-343
 - HCV infection and, 629-634
 - IL-6 as predictor of hypoalbuminemia, hypocholesterolemia and, 107-114
 - USRDS 1998 ADR on causes of, S1:82-85
 - see also* Mortality of ESRD patients, USRDS 1998 ADR on; Mortality of ESRD patients on HD and/or PD with CVD
- Mortality of ESRD patients on HD and/or PD with CVD, 870
- HTN, S3:128
 - malnutrition and, 834-841
- MPA (maximal planar area) of glomerular tuft, donor's race and, 43-46
- MPGN, *see* Membranoproliferative glomerulonephritis type I; Membranoproliferative glomerulonephritis type III
- mRNA (messenger ribonucleic acid)
- down-regulated CHIF, in hyperkalemia of ATN, 600-604
 - IGFBP, in early diabetic renal hypertrophy, 1000-1010, 6:E6
 - PB monocyte ET-1, effects of hemoperfusion with PMX-F on, in sepsis, 953-961
- MRSA (methicillin-resistant *Staphylococcus aureus*) infections, *see* Cefazolin in ESRD patients on HD
- MTHFR (5,10-methylenetetrahydrofolate reductase), *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
- Multicystic renal dysplasia, defined, 536-537
- Multidose recombinant human erythropoietin (rHuEPO) for ESRD patients on HD versus single-dose formulation, pain with, 470-474

- Multivariate risk profiles for CVD in general population, S3:61-62
- Muscular symptoms in HD for ESRD, effects of L-carnitine supplementation on, 258-264
- Mutations, *see specific conditions*
- Myalgias, fever, rash and, with SLE, renal biopsy of, 848-852
- Mycophenolate mofetil (MMF) for lupus nephritis refractory to IV cyclophosphamide, 318-322
- Myeloma cast nephropathy, 4:E1
- Myocardial infarction (MI) in general population
DM and, S3:91-92
and post-MI risk factors for CVD, S3:61
- Myocardial ischemia, DM-associated, in general population, S3:91
- Myofibroblasts, α -SMA in periglomerular, and GN progression, 419-425
- Na (sodium)
dietary, nephrolithiasis and, 804
in ESRD patients on CAPD and/or HD, 455, 708, 710
plasma, AD, AFB, and HCO_3 dialysate effects on, 118
serum, in hyperkalemia of ATN, 601
see also Hyponatremia; Hyponatremia Urinary excretion, Na
- NaCl (sodium chloride), *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension; Salt wasting, and hypouricemia
- National death rates, S1:74-75, S1:79
- National Health and Nutrition Examination Survey (NHANES) III of serum creatinine levels in U.S. population, 992-999
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), USRDS, S1:4
- National Kidney Foundation (NKF)
Research and Training Program of, FLAG:
see also Cardiovascular disease in CRD, NKF Task Force report on control of
- Natriuresis, *see* Urinary excretion, Na
- Natriuretic factor, plasma, urate excretion and, 926-927
- Natural killer (NK) cells, IV alfacalcidol effects on, in ESRD patients on HD, 1036-1040
- NCGN (necrotizing and crescentic glomerulonephritis), CMV-induced, in RTRs, 820-824
- Necrosis, *see* Acute tubular necrosis; Cutaneous necrosis in calciphylaxis
- Necrotizing and crescentic glomerulonephritis (NCGN), CMV-induced, in RTRs, 820-824
- Necrotizing glomerulonephritis (GN), anti-MPO-ANCA, RA and, 5:E6
- Negative acute-phase responses to inflammatory stimuli, hypoalbuminemia and hypocholesterolemia as, in ESRD patients on HD, 107-114
- Negative genetic testing for renal diseases, ethical considerations on, 940
- Nephritic factor (NF)-stabilized convertase, circulating, glomerular deposits with, in MPGN types I and III, 56-63
- Nephritis, *see specific types of nephritis; for example: Glomerulonephritis; Interstitial nephritis*
- Nephrogenesis, molecular control of, 538-539
- Nephrolithiasis
ephedrine, 153-159
and risk of HTN, sex and, 802-807
- Nephrology manpower, and patterns of ESRD care, 551-556, 672-675
- Nephronophthisis (NPH), autosomal recessive, with homozygous deletion of NPH1 gene locus, retinal dystrophy with, 1059-1062, 1084-1085
- Nephrosclerosis, and secondary HPT in HD patients, 240
- Nephrotic syndrome (NS)
Budd-Chiari syndrome during NS relapse in patient with resistance to activated PC clotting inhibitor, 657-660
CRI with and without, hyperlipidemia and, and CVD, 881-882, S3:143-148
FGN, CMT syndrome and, 5:E3
FSGS and, 73
minimal change, *see* Minimal change disease
with persistent microscopic hematuria, renal biopsy of, 1098-1105
remission of, in renal amyloidosis due to RA treated with prednisone and methotrexate, 5:E7
- Nephrotoxicity
of carboplatin, *see* Cisplatin
chronic, due to CsA, arteriopathy and, 247-253; *see also* Cyclosporine
CVD and uremic toxins, research recommendations on, 903-904
of foscarnet therapy for CMV retinitis with AIDS, glomerular crystals and, 392-400, 519-520
of specific analgesics, AN and, 353-356
- Nerves, renal, and pressure natriuresis in aging kidney, 605-610
- Networks
USRDS, and their states, S1:6
see also Networks, ESRD
- Networks, ESRD
census of, S1:146
incidence and prevalence of treated ESRD by, S1:48
patient survival by treatment modality and, S1:54
role in quality activities, S4:177-181, S4:182-189
- Neurectomy, radical renal, for LPHS, 215-220
- NF (nephritic factor)-stabilized convertase, circulating, glomerular deposits with, in MPGN types I and III, 56-63
- NHANES III (third National Health and Nutrition Examination Survey) of serum creatinine levels in U.S. population, 992-999
- Nicotine, *see* Tobacco use
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), USRDS, S1:4
- Nitrates for CAD in general population, S3:104
- Nitric oxide (NO), AFB, AD, and HCO_3 dialysate effects on synthesis of, dialysis hypotension and, 115-124
- Nitrogen, *see* Urea nitrogen
- NK (natural killer) cells, IV alfacalcidol effects on, in ESRD patients on HD, 1036-1040
- NKF, *see* National Kidney Foundation
- NO (nitric oxide), AFB, AD, and HCO_3 dialysate effects on synthesis of, dialysis hypotension and, 115-124
- Nocturnal hemodialysis, renewed interest in, S4:76-82

- Noncompliance, *see* Compliance
- Nondiabetic chronic renal disease, renoprotective effects of antihypertensive drugs in, 9-11
- Nonfunctioning renal transplant, quality of life with, 96
- Nongenomic actions of calcitriol, S2:18, S2:34-35
- Nonimmunosuppressed renal transplant recipients, pregnancy in, 661-663
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus)
- plasma matrix MMP-9 and microalbuminuria in, 544-550, 669-671
 - see also* Non-insulin-dependent diabetes mellitus, CVD and
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), CVD and
- glycemic control in, S3:160-164
 - tobacco use and, S3:173
- Noninvasive diagnosis
- of CAD, S3:101-102
 - see also specific diagnostic techniques*
- Nonmaleficence principle, 680-681
- Nonspecific factors in *P falciparum* malaria, 367
- 19-Nor-1 α ,25(OH) $_2$ D $_2$, *see* Paricalcitol for secondary HPT in ESRD patients on HD
- Normal glomerular function, physiological role of UG in, gene knockout technique and discovery of, 1084-1086, 1106-1120
- Normotensive young adults with ADPKD, LVM and diastolic function in, 970-975
- NPH (nephronophthisis), autosomal recessive, with homozygous deletion of NPH1 gene locus, retinal dystrophy with, 1059-1062, 1084-1085
- NPH1 gene locus, homozygous deletion of, in autosomal recessive NPH with retinal dystrophy, 1059-1062, 1084-1085
- NS, *see* Nephrotic syndrome
- Nuclear receptor coactivators, VDR interactions with, S2:18
- Nutcracker syndrome, gross hematuria and, 3:E3
- Nutrition
- and caloric intake of PD patients, 1019-1022
 - and outcomes in pre-ESRD and ESRD patients, S4:96, S4:97-104, S4:105-112, S4:113-117, S4:118-125, S4:126-130
 - effectiveness of interventions in pre-ESRD and ESRD patients, S4:126-130
 - on CRRTs, 189-190
 - NHANES III, 992-999
 - see also* L-Carnitine supplementation for ESRD patients on HD; Diet; Malnutrition in ESRD patients
- Obesity
- calciophylaxis and, 376-383, 514-518
 - long-term renal function and CsA disposition in 500-pound transplant recipient, 4:E4
 - and weight loss in HTN management, S3:69
- Observational studies, NKF Task Force research recommendations on CVD, 856, S3:12
- of CAD and LVH, 904, S3:194-195
 - of CVD epidemiology, 900-901, S3:117-118
 - of DM, 902, S3:167
 - of homocysteine level, 903, S3:182
 - of HTN, 901, S3:133-134
 - of hyperlipidemia, 902, S3:151-152
 - of menopause, 903, S3:180
 - of physical inactivity, 902-903, S3:177-178
 - of tobacco use, 902, S3:174
- Obstructive renal dysplasia, defined, 537
- Obstructive uropathy, as primary disease in ESRD, ER and, 279
- OCT, *see* 22-Oxacalcitriol
- Ofloxacin, clearance of, with polysulfone and cellulose acetate hemodialyzers, 642-645
- 1 α (OH)D $_2$ (1 α -hydroxyvitamin D $_2$), therapeutic uses of, S2:26-27
- 1 α (OH)D $_3$, *see* Alfacalcidol in ESRD patients on HD
- 1,24(OH) $_2$ D $_3$ (tacalcitol), therapeutic uses of, S2:26, S2:27
- 1,25(OH) $_2$ D $_3$, *see* Calcitriol
- 1,25(OH) $_2$ -24-dihomo-22-ene-D $_3$, therapeutic uses of, S2:35
- 1,25(OH) $_2$ -16-ene-23-yne-D $_3$, therapeutic uses of, S2:26, S2:29
- 1,25(OH) $_2$ -16-ene-23-yne-26,27-hexafluoro-D $_3$, mechanisms for selectivity of, S2:34, S2:35
- therapeutic uses of, S2:26, S2:28-29
- 1,25(OH) $_2$ -24-trihomo-22-ene-D $_3$, therapeutic uses of, S2:35
- OHT (orthotopic heart transplantation), CVVH and/or HD after, 290-294
- OKT3 induction therapy, CsA or, for renal transplantation, coagulation and fibrinolysis following, 575-581
- Older hypertensive patients in general population, HTN management in, S3:73-74
- Organ donations, *see* Donors
- Organ weight, kidney, in CsA-induced arteriopathy subjects, 248
- Organisms
- responsible for peritonitis on CAPD, 625
 - see also specific organisms*
- Organizational structure of USRDS, S1:21-22
- Orthotopic heart transplantation (OHT), CVVH and/or HD after, 290-294
- Osteitis fibrosa cystica, secondary HPT and, S2:3, S2:9, S2:48; *see also* Secondary hyperparathyroidism in ESRD patients on HD
- Osteocalcin in ESRD patients with secondary HPT, 466, 467
- Osteodystrophy, renal, secondary HPT and, S2:3, S2:48; *see also* Secondary hyperparathyroidism in ESRD patients on HD
- Osteomalacia, Fanconi syndrome and severe, due to lambda light chain nephropathy, 6:E3
- Osteoporosis, vitamin D analogues for, S2:30
- Ostial renal artery stenosis (RAS), atherosclerotic, intravascular stent for, 611-622
- Outcome
- of ARF, 191-192
 - of autologous LAK cell therapy of high-grade PTLN, 816
 - of childhood MCNS, early course and, 176-178
 - of combined MN-IgAN, 650
 - of gram-positive and gram-negative peritonitis on CAPD, 623-628
 - of ostial atherosclerotic RAS with intravascular stent, 614-617

- see also Follow-up; Long-term outcome; Mortality; Outcome of CRD with CVD; Outcome of CVD; Outcome of ESRD; Outcomes in pre-ESRD and ESRD; Patient survival
- Outcome of CRD with CVD
in CRI, S3:114, S3:122-124
defined, 859-860, S3:16
in ESRD patients on HD, 869-871, S3:114-116
in ESRD patients on PD, 871-872, S3:116
with HTN, 874-878, S3:122-123, S3:132
with hyperlipidemia, 881-883, S3:144, S3:146-147, S3:150-151
and PTCA of CAD, S3:189
in RTRs, S3:117
- Outcome of CVD
in CRI, S3:113, S3:122
defined, 859-860, S3:15-16
with HTN, S3:127-128, S3:132
with hyperlipidemia, S3:144, S3:146-151
in RTRs, S3:116-117
see also Outcome of CRD with CVD; Outcome of ESRD with CVD
- Outcome of ESRD
impact of ER on, 278-283
with renal transplantation, see Graft survival; Long-term outcome of renal transplantation; Renal transplantation for ESRD, outcome of, USRDS 1998 ADR on
see also Mortality of ESRD patients on HD and/or PD; Outcome of ESRD with CVD; Outcomes in pre-ESRD and ESRD patients; Patient survival with ESRD
- Outcome of ESRD with CVD
in HD patients, 869-871, S3:114-116
in PD patients, 871-872, S3:116
- Outcomes in pre-ESRD and ESRD patients, strategies for influencing (special conference)
anemia and, S4:131-132, S4:133-141, S4:142-146, S4:147-151, S4:152-156, S4:157-160
conclusions, S4:190-193
global trends in morbidity and mortality in dialysis patients, S4:5, S4:6-8, S4:9-15, S4:16-31
introduction, S4:2-4
nutrition and, S4:96, S4:97-104, S4:105-112, S4:113-117, S4:118-125; S4:126-130
quality improvement and, S4:161-164, S4:165-172, S4:173-176, S4:177-181, S4:182-189
quantity of dialysis, solute removal, time, and membranes, S4:32-33, S4:34-38, S4:39-43, S4:44-51, S4:52-57, S4:58-62, S4:63-70, S4:71-75, S4:76-82, S4:83-85, S4:86-87, S4:88-92, S4:93-95
- Overall incidence and prevalence of treated ESRD, USRDS 1998 ADR on, S1:39-42
- 22-Oxalacetic acid [OCT; 22-oxa-1,25(OH)₂D₃]
mechanisms for selectivity of, S2:32
therapeutic uses of, S2:26, S2:28
- Oxidative stress, CVD and, research recommendations on, 903-904
- Oxygen free radicals, contrast nephropathy and, 64-71
- P_{GC} (glomerular capillary hydraulic pressure), antihypertensive drugs and control of, 2-3
- P. falciparum* malaria, see: *Plasmodium falciparum* malaria
- Page disease (hyperreninemic hypertension secondary to subcapsular perinephric hematoma) in PAN, 503-507
- PAI-1 (plasminogen activator inhibitor-1) in hypercoagulable state of NS, 658
- Paid claims, HCFA records of, S1:145-146, S1:160
- Pain
LPHS, renal autotransplantation or radical renal neurectomy for, 215-220
after SC administration of single-dose versus multidose formulation of rHuEPO to HD patients, compared, 470-474
- PAN (polyarteritis nodosa), hyperreninemic HTN secondary to subcapsular perinephric hematoma in, 503-507
- Pancreatic cancer, vitamin D analogues for, S2:26, S2:29
- Parasitized erythrocytes in *P. falciparum* malaria, 362-364
- Parathyroid hormone (PTH)
in calciphylaxis, 379, 386
with LVH, 726
see also Parathyroid hormone in secondary HPT
- Parathyroid hormone (PTH) in secondary HPT
levels of, S2:8-9
see also Parathyroid hormone suppression in secondary HPT; Secondary hyperparathyroidism in ESRD patients on HD
- Parathyroid hormone (PTH) suppression in secondary HPT
with calcitriol, S2:4-5, S2:9
falecalcitriol versus alfacalcidol effects on, compared, 238-246
with paricalcitol, S2:48-54, S2:61-66
- Paricalcitol (19-nor-1 α ,25(OH)₂D₃) for secondary HPT in ESRD patients on HD, S2:1-2, S2:4, S2:25-26
effects of, S2:40-47
HD effects on pharmacokinetics of, S2:55-60
mechanisms of selectivity of, S2:33-35
PTH suppression with, S2:48-54, S2:61-66
therapeutic advantages of, S2:61-66
- Parietal epithelial cells in CG, 962-969
- Partial thromboplastin time, renal biopsy and, 429
- Paternalism in living related organ donations, ethical issues in, 682-683
- Pathology and pathophysiology
of HTN in CRD, S3:121
of *P. falciparum* malaria, 362-369
of schistosomiasis, 4:xlili
see also Pathology and pathophysiology, renal and specific conditions
- Pathology and pathophysiology, renal
atlas of, 1:E1, 2:E1, 3:E1, 4:E1, 5:E1, 6:E1
of calciphylaxis, 387
of hyperkalemia of ATN, down-regulated CHIF mRNA, 600-604
of hypertensive ESRD, 708-709, 722
see also Renal diseases and disorders and specific conditions
- Patient care, patterns of ESRD, 551-556, 672-675
- Patient characteristics, see Age; Body mass and body mass index; Body weight; Educational status; Sex; Race
- Patient exclusion, see Exclusion
- Patient selection for DMMS on medication use, S1:60-61
- Patient Standard Analysis File (SAF), S1:28, S1:33

- Patient survival
 with ESRD, *see* Patient survival with ESRD and Patient survival with pre-ESRD and ESRD
 with FSGS, 76
 with HD for ARF, APACHE II score and, 434-437
- Patient survival with ESRD
 impact of ER on, 278-283
 long-term, with renal transplantation, 101-106
 and noncompliance with HD, 139-145
see also Patient survival with ESRD, USRDS 1998 ADR on
- Patient survival with ESRD, USRDS 1998 ADR on, S1:14-15
 and expected remaining years of life, S1:78-79
 international, S1:140-141
 by networks, S1:54
see also Patient survival with ESRD by treatment modality, USRDS 1998 ADR on
- Patient survival with ESRD by treatment modality, USRDS 1998 ADR on
 analytical methods used for, S1:158-159
 on CAPD and CCPD, S1:54
 long-term, S1:74-75
 pediatric, S1:105-106
 with transplantation, S1:54, S1:89-90, S1:93-94, S1:105-106, S1:159
- Patient survival with pre-ESRD and ESRD
 status of HD adequacy in US and improved, S4:39-43
 trends in HD patients in US, S4:34-38
 trends in outcomes over last decade, S4:9-15
- Patterns of ESRD care, 551-556, 672-675
- Pauci-immune vasculitides, ANCA test in, 344-349
- PB monocytes *see* Peripheral blood monocytes
- PC, *see* Protein C
- PCR, *see* Protein catabolic rate
- PD, *see* Peritoneal dialysis for ESRD
- Pediatric end-stage renal disease (ESRD), USRDS 1998 ADR on, S1:16-17, S1:98-108
 diabetic, S1:101, S1:102
 Growth and Development Study on, S1:30, S1:33
 hospitalization for, S1:106-107
 incidence of, S1:98-99, S1:101
 mortality causes in, S1:107
 primary disease in, S1:99-103
 treatment modalities for, *see* Hemodialysis for pediatric ESRD, USRDS 1998 ADR on; Peritoneal dialysis for pediatric ESRD, USRDS 1998 ADR on; Renal transplantation for pediatric ESRD, USRDS 1998 ADR on
- Pediatric patients
 with FSGS, long-term outcome of, 72-79
 MCNS in, outcome and early course of, 176-178
 with MN, circulating antibodies to 58-kD TIN antigen, anti-tubular basement membrane nephritis and, 1068-1074
see also Pediatric end-stage renal disease, USRDS 1998 ADR on; Renal transplantation for pediatric ESRD
- Peptide, C-, in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 460
- Percutaneous renal biopsy, manual and automated, 426-431
- Percutaneous transluminal coronary angioplasty, *see entries beginning with terms*: Coronary artery revascularization
- Performance measures, and clinical practice guidelines in ESRD, S4:173-176
- Periglomerular myofibroblasts, α -SMA in, and GN progression, 419-425
- Perinephric hematoma, *see* Perirenal hematoma
- Peripheral blood (PB) monocytes (mononuclear cells)
 AD, AFB, and HCO₃ dialysate effects on, 119-120
 eicosanoid synthesis in, as marker of disease activity in lupus nephritis, 778-784
 ET-1 mRNA in, in sepsis, effects of hemoperfusion with PMX-F on, 953-961
- Peripheral vascular disease
 in diabetic ESRD patients on PD, rHuEPO and, 488-493
 in hypertensive general population, effects of, on antihypertensive drug selection, S3:72-73
- Perirenal (perinephric) hematoma
 due to renal biopsies, 426-431
 subcapsular, in PAN, hyperreninemic HTN secondary to, 503-507
- Peritoneal dialysis (PD) for ESRD
 catheter-related infections on, silver ring device in prevention of, 752-760
 changes in demographics and prescription of, S4:44-51
 changes in dose of, effect on outcome, S4:52-57
 delivered dose and membrane transport, S4:58-62
 IV infusion total iron dose in patients on, 1086-1090
 malnutrition in patients on, 1.1% amino acid solution for, 761-769
 mortality on, *see* Mortality of ESRD patients on HD and/or PD
 patient ratings of, 284-289
 patterns of care on, 551-556
 trends over last decade, S4:9-15, S4:190
 unresolved issues, S4:190
 VRE and, 415-418
see also Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Diabetic end-stage renal disease, CAPD, HD, and/or PD for; Hypertensive end-stage renal disease, CAPD, HD, and/or PD for; Peritoneal dialysis for ESRD, CVD in, NKF Task Force report on; Peritoneal dialysis for ESRD, USRDS 1998 ADR on; Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
- Peritoneal dialysis (PD) for ESRD, CVD in, NKF Task Force report on
 diabetic ESRD, glycemic control of, 887, S3:166
 epidemiology of CVD in, 871-872, S3:116
 homocysteine level and, S3:180, S3:181
 HTN and, 877-878, S3:129, S3:131-132
 hyperlipidemia and, 883, S3:149-150
 physical inactivity and, S3:175
 research recommendations on, 899-900, S3:117-118
- Peritoneal dialysis (PD) for ESRD, USRDS 1998 ADR on
 causes of mortality on, S1:82-85
 data for analysis of, S1:52
 described, S1:51-52
 and DMMS data on medication use, S1:62
 by facilities, S1:134
 history of, S1:50
 international use of, S1:138-139

- patient survival on, S1:54, S1:105-106
 trends in utilization of, S1:52-55
 utilization of, by age, sex, race, and primary disease, S1:56-58
see also Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1998 ADR on; Continuous cycling peritoneal dialysis for ESRD, USRDS 1998 ADR on; Peritoneal dialysis for pediatric ESRD, USRDS 1998 ADR on
- Peritoneal dialysis (PD) for pediatric ESRD, USRDS 1998 ADR on, S1:103-104
 patient survival with, S1:105-106
- Peritoneal Dialysis-Core Indicators Report (1996), 1:E3
- Peritoneal fibrosis (PF), and CAPD for ESRD, 946-952
- Peritoneal membrane, improving outcomes in PD patients, S4:58-62
- Peritoneal sclerosis (PS), and CAPD for ESRD, 946-952
- Peritonitis on CAPD
 Continuous Ambulatory Peritoneal Dialysis and Peritonitis Rates Study of 1998 USRDS, S1:29-30, S1:33
 outcome of gram-positive and gram-negative, 623-628 SEP, 946-952
- Permeability of glomerular capillary albumin in steroid-resistant FSGS, 230-237
- Permselectivity, glomerular, in SCA, 208-214
- Persistent microscopic hematuria, NS with, renal biopsy of, 1098-1105
- Persistent ultrafiltration
 for dilated uremic cardiomyopathy in ESRD patients on HD, 664-668
see also slow continuous ultrafiltration
- PF (peritoneal fibrosis), and CAPD for ESRD, 946-952
- PGE₂ (prostaglandin E₂), synthesis of, in PB monocytes, as marker of disease activity in lupus nephritis, 778-784
- PGHS (prostaglandin endoperoxide synthetase), as marker of disease activity in lupus nephritis, 778-784
- pH
 AD, AFB, and HCO₃ dialysate effects on, 118
 GI, influence of, on phosphate binder disintegration of, 808-812
- Pharmacokinetics
 of ofloxacin, 642-645
 of paricalcitol, HD effects on, S2:55-60
see also specific drugs
- Phenacetin, nephrotoxicity of, 355-356
- Phenotype
 CF and phenotypic expression of ADPKD, 976-983, 1081-1083
 changes in mesangial cell, in IgAN, 146-152
 lymphocyte phenotyping in HD patients, effects of IV alfacalcidol on, 1036-1040
 phenotypic features of hyperplastic epithelial cells in CG, 962-969
- PHM-5, as marker for epithelial cells in CG, 962-969
- Phosphate, *see* Pi
- Phosphorus
 balance of Ca and, DMMS on use of medications to maintain, S1:65
 in malnourished ESRD patients on CAPD, HD, and/or PD, 458, 764
- Physical inactivity, and CVD in CRD, NKF Task Force report on, 855, 888-890, S3:11, S3:174-178
 of diabetic CRD patients, S3:162
 of ESRD patients on HD, S3:174-176
 introduction to, 890, S3:174
 research recommendations on, 902-903, S3:177-178
- Physical inactivity, and CVD in general population
 epidemiology of CVD and, S3:59-60
 hyperlipidemic, beneficial effects of physical activity on, S3:85-87
- Physical rehabilitation, and exercise training for ESRD patients on CAPD, 1011-1018
- Physician specialty, Medicare expenditures by, USRDS 1998 ADR on, S1:128-131
- Physicochemical characteristics of UG, 1107-1108
- Physiological role of UG in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120
- Pi (phosphate)
 metabolism of, in calciphylaxis, 379-380
 pyridoxal-5'-, *see* Homocysteine, vitamin B₆, folate, MTHFR and
see also Hyperphosphatemia in ESRD patients on HD; Hypophosphatemia; Pi binders; Serum Pi in ESRD patients on HD
- Pi (phosphate) binders for hyperphosphatemia of ESRD, effects of GI pH on disintegration of, 808-812
- PKD (polycystic kidney disease), *see* Autosomal dominant polycystic kidney disease; Polycystic kidney disease, as primary disease in ESRD
- PKK (prekallikrein), posttransplantation coagulation and fibrinolysis and, 576
- Planar area, maximal glomerular tuft, donor's race and, 43-46
- Plasma β_2 (beta₂)-microglobulin (β_2 -m), clearance of, with reused HD dialyzers, 298
- Plasma cell dyscrasias, renal biopsy of, 529-532
- Plasma endothelin-1 (ET-1) in sepsis, effects of hemoperfusion with PMX-F on, 953-961
- Plasma exchange, *see* Plasmapheresis
- Plasma glucose, and early diabetic renal hypertrophy, 1002
- Plasma glycoalbumin, ristocetin-induced platelet agglutination and, in ESRD patients on HD, 132-138
- Plasma leptin, effects of high-flux HD on concentrations of, 1031-1035
- Plasma lipids in ESRD patients on HD, effects of L-carnitine supplementation on, 262
- Plasma matrix metalloproteinase-9 (MMP-9), and microalbuminuria in NIDDM, 544-550, 669-671
- Plasma Na (sodium), AD, AFB, and HCO₃ dialysate effects on, 118
- Plasma natriuretic factor, urate excretion and, 926-927
- Plasma proteins in SCA, 210
- Plasma renin activity (PRA)
 and ATN-induced DGF, 987
 in CsA-induced arteriopathy subjects, 248
 mineralocorticoid effects on, 48
 reversible renin-aldosterone axis suppression after unilateral adrenalectomy for adrenal adenoma and, 160-163
 in screening for RAS, 842-844, 846

- Plasma urea, AD, AFB, and HCO_3 dialysate effects on, 118
- Plasmapheresis (plasma exchange), 309-317
 for cisplatin-induced HUS, 314-317
 effects of, on infective endocarditis-induced CGN, 309-313
 for steroid-resistant FSGS, 230-237
- Plasminogen
 in hypercoagulable state of NS, 658
 posttransplantation coagulation and fibrinolysis and, 577
- Plasminogen activator, *see* Tissue plasminogen activator
- Plasminogen activator inhibitor-1 (PAI-1) in hypercoagulable state of NS, 658
- Plasmodium falciparum* (*P. falciparum*) malaria, 361-375
 pathophysiology of, 362-369
 renal disorders related to, 361-362
 therapy of, 369-370
- Platelet(s)
 plasma glycolalcin and ristocetin-induced agglutination of, in ESRD patients on HD, 132-138
 see also Antiplatelet therapy of CAD, NKF Task Force report on; Coagulation
- PLP (pyridoxal-5'-phosphate), *see* Homocysteine, vitamin B_{12} , vitamin B_6 , folate, MTHFR and
- PMMIS (Program Management and Medical Information System), S1:144
- PMX-F (polymyxin B-immobilized fiber), effects of hemoperfusion with, on plasma ET-1 and PB monocyte ET-1 mRNA in sepsis, 953-961
- Podocytes in CG, 962-969
- Poisoning, CRRTs for, 192-193
- Polyangiitis, microscopic, ANCA test in, 344-349
- Polyarteritis nodosa (PAN), hyperreninemic HTN secondary to subcapsular perinephric hematoma in, 503-507
- Polyclonal IgG (immunoglobulin G) deposition disease, 328-333
- Polycystic kidney disease, *see* Autosomal dominant polycystic kidney disease; Polycystic kidney disease, as primary disease in ESRD
- Polycystic kidney disease (PKD), as primary disease in ESRD
 and ATN-induced DGF, 986
 calciophylaxis and, 386
 catheter-related infections and, 755
 ER and, 279
 and exclusion from renal transplantation, 568
- Polymorphism
 I/D, of intron 16 of ACE gene in LVH with ESRD, 725-730
 of VDR gene in secondary HPT of ESRD patients on HD, 461-469, S2:14
- Polymyxin B-immobilized fiber (PMX-F), effects of hemoperfusion with, on plasma ET-1 and PB monocyte ET-1 mRNA in sepsis, 953-961
- Polysulfone hemodialyzers
 for chronic HD of ESRD patients on cefazolin therapy, 401-409
 ofloxacin clearance with, 642-645
- Population, *see* General population; Population in USRDS 1998 ADR
- Population in USRDS 1998 ADR
 census of, as base for computing incidence and prevalence of treated ESRD, S1:150-151
 general, expected remaining years of life of, S1:78-79
 standard, for adjustment, S1:11, S1:144
- Portal cavernoma, NS and, 657-660
- Positive genetic testing for renal diseases, ethical considerations on, 940-941
- Postmenopausal hormone therapy, *see* Hormone replacement therapy
- Postmyocardial infarction (MI) risk factors for CVD in general population, S3:61
- Posttransplantation lymphoproliferative disorder (PTLD), high-grade, autologous LAK cell therapy of, 813-819
- Potassium, *see* K
- PRA, *see* Plasma renin activity
- Prealbumin in malnourished ESRD patients
 1.1% amino acid PD solution effects on, 765, 766
 rhGH therapy and, 455, 458
- Prednisone, amyloidosis due to RA treated with methotrexate and, remission of NS due to, S:E7
- Pre-ESRD patients
 strategies for influencing outcomes in ESRD and (special conference), S4:1-193
 nutrition interventions in, S4:126-130
- Pregnancy in RTRs
 in long-term renal transplant survivors, 104
 in nonimmunosuppressed recipients, 661-663
- Prekallikrein (PKK), posttransplantation coagulation and fibrinolysis and, 576
- Prescribed dialysis dose, *see* Delivered dialysis dose
- Pressure natriuresis in aging kidney, renal nerves in, 605-610
- Prevalence
 of AN, 352-353
 of DM in general population, S3:89-90
 of tobacco use in CRD, S3:173
 see also Incidence and prevalence of treated ESRD, USRDS 1998 ADR on; Prevalence of CVD; Prevalence of HTN; Prevalence of hyperlipidemia and specific conditions
- Prevalence of CVD
 in CRI, S3:112-113
 in ESRD patients on HD, S3:114
 in ESRD patients on PD, S3:116
 in RTRs, S3:116
- Prevalence of HTN, 706, 874, 876, 878
 in CRI, S3:121-122
 in ESRD patients on HD, S3:125-127
 in ESRD patients on PD, S3:129, S3:131-132
 in RTRs, S3:132
- Prevalence of hyperlipidemia, 881-883
 in CRI with and without NS, S3:143-144, S3:146
 in ESRD patients on HD, S3:148
 in ESRD patients on PD, S3:149
 in RTRs, S3:150
- Prevention
 of catheter-related infections on PD with silver ring device, 752-760
 UG and, of glomerulopathy due to Fn deposition, 1084-1086, 1106-1120

- see also entries beginning with terms:* Primary and secondary prevention
- Previously transplanted patients in USRDS 1998 ADR, S1:155
- Primary care, dialysis patients' ratings of, 284-289
- Primary disease in ESRD, *see* Primary disease in ESRD, USRDS 1998 ADR on *and specific conditions; for example:* Glomerulonephritis, as primary disease in ESRD
- Primary disease in ESRD, USRDS 1998 ADR on, S1:11, S1:12
- DMMS data on medication use by, S1:62
- first-year death rates and, S1:73
- incidence and prevalence of treated ESRD by, S1:40, S1:43-47
- patient survival by, S1:54
- in pediatric ESRD, S1:99-103
- utilization of RRT modalities by, S1:56-58
- see also* Diabetic end-stage renal disease, USRDS 1998 ADR on
- Primary and secondary prevention of CVD in CRD, NKF Task Force report on, 856-857
- see also* Cardiovascular disease in CRD, NKF Task Force report on control of; Evidence for primary and secondary prevention of CVD, NKF Task Force report on *and specific conditions; for example:* Left ventricular hypertrophy in CRD, NKF Task Force report on
- Primary and secondary prevention of CVD in general population, NKF Task Force report on
- of CAD, S3:105
- implications of epidemiological data for, S3:62
- see also specific conditions; for example:* Coronary artery disease in general population, NKF Task Force report on
- Privacy, legislation on genetic, 941
- Procainamide-induced lupus nephritis in absence of extrarenal disease, 698-702
- Products, USRDS, S1:11-13
- on Internet World Wide Web, S1:23, S1:25
- new, S1:20
- see also specific USRDS products*
- Prognosis
- of ARF requiring HD with APACHE II, 432-443
- see also* Outcome
- Program Management and Medical Information System (PMMIS), S1:144
- Progression
- GN, periglomerular myofibroblast α -SMA and, 419-425
- to renal failure in ADPKD, S:i-iii
- see also* Course and specific conditions
- Proposal, research, S1:36
- Prostaglandin E₂ (PGE₂), synthesis of, in PB monocytes, as marker of disease activity in lupus nephritis, 778-784
- Prostaglandin endoperoxide synthetase (PGHS), as marker of disease activity in lupus nephritis, 778-784
- Prostate cancer, vitamin D analogues for, S:26, S2:29
- Protein(s)
- CFTR, ADPKD and, 976-983, 1081-1083
- Clara cell 10-kD, 1084-1086, 1106-1120
- IGFBP mRNA in early diabetic renal hypertrophy, 1000-1010, 6:E6
- plasma, in SCA, 210
- see also* Protein C; Protein catabolic rate; Protein, dietary; Proteinuria; Serum protein(s); Total protein in malnourished ESRD patients
- Protein C (PC)
- posttransplantation coagulation and fibrinolysis and, 577
- resistance to activated clotting inhibitor of, Budd-Chiari syndrome during NS relapse and, 657-660
- Protein, C-reactive, *see* C-reactive protein
- Protein-calorie malnutrition, systemic inflammatory response syndrome and, S4:113-117
- Protein catabolic rate (PCR)
- in ARF patients on CRRT, 444-453
- see also* Protein catabolic rate in ESRD patients on HD and/or CAPD
- Protein catabolic rate (PCR) in ESRD patients on HD and/or CAPD
- exercise effects on, 1014
- in malnourished patients, rhGH therapy and, 455
- Protein, dietary, and energy requirements in ESRD patients, S4:97-104
- Proteinuria
- in CG, 963
- in combined MN-IgAN, 650, 654
- and coronary angiography with contrast medium, 66
- in FSGS, 74-75, 234
- in GN, 420
- interaction of hyperglycemia and, in atherogenesis in diabetic CRD patients, S3:159-160
- in RTRs, *see* Proteinuria in RTRs
- see also* Microalbuminuria in DM; Urinary excretion, protein
- Proteinuria in RTRs
- in long-term survivors, 102-103, 105
- pregnant, 662
- and recurrent type I MPGN and CTG, 583, 584
- Prothrombin time (PT)
- in hypercoagulable state of NS, 658
- posttransplantation coagulation and fibrinolysis and, 576
- renal biopsy and, 427, 429
- Proximal calciphylaxis, *see* Calciphylaxis, ESRD and
- PS (peritoneal sclerosis), and CAPD for ESRD, 946-952
- Pseudoephedrine nephrolithiasis, 153-159
- Psoriasis, vitamin D analogues for, S2:27-28
- Psychiatric medications, DMMS on use of, S1:67-68
- Psychosocial factors in CVD, NKF Task Force research recommendations on, 903-904
- Psychosocial relationships, quality of life and, of CRI patients, 557-566
- PT, *see* Prothrombin time
- PTCA (percutaneous transluminal coronary angioplasty), *see* entries beginning with terms: Coronary artery revascularization
- PTH, *see* Parathyroid hormone
- PTLD (posttransplantation lymphoproliferative disorder), high-grade, autologous LAK cell therapy of, 813-819
- Pulmonary-renal syndrome, FGN in renal allograft and, 5:E4
- Purpura, *see* Thrombocytopenic thrombotic purpura

- Pyrazinamide, effects of, on urate transport, 919-920
- Pyridoxal-5'-phosphate, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
- Quality improvement, in pre-ESRD and ESRD
 clinical practice guidelines and performance measures, S4:173-176
 continuous, role of networks, USRDS, and facility-specific reports, S4:182-189
 data management to understand outcomes and trends, S4:165-172
 introduction to, S4:161-164
 role of external oversight in, S4:177-181
 strategies for, in pre-ESRD and ESRD patients (special conference), S4:161-189
- Quality of care, HD and PD patients' ratings of, 284-289
- Quality of life (QOL)
 of ESRD patients on CAPD, exercise effects on, 1011-1018
 during and between HD, role of L-carnitine supplementation on, 265-272
 psychosocial relationships of CRI patients and, 557-566
 renal transplantation and changes in, 93-100
 trends in outcomes over last decade, S4:9-15
- Quantity of dialysis
 consensus report on time and, S4:86-87
 impact on outcomes, S4:32-33
 see also Adequacy of dialysis and Dialysis dose
- RA (rheumatoid arthritis), *see* Immunosuppression in RA
- Race
 age and, *see* Age, race and
 of ARF patients, 733, 735
 of combined MN-IgAN patients, 650
 of CRD patients with CVD, mortality and, 870
 of ESRD patients, *see* Race of ESRD patients, USRDS
 1998 ADR on; Race of ESRD patients on CAPD, HD, and/or PD
 and exclusion from renal transplantation, 568, 570
 and HTN, *see* Race, and HTN
 impact of kidney donors', on glomerular size, 43-46
 NHANES III of serum creatinine levels by, 992-999
 of OHT recipients, 291
 of RTRs, 102, 103, 772
- Race, and HTN
 CrCl measuring GFR in black patients, 32-42
 with normal renal function in general population, recommendations for HTN management, S3:74-75
- Race of ESRD patients, USRDS 1998 ADR on, S1:11, S1:12
 and access to transplantation, S1:16, S1:92-93, S1:105
 and DMMS data on medication use, S1:62
 expected remaining years of life by, S1:79
 first-year death rates and, S1:72-73
 incidence and prevalence of treated ESRD by, S1:40, S1:43-47, S1:151, S1:152
 Medicare expenditures by, S1:127, S1:128
 of pediatric ESRD patients, incidence by, S1:101, S1:102
 quality of care ratings and, 286, 287
 utilization of RRT modalities by, S1:56-58
 withdrawal from dialysis and, S1:86, S1:87
- Race of ESRD patients on CAPD, HD, and/or PD
 anemia treatment algorithm and, 637
 AVG thrombosis and stenosis and, 305, 477
 awaiting renal transplantation, 223
 colonization with VRE and, 255, 256
 ER and, 279
 with HIV infection, mortality and, 630, 632
 and noncompliance with HD, 139-145
 with peritonitis, 624
 with secondary HPT on paricalcitol therapy, S2:50
 and survival, 110
 and on rHuEPO therapy, 472
- Radical renal neurectomy for LPHS, 215-220
- Rapidly progressive glomerulonephritis (RPGN)
 ARF and, 735
 and FGN in renal allograft, 5:E4
 as primary disease in ESRD, calciphylaxis and, 386
- RAS, *see* Renal artery stenosis
- Rash, fever, and myalgias with SLE, renal biopsy of, 848-852
- RCC (Renal Community Council), USRDS, S1:22
- REBUS (Renal Beneficiary and Utilization System), S1:144
- Recessive nephronophthisis (NPH), autosomal, with homozygous deletion of NPH1 gene locus, retinal dystrophy with, 1059-1062, 1084-1085
- Recirculation, flawed measurements of, due to intradialytic disequilibrium or recirculation at low flow, 1046-1058, 6:E5
- Recombinant human erythropoietin (rHuEPO) for ESRD patients on CAPD, HD, and/or PD
 AVG thrombosis and stenosis and, 305
 for diabetic patients, *see* Diabetic end-stage renal disease, CAPD, HD, and/or PD for, with rHuEPO therapy
 dialysis dose, membrane type, and anemia control, S4:157-160
 DMMS on use of, S1:65-66
 exercise training and, 1012
 optimal hematocrit in dialysis patients, S4:142-146
 patient outcomes in anemia treatment with, S4:133-141
 rhGH and, for malnourished patients, 455
 role of, in HTN, 709
 subcutaneous, efficacy and economic implications, S4:147-151
 trends in anemia treatment with, S4:133-141
 see also Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD, dose of
- Recombinant human erythropoietin (rHuEPO) for ESRD patients on CAPD, HD, and/or PD, dose of
 mortality and, 110
 pain after SC administration of single-dose versus multidose formulation of, compared, 470-474
 treatment algorithm for dose adjustment, 635-641
- Recombinant human growth hormone (rhGH) for malnourished ESRD patients on CAPD and/or HD, 454-463
- Recombinant tissue plasminogen activator (rTPA) for acute unilateral renal vein and inferior vena cava thrombosis, 1075-1079
- Recurrent fulminant anti-glomerular basement membrane (GBM) glomerulonephritis (GN) in RTRs, 323-327

- Recurrent membranoproliferative glomerulonephritis (MPGN) type I, posttransplantation, differences between recurrent CTG and, 582-588
- Red blood cells, *see entries beginning with element*; Erythro-Referral, impact of early, for ESRD, on dialysis, health care costs, and outcome, 278-283
- Reflux nephropathy, and exclusion from renal transplantation, 568
- Refractory hypertension (HTN) in ESRD, management of, 712
- Regurgitation, mitral and tricuspid, in ESRD patients on HD, 664-668
- Rehabilitation, physical, and exercise training by ESRD patients on CAPD, 1011-1018
- Reimbursement
obstacle to achieving adequate dialysis dose, S4:93-95
- Reinforced intradermal hepatitis B (ID HBV) vaccination of ESRD patients on HD, antibody response to IM and SC vaccination compared with, 1041-1045
- Rejection, *see* Acute graft rejection
- Relapse, NS, Budd-Chiari syndrome during, and resistance to activated PC clotting inhibitor, 657-660
- Release of USRDS data, S1:35, S1:36-37
- Remaining years of life, expected, of ESRD patients, USRDS 1998 ADR on, S1:78-79, S1:159
- Remission
FSGS, 73
of NS in renal amyloidosis due to RA treated with prednisone and methotrexate, 5:E7
- Renal amyloidosis, *see* Amyloidosis
- Renal artery stenosis (RAS)
atherosclerotic ostial, intravascular stent for, 611-622
screening for, 842-851
- Renal autotransplantation for LPHS, 215-220
- Renal Beneficiary and Utilization System (REBUS), S1:144
- Renal biopsy
of childhood MN, 1070
of combined MN-IgAN, 651
of GN, 82, 179-184
of nephrotic syndrome with persistent microscopic hematuria, 1098-1105
percutaneous manual and automated, 426-431
of plasma cell dyscrasias, 529-532
of procainamide-induced lupus nephritis, 698-702
of SLE with rash, fever, and myalgias, 848-852
of steroid-resistant FSGS, 233
see also Histology and histopathology
- Renal Community Council (RCC), USRDS, S1:22
- Renal diseases and disorders
with *P falciparum* malaria, 361-362
in schistosomiasis, 4:xliv-xlv
see also Pathology and pathophysiology, renal and specific conditions
- Renal dysplasia, 535-543
defined, 535-538
mechanisms of, 539-541
molecular control of nephrogenesis and, 538-539
- Renal failure
ADPKD and progression to, 5:ii-iii
deafness and, in BOR syndrome, 334-337
familial HUS, TTP and, 1063-1067
hyperuricemia and, 928-929
see also Acute renal failure; Chronic renal failure
- Renal function
with atherosclerotic ostial RAS, effects of intravascular stent on, 611-622
in CRF, Cr measurement of, 23-31
long-term, and CsA disposition in 500-pound transplant recipient, 4:E4
of long-term renal transplant survivors, 102-103
normal, *see* Hypertension in general population with normal renal function, CVD prevention in
recovery of, with HD for ARF, APACHE II score and, 434, 437-438
and serum creatinine levels in NHANES III, 992-999
and tubulointerstitial mast cell infiltration, 595
see also Renal insufficiency and specific aspects of renal function
- Renal hemodynamics
and glomerular permselectivity in SCA, 210
in *P falciparum* malaria, 367-369
stability of, with slow continuous ultrafiltration, 188-189
- Renal hypertrophy, early diabetic, IGFBP mRNA in, 1000-1010, 6:E6
- Renal insufficiency
chronic, *see* Chronic renal insufficiency
in GN, 82
- Renal nerves, and pressure natriuresis in aging kidney, 605-610
- Renal neurectomy, radical, for LPHS, 215-220
- Renal osteodystrophy, secondary HPT and, S2:3, S2:48; *see also* Secondary hyperparathyroidism in ESRD patients on HD
- Renal pathology, *see* Pathology and pathophysiology, renal
- Renal protective actions of antihypertensives, *see* Antihypertensive drugs, renal protective actions of
- Renal replacement therapies (RRTs)
cell therapy and tissue engineering for, 6: FLAG;
see also Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Continuous renal replacement therapy(ies); Hemodialysis; Peritoneal dialysis for ESRD; Renal replacement therapies for ESRD, USRDS 1998 ADR on; Renal transplantation for ESRD
- Renal replacement therapies (RRTs) for ESRD, USRDS 1998 ADR on
analytical methods applied to, S1:160
Modality Sequence SAF, S1:28, S1:33, S1:160
options in, S1:50-52; *see also* Hemodialysis for ESRD, USRDS 1998 ADR on; International renal replacement therapy modality(ies) for ESRD, USRDS 1998 ADR on; Peritoneal dialysis for ESRD, USRDS 1998 ADR on; Renal transplantation for ESRD, USRDS 1998 ADR on
outcome of, *see* Mortality of ESRD patients, USRDS 1998 ADR on; Patient survival with ESRD, USRDS 1998 ADR on
summary on, S1:13-14
utilization of, S1:52-58
see also Incidence and prevalence of treated ESRD, USRDS 1998 ADR on
- Renal-retinal syndromes, 1059-1062

- Renal salt wasting, and hypouricemia, 924-925
- Renal transplantation for ESRD, 93-106, 215-219, 813-824
 AF in patients awaiting, 221-229
 and autologous LAK cell therapy of high-grade PTLD, 813-819
 CMV-induced necrotizing and crescentic GN in recipients of, 820-824
 de novo minimal change disease and, 508-513
 evaluation of candidates to, 567-574
 and FGN in renal allograft, 5:E4
 outcome of, *see* Acute graft rejection; Graft function; Graft survival; Long-term outcome of renal transplantation; Renal transplantation for ESRD, outcome of, USRDS 1998 ADR on
 pregnancy and, *see* Pregnancy in RTRs
 quality of life changes and, 93-100
 recurrent fulminant anti-glomerular basement membrane GN, 323-327
 recurrent MPGN type I and CTG after, differences between, 582-588
 risk factors in, *see* Risk factors in renal transplantation
 trends in outcomes over last decade, S4:9-15
see also Diabetic end-stage renal disease, renal transplantation for; Immunosuppression in renal transplantation; Renal transplantation for ESRD, CVD in recipients of, NKF Task Force report on; Renal transplantation for ESRD, USRDS 1998 ADR on; Renal transplantation for pediatric ESRD
- Renal transplantation for ESRD, CVD in recipients of, NKF Task Force report on
 for diabetic ESRD, glycemic control in, 887-888, S3:166-167
 epidemiology of CVD and, 872, S3:116-117
 homocysteine level and, S3:180-182
 HTN and, 878, S3:132-133
 hyperlipidemia and, 883-884, S3:150-151
 in menopausal RTRs, S3:180
 physical inactivity and, S3:175, S3:176
 research recommendations on, 900, S3:117-118
 and screening for CAD, S3:191, S3:192
- Renal transplantation for ESRD, outcome of, USRDS 1998 ADR on, S1:16
 mortality, S1:85-86
 patient survival with, S1:54, S1:89-90, S1:93-94, S1:105-106, S1:159
see also Graft survival, USRDS 1998 ADR on
- Renal transplantation for ESRD, USRDS 1998 ADR on
 ABO blood group and, S1:93
 access to, *see* Access to renal transplantation, USRDS 1998 ADR on
 annual death rate with, S1:157-158
 causes of mortality in recipients of, S1:85-86
 described, S1: 50-51
 first, S1:144, S1:157, S1:159
 graft survival, *see* Graft survival, USRDS 1998 ADR on
 history of, S1:50
 international, S1:139-140
 kidney supply and, S1:90-91
 Medicare expenditures for, S1:120-122, S1:126, S1:128
 patient survival with, S1:54, S1:89-90, S1:93-94, S1:105-106, S1:159
 previously transplanted patients, S1:155
 Transplant SAF and Transplant Waiting List SAF, S1:29-31, S1:33
 trends in utilization of, S1:52-55
 United Network for Organ Sharing Transplant data, S1:143, S1:146
 utilization of, by age, sex, race, and primary disease, S1:56-57
see also Renal transplantation for ESRD, outcome of, USRDS 1998 ADR on; Renal transplantation for pediatric ESRD, USRDS 1998 ADR on
- Renal transplantation for pediatric ESRD
 due to MN with circulating antibodies to 58-kD TIN antigen and anti-tubular basement membrane nephritis, 1068-1074
see also Renal transplantation for pediatric ESRD, USRDS 1998 ADR on
- Renal transplantation for pediatric ESRD, USRDS 1998 ADR on
 access to, S1:104-105
 graft survival with, S1:106
 number of, S1:104
 patient survival with, S1:105-106
- Renal tubule, *see* Tubule
- Renal vein thrombosis, unilateral, rTPA for, 1075-1079
- Renalin, reuse of dialyzers and clinical outcome, S4:88-92
- Renin, *see* Plasma renin activity; Renin-aldosterone axis; Renin-angiotensin-aldosterone axis
- Renin-aldosterone axis, reversible suppression of, after unilateral adrenalectomy for adrenal adenoma, 160-163
- Renin-angiotensin-aldosterone axis, and HTN in ESRD, 708
- Renovascular disease, as primary disease in ESRD, 279, 709, 755
- Replacement fluid on CRTs, 196-197
- Requests for USRDS data, S1:25-26
- Research, NKF Task Force recommendations on, 856-857, 898-904, S3:12
 on antihypertensive drugs, 904
 on CAD, 904, S3:194-195
 on CRI, 899
 on diabetic CRD, 902, S3:167
 on epidemiology of CVD, 900-901, S3:117-118
 on ESRD patients on HD, 899, S3:117-118
 on ESRD patients on PD, 899-900, S3:117-118
 executive summary of, 856-857, S3:12
 on glycemic control, S3:167
 on homocysteine, 903, S3:182
 on HTN, 901, S3:133-134
 on hyperlipidemia, 902, S3:151-152
 introduction to, 898
 on LVH, 903-904, S3:194-195
 on menopause, 903, S3:180
 on physical inactivity, 902-903, S3:177-178
 on RTRs, 900, S3:117-118
 on screening, 904, S3:194-195
 on thrombogenic factors, 903
 on tobacco use, 902, S3:174
- Research, USRDS 1998 ADR on
 independently supported, S1:27
 investigator-initiated, policy on data release for, S1:33-35

- proposal for, S1:36
 USRDS products available for, *see* Standard Analysis Files, USRDS
- Research and Training Program, NKF, FLAG:
Researcher's Guide to the USRDS Database, USRDS, S1:13, S1:33, S1:160
- Residence of ESRD patients, S1:149
 SAF for, S1:28, S1:33
- Resistance
 to activated PC clotting inhibitor, Budd-Chiari syndrome during NS relapse and, 657-660
 of FSGS to steroids, plasmapheresis for, 230-237
see also Cefazolin in ESRD patients on HD; Vancomycin-resistant enterococci in ESRD patients on chronic HD
- Respect for autonomy principle, 679-680
- Retinal dystrophy, and autosomal recessive NPH with homozygous deletion of NPH1 gene locus, 1059-1062, 1084-1085
- Retinitis, CMV, with AIDS, glomerular crystals due to nephrotoxicity of foscarnet therapy of, 392-400, 519-520
- Reuse of hemodialyzers
 and clinical outcomes, S4:88-92
 dissociation between small and large solute clearance and, 295-301
- Revascularization, *see* Coronary artery revascularization
- Reversible renin-aldosterone axis suppression after unilateral adrenalectomy for adrenal adenoma, 160-163
- Rheumatoid arthritis, *see* Immunosuppression in RA
- rhGH (recombinant human growth hormone) for malnourished ESRD patients on CAPD and/or HD, 454-463
- rHuEPO, *see* Recombinant human erythropoietin for ESRD patients on CAPD, HD, and/or PD
- Ribonucleic acid, *see* mRNA
- RIPA (ristocetin-induced platelet agglutination), plasma glycolalcin and, in ESRD patients on HD, 132-138
- Risk factors
 for ATN-induced DGF, 984-991
 for ESRD in first-degree relatives of ESRD patients, 794-801
 for HTN, nephrolithiasis, sex and, 802-807
see also Risk factors for CVD; Risk factors in renal transplantation
- Risk factors for CVD, 714
 in atherosclerotic ostial RAS, 614
 executive summary of, in NKF Task Force report, 854-856; *see also* specific risk factors; for example: Hyperlipidemia, and CVD in CRD, NKF Task Force report on; Physical inactivity, and CVD in CRD, NKF Task Force report on
- Risk factors in renal transplantation
 for ATN-induced DGF, 984-991
 in long-term renal transplant survivors, 104
 for thrombosis with OKT3 or CsA induction therapy, 575-581
- Ristocetin-induced platelet agglutination (RIPA), plasma glycolalcin and, in ESRD patients on HD, 132-138
- RNA (ribonucleic acid), *see* mRNA
- RPGN, *see* Rapidly progressive glomerulonephritis
- RRTs, *see* Renal replacement therapies
- rTPA (recombinant tissue plasminogen activator) for acute unilateral renal vein and inferior vena cava thrombosis, 1075-1079
- RXR-VDR heterodimerization, S2:17-18
 heterodimer binding to VDR DNA, S2:17-18, S2:20
- S aureus* (*Staphylococcus aureus*) infections, methicillin-resistant, *see* Cefazolin in ESRD patients on HD
- SACs (Scientific Advisory Committees), USRDS, S1:22
- Safety of falecalcitriol and alfacalcidol, 243-244
- Safety of iron treatment, for anemia in ESRD, S4:152-156
- SAFs, *see* Standard Analysis Files, USRDS
- Salt, *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension; Salt wasting, and hypouricemia
- Salt (NaCl)-sensitive hypertension (HTN), and blunted pressure natriuresis in aging kidney, 605-610
- Salt (NaCl) wasting, and hypouricemia
 cerebral, 925-926
 renal, 924-925
- SBP (systolic blood pressure), *see* Blood pressure
- SC (subcutaneous) administration of single-dose versus multidose formulation of rHuEPO to HD patients, pain with, 470-474
- SC HBV (subcutaneous hepatitis B) vaccination, of ESRD patients on HD, antibody response to ID vaccination compared with, 1041-1045
- SCA (sickle cell anemia), glomerular permselectivity in, 208-214
- Schistosomiasis, urinary, 4:xlili-xlvi
- Scientific Advisory Committees (SACs), USRDS, S1:22
- Sclerosing encapsulating peritonitis (SEP), and CAPD for ESRD, 946-952
- Sclerosis
 peritoneal, and CAPD for ESRD, 946-952
see also Glomerulosclerosis
- Screening
 for RAS, 842-851
see also Diagnosis; Screening for CVD in CRD patients, NKF Task Force report on
- Screening for CVD in CRD patients, NKF Task Force report on, S3:191-195
 for CAD, 856, 896-898, 904, S3:12, S3:191-195
 for LVH, 856, 898, S3:12, S3:193-195
- Secondary hyperparathyroidism (HPT) in ESRD patients on HD, S2:3-12
 clinical manifestations of, S2:6-9; *see also* Calciphylaxis, ESRD and
 and hypercalcemia, *see* Hypercalcemia in secondary HPT and hyperphosphatemia, *see* Hyperphosphatemia in ESRD patients on HD with secondary HPT
 therapeutic considerations on, S2:9; *see also* Calcitriol; Secondary hyperparathyroidism in ESRD patients on HD, vitamin D analogue(s) for
see also Vitamin D receptor
- Secondary hyperparathyroidism (HPT) in ESRD patients on HD, vitamin D analogue(s) for, S2:9, S2:25-27
 effects of falecalcitriol versus alfacalcidol on, compared, 238-246
see also Paricalcitol for secondary HPT in ESRD patients on HD

- Secondary prevention of CVD, *see entries beginning with terms*: Primary and secondary prevention
- Selection
- antihypertensive drug, for general population, effects of concomitant diseases on, S3:70-72
 - patient, for DMMS on medication use, S1:60-61
- Selectivity of vitamin D analogues, S2:30-35
- altered binding of VDR and, S2:30-31
 - interaction with serum vitamin D-binding protein and, S2:31-33
 - nongenomic activity mediated by cell-surface receptors, S2:34-35
 - of paricalcitol, S2:33-35
 - vitamin D 24-hydroxylase and metabolism of, S2:33-34
- SEP (sclerosing encapsulating peritonitis), and CAPD for ESRD, 946-952
- Sepsis
- effects of hemoperfusion with PMX-F on plasma ET-1 and PB monocyte ET-1 mRNA in, 953-961
 - see also* Infections; Septic mediators
- Septic mediators, elimination of, on CRRTs, 190-191
- Serum albumin
- in de novo minimal change disease, 511
 - see also* Serum albumin in ESRD patients on CAPD, HD, and/or PD
- Serum albumin in ESRD patients on CAPD, HD, and/or PD
- anemia treatment algorithm and, 637
 - with calciphylaxis, 379
 - factors influencing, S4:118-119
 - and long-term CAPD effects on cardiac function and, 483
 - on PD, catheter-related infections and, 755, 758
 - reinfusion and concentration of ascitic fluid in ESRD cirrhotic patients, 166
- Serum aldosterone in hyperkalemia of ATN, 601
- Serum alkaline phosphatase (ALP) in ESRD patients with secondary HPT, 466, 467, S2:9, S2:63-65
- Serum Ca (calcium) in ESRD patients on CAPD and/or HD
- alfacalcidol effects on lymphocyte phenotyping and, 1037
 - with calciphylaxis, 379
 - with secondary HPT, 241, 242, 466, 467
- Serum calcitonin in HD patients with secondary HPT, 242
- Serum cholesterol in de novo minimal change disease, 511
- Serum creatinine (Cr)
- in ADPKD, 978
 - in combined MN-IgAN, 654
 - coronary angiography with contrast medium and, 67
 - in ESRD patients, *see* Serum creatinine in ESRD patients on CAPD and/or HD
 - in GN, 82, 420, 594
 - in HTN, race and, 35
 - in hyperkalemia of ATN, 601
 - levels of, in U.S. population, NHANES III of, 992-999
 - in NIDDM, 545
 - in RTRs, *see* Serum creatinine in RTRs
- Serum creatinine (Cr) in ESRD patients on CAPD and/or HD
- anemia treatment algorithm and, 637
 - and ATN-induced DGF, 987, 988
 - and long-term CAPD effects on cardiac function, 483
- Serum creatinine (Cr) in RTRs
- with CsA-induced arteriolopathy, 249
 - de novo minimal change disease and, 511
 - in long-term renal transplant survivors, 103, 105
 - in pregnant RTRs, 662
 - and recurrent type I MPGN and CTG, 583, 584
- Serum K (potassium)
- in hyperkalemia of ATN, 601
 - in malnourished patients on PD, 764
- Serum Na (sodium) in hyperkalemia of ATN, 601
- Serum phosphorus in malnourished patients on PD, 764
- Serum Pi (phosphate) in ESRD patients on HD
- with calciphylaxis, 379
 - with secondary HPT, 241, 242, 466, 467
- Serum protein(s)
- reinfusion and concentration of ascitic fluid in cirrhotic ESRD patients on HD, 166
 - vitamin D-binding, interaction of vitamin D analogues with, S2:31-33
- Serum urea, reinfusion and concentration of ascitic fluid in ESRD cirrhotic patients on HD, 166
- Serum uric acid in malnourished patients on PD, 764
- Session time, *see* Time on CAPD, HD, and/or PD for ESRD
- Severe hyponatremia, CVVHD in treatment of, 829-831
- Severe osteomalacia, Fanconi syndrome and, due to lambda light chain nephropathy, 6:E3
- Sex
- of ADPKD patients, 968, 971
 - of ARF patients, 733, 735
 - of atherosclerotic ostial RAS patients, 613
 - of combined MN-IgAN patients, 650, 654
 - of CRD patients with CVD, mortality and, 870
 - of critically ill patients on CRRT, 1025, 1026
 - of endotoxemic patients, 955
 - of ESRD patients, *see* Sex of ESRD patients, USRDS 1998 ADR on; Sex of ESRD patients on CAPD, HD, and/or PD; Sex of RTRs
 - and exclusion from renal transplantation, 568
 - of FSGS patients, 73, 74
 - of GN patients, 420, 594, 963
 - kidney donor's race and, impact of, on glomerular size, 43-46
 - and nephrolithiasis as risk for HTN, 802-807
 - NHANES III of serum creatinine levels by, 992-999
 - of NIDDM patients, plasma matrix MMP-9 levels and microalbuminuria and, 545
 - of OHT recipients, 291
 - as risk factor for CVD, S3:7
 - of SCA patients, 210
- Sex of ESRD patients, USRDS 1998 ADR on, S1:12
- and DMMS data on medication use, S1:62
 - expected years of life by, S1:79
 - first-year death rates and, S1:73-74
 - incidence and prevalence of treated ESRD by, S1:40, S1:43-47
 - Medicare expenditures by, S1:127, S1:128
 - utilization of RRT modalities by, S1:56-58
- Sex of ESRD patients on CAPD, HD, and/or PD
- alfacalcidol effects on lymphocyte phenotyping and, 1037
 - and antibody response to HBV vaccination, 1043
 - AVG thrombosis and, 477
 - awaiting renal transplantation, 223
 - with calciphylaxis, 378

- cefazolin therapy and, 411
- colonization with VRE and, 255, 256
- ER and, 279
- exercise effects and, 1012
- with HIV infection, mortality and, 632, 634
- and long-term CAPD effects on cardiac function, 483, 486
- with LVH, 726
- of malnourished patients on rhGH therapy, 455
- noncompliance and, 140, 141
- with peritonitis, 624
- PS, SEP and, 947
- quality of care ratings and, 286, 287
- on rHuEPO therapy, 472, 637
- with secondary HPT, *see* Sex of ESRD patients on CAPD, HD, and/or PD with secondary HPT
- and survival, 110
- Sex of ESRD patients on CAPD, HD, and/or PD with secondary HPT
 - on falcocalcetriol and alfacalcidol therapy, 240
 - on paricalcitol therapy, S2:50, S2:58
 - VDR gene polymorphism and, 466, 467
- Sex of RTRs
 - and ATN-induced DGF, 986
 - and changes in quality of life, 95-96
 - frequency and cost of posttransplantation hospitalization with CsA and FK506 and, 772
 - long-term survival and, 102, 103
 - recurrent type I MPGN and CTG, 583, 584
- Short-term renal graft survival, USRDS 1998 ADR on, S1:94-95
- SHR, *see* Standard Hospitalization Ratio
- SI units (Système international d'unités), conversions to, 905
- Sickle cell anemia (SCA), glomerular permselectivity in, 208-214
- Side effects, *see* Adverse effects
- Silver ring device in prevention of catheter-related infections on PD, 752-760
- Single-dose recombinant human erythropoietin (rHuEPO) for ESRD patients on HD versus multidose formulation, pain with, 470-474
- Skin lesions in calciphylaxis, *see* Cutaneous necrosis in calciphylaxis
- SLE, *see* Systemic lupus erythematosus
- Slow continuous ultrafiltration
 - for CHF, 192
 - renal hemodynamic stability and, 188-189
- Slow-flow method of recirculation measurements, 1046-1058, 6:E5
- α -SMA (α -smooth muscle actin) in periglomerular myofibroblasts, GN progression and, 419-425
- Small artery disease, uremic, with medial calcification and intimal hyperplasia, 499-502
- Smoking, *see* Tobacco use
- α (alpha)-Smooth muscle actin (α -SMA) in periglomerular myofibroblasts, GN progression and, 419-425
- SMR, *see* Standard Mortality Ratio
- Social support of CRI patients, quality of life and, 557-566
- Sodium, *see* Na
- Sodium chloride (NaCl), *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension
- Sodium diatrizoate, contrast nephropathy and, 64-71
- Software, SAF, S1:32
- Software experience needed to use SAFs, S1:32
- Solute clearance, dissociation between large and small, with reused HD dialyzers, 295-301
- Sonography, *see* Ultrasound
- Special studies, USRDS, S1:29
- Special Studies Review and Implementation Committee (SSRIC), USRDS, S1:6, S1:22
- Spironolactone, effects of, on TTKG, urinary K/Na ratio, and fractional excretion of K, 47-51
- SSRIC (Special Studies Review and Implementation Committee), USRDS, S1:6, S1:22
- Staggered-tip catheters, recirculation with, 1046-1058, 6:E5
- Standard Analysis Files (SAFs), USRDS, S1:26-35
 - core SAF CD-ROM, S1:28-35
 - see also specific Standard Analysis Files*
- Standard Hospitalization Ratio (SHR), S1:17-18, S1:23-25
 - facility-specific, S1:24-25
 - methodology used with, S1:23-24, S1:114-115
 - by states, S1:115-116
 - time trends in, S1:116-117
- Standard Mortality Ratio (SMR), S1:23-25
 - facility-specific, S1:24-25
 - by state, S1:77-78
- Standard population for adjustment in USRDS 1998 ADR, S1:11, S1:144
- Standard Transplantation Ratio (STR), S1:23-25
- Standardization of rates, *see* Adjustment, rate, in USRDS 1998 ADR
- Staphylococcus aureus* infections, methicillin-resistant, *see* Cefazolin in ESRD patients on HD
- States
 - SMR by, S1:77-78
 - surveyors, role in quality activities in ESRD care, S4:177-181
 - USRDS networks and their, S1:6
- Statistics, USRDS 1998 ADR
 - on graft and patient survival, S1:89-90
 - summary of ESRD, S1:11, S1:12
- Stenosis, *see* Arteriovenous graft, HD, stenosis of; Renal artery stenosis
- Stent, intravascular, for atherosclerotic ostial RAS, 611-622
- Steroid pulse therapy for immunotactoid glomerulopathy with hypocomplementemia, 1:E4
- Steroid-resistant focal segmental glomerulosclerosis (FSGS), plasmapheresis for, 230-237
- Stone disease, *see* Nephrolithiasis
- Stop-flow method of recirculation measurements, 1046-1058, 6:E5
- STR (Standard Transplantation Ratio), S1:23-25
- Stress
 - effects of surgical, on fibrinolysis and coagulation following renal transplantation, 575-581
 - oxidative, CVD and, 903-904
- Striated membranous structure of mesangial type III collagen deposition in IgAN, 146-152
- Structure, UG, 1107-1108
- Subcapsular perinephric hematoma in PAN, hyperreninemic HTN secondary to, 503-507

- Subcutaneous (SC) administration of single-dose versus multidose formulation of rHuEPO to HD patients, pain with, 470-474
- Subcutaneous erythropoietin therapy, efficacy and economic implications, S4:147-151
- Subcutaneous (SC) hepatitis B (HBV) vaccination of ESRD patients on HD, antibody response to ID vaccination compared with, 1041-1045
- Summary statistics on ESRD, USRDS 1998 ADR on, S1:11, S1:12
- Supplementation, *see* L-Carnitine supplementation for ESRD patients on HD and specific vitamins and dietary supplements
- Supplier, medical, Medicare expenditures by type of, USRDS 1998 ADR on, S1:128-131
- Surface area of mesothelial cells in CAPD effluent of ESRD patients, 946-952
- Surgery
of thrombosed vascular access grafts, 168-171
see also Adrenalectomy; Heart transplantation; Renal transplantation for ESRD; Surgical stress
- Surgical stress, effects of, on fibrinolysis and coagulation following renal transplantation, 575-581
- Surveyors, *see* States
- Survival, *see* Patient survival
- Sympathetic activity, HTN in ESRD and increased, 708
- Système international d'unités (SI units), conversions to, 905
- Systemic blood pressure, *see* Blood pressure
- Systemic hemodynamics
in *P. falciparum* malaria, 367-369
see also Blood pressure; Cardiac output; Heart rate
- Systemic inflammatory response syndrome, and protein-calorie malnutrition in ESRD, S4:113-117
- Systemic lupus erythematosus (SLE)
acute EBV infection associated with, 785-793
as primary disease in ESRD, exercise training and, 1012
with rash, fever, and myalgias, renal biopsy of, 848-852
see also Lupus nephritis
- Systolic blood pressure, *see* Blood pressure
- T4 (thyroxine), free, in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 455, 460
- Table salt, *see* Dietary management of HTN with NaCl restriction; Salt-sensitive hypertension; Salt wasting, and hypouricemia
- Tacalcitol [$1,24(\text{OH})_2\text{D}_3$], therapeutic uses of, S2:26, S2:27
- Tacrolimus (FK506), frequency and cost of and of posttransplantation hospitalization with CsA and, compared, 770-777
- Target conditions in NKF Task Force report, S3:5-6
defined, 858-859, S3:14
see also specific conditions; for example: Hypertension, and CVD in CRD, NKF Task Force report on
- Target populations in NKF Task Force report, S3:5-6
defined, 859, S3:14-15
see also specific target populations; for example: Chronic renal insufficiency, CVD and, NKF Task Force report on
- TATc (thrombin-antithrombin complexes), posttransplantation coagulation and fibrinolysis and, 576
- TEE (transesophageal echocardiography) in calciphylaxis, 499-502
- TGF- β (transforming growth factor- β), effects of hemoperfusion with PMX-F on, 953-961
- Therapeutic plasma exchange, *see* Plasmapheresis
- Therapy, *see specific conditions and therapeutic modalities*
- Thrombin-antithrombin complexes (TATc), posttransplantation coagulation and fibrinolysis and, 576
- Thrombocytopenia, heparin-induced, during CRRT, management of, 4:E3
- Thrombocytopenic thrombotic purpura (TTP)
cisplatin-induced, 314-317
familial HUS and, 1063-1067
- Thromboembolic disorders, cryofibrinogenemia and, 494-498
- Thrombogenic factors, and CVD in CRD, 855-856, 903
- Thrombomodulin (TMD), posttransplantation coagulation and fibrinolysis and, 578-579
- Thrombosis
acute unilateral renal vein and inferior vena cava, rTPA for, 1075-1079
risk factors for, with OKT3 or CsA induction therapy for renal transplantation, 575-581
see also Thrombosis of HD vascular access grafts
- Thrombosis of HD AVGs
homocysteine, vitamin B₁₂, vitamin B₆, folate, and MTHFR and, 475-481
management of, with venous pressure-driven protocol, 302-308
- Thrombosis of HD vascular access grafts, 168-175
endovascular management of, 172-175
surgical management of, 168-171
see also Thrombosis of HD AVGs
- Thrombotic purpura, *see* Thrombocytopenic thrombotic purpura
- Thromboxane B₂ (TxB₂), synthesis of, in PB monocytes, as marker of disease activity of lupus nephritis, 778-784
- Thyroid replacement therapy, DMMS data on use of, S1:67
- Thyrotropin (TSH) in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 455, 460
- Thyroxine (T4), free, in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 455, 460
- Time allocation to ESRD patient care, nephrology manpower and, 551-556, 672-675
- Time on CAPD, HD, and/or PD for ESRD
AF and, 223, 225
alfacalcidol effects on lymphocyte phenotyping and, 1037
calciphylaxis and, 378
cardiac function and, 483
consensus report on quantity and, S4:86-87
for diabetic ESRD, peripheral vascular disease and, 489
exercise training effects and, 1012
HD AVG thrombosis and, 477
intradialytic hypotension and, 127
long or short, S4:83-85
with LVH, 726
mortality and, 110
noncompliance and, 140-142
posttransplantation coagulation and fibrinolysis and, 576
PS, SEP and, 947
quality of care ratings and, 286, 287

- rhGH and, 455
 secondary HPT and, 241
 trends in HD, S4:63-70
 Time trends in hospitalization for ESRD, S1:116-117
 TIN (tubulointerstitial nephritis) antigen, 58-kD, circulating antibodies to, in childhood MN with anti-tubular basement nephritis, 1068-1074
 Tissue engineering, cell therapy and, for RRT, 6: FLAG:
 Tissue negative staining of mesangial type III collagen deposition in IgAN, 146-152
 Tissue plasminogen activator (TPA)
 posttransplantation coagulation and fibrinolysis and, 578
 recombinant, for acute unilateral renal vein and inferior vena cava thrombosis, 1075-1079
 TMD (thrombomodulin), posttransplantation coagulation and fibrinolysis and, 578-579
 TNF- α , *see* Tumor necrosis factor- α
 Tobacco use
 and ATN-induced DGF, 986, 987
 and CVD in atherosclerotic ostial RAS, 614; *see also* Tobacco use, and CVD in CRD, NKF Task Force report on
 by diabetic ESRD patients on rHuEPO therapy, peripheral vascular disease and, 489, 490
 and noncompliance with HD, 140, 141
 Tobacco use, and CVD in CRD, NKF Task Force report on, 855, 888, S3:11, S3:172-174
 research recommendations on, 902, S3:174
 α (alpha) Tocopherol (vitamin E), cardioprotective effects of, S3:59
 Total admissions, hospitalization rates based on, USRDS 1998 ADR on, S1:111-114
 Total cholesterol in ESRD patients on CAPD
 exercise effects on, 1014
 long-term CAPD, 483
 Total dose iron (Fe), IV infusion of, in PD patients, 1086-1090
 Total Medicare expenditures for ESRD, USRDS 1998 ADR on (1992-1996), S1:123
 by physician specialty and supplier type, S1:129
 Total protein in malnourished ESRD patients
 1.1% amino acid PD solution effects on, 765, 766
 and rhGH therapy, 455, 458
 Toxicity, *see* Nephrotoxicity
 TPA, *see* Tissue plasminogen activator
 TPE (therapeutic plasma exchange), *see* Plasmapheresis
 Tracking system, BV, during HD, 740-741
 Transcription factor for calcitriol, *see* Vitamin D receptor
 Transcriptional cofactors, calcitriol, regulation of, S2:20
 Transesophageal echocardiography (TEE) in calciphylaxis, 499-502
 Transferrin in malnourished ESRD patients
 1.1% amino acid PD solution effects on, 765, 766
 and rhGH therapy, 455, 458
 Transforming growth factor- β (TGF- β), effects of hemoperfusion with PMX-F on, 953-961
 Transfusions with renal biopsies, 428
 Transitional epithelium of urinary bladder, carboplatin toxicity to, 5:E5
 Transmembrane conductance regulator protein, cystic fibrosis, ADPKD and, 976-983, 1081-1084
 Transplant centers for ESRD, USRDS 1998 ADR on, S1:133
 Transplant Standard Analysis File (SAF), S1:29-31, S1:33
 Transplant Waiting List Standard Analysis File (SAF), S1:29-31, S1:33
 Transplantation
 orthotopic heart, CVVH and/or HD after, 290-294
 see also Renal transplantation for ESRD
 Transportation, patient, obstacle to achieving adequate dialysis dose, S4:93-95
 Transtubular potassium gradient (TTKG), mineralocorticoid effects on urinary K/Na ratio, fractional excretion of K and, 47-51
 Treatment History (Modality Sequence) Standard Analysis File (SAF), S1:28, S1:33, S1:160
 Trends, in ESRD outcomes
 data management to understand, S4:165-172
 for HD patients in US, S4:34-38
 from 1989 to 1998 in HD, S4:63-70
 in demographics and prescription of PD, S4:44-51
 status of HD adequacy in US and, S4:39-43
 see also Global trends
 Tricuspid regurgitation in ESRD patients on HD, 664-668
 Triglycerides, *see* Triglycerides in ESRD patients on CAPD, HD, and/or PD and entries beginning with term: Hyperlipidemia
 Triglycerides in ESRD patients on CAPD, HD, and/or PD
 catheter-related infections on PD and, 755
 exercise effects on, 1014
 on long-term CAPD, 483
 in malnourished ESRD patients on rhGH therapy, 455
 1,25,28-Trihydroxyvitamin D $_3$, therapeutic uses of, S2:35
 γ (gamma)-Trimethyl-ammonium- β -hydroxybutyrate, *see* L-Carnitine supplementation for ESRD patients on HD
 Tru-cut needle, manual renal biopsies with, 426-431
 TSH (thyrotropin) in malnourished ESRD patients on HD and/or CAPD and rhGH therapy, 455, 460
 TTKG (transtubular potassium gradient), mineralocorticoid effects on urinary K/Na ratio, fractional excretion of K and, 47-51
 TTP, *see* Thrombocytopenic thrombotic purpura
 Tubular acidosis, hyperkalemic distal, H $^+$ -ATPase in 1091-1097
 Tubule
 bioartificial, 6: FLAG:
 see also Acute tubular necrosis; Tubular acidosis and entries beginning with term: Tubulointerstitial
 Tubulointerstitial fibrosis due to mast cell infiltration in GN, 593-599
 Tubulointerstitial injury due to mast cell infiltration in GN, 593-599
 Tubulointerstitial nephritis (TIN) antigen, 58-kD, circulating antibodies to, in childhood MN with anti-tubular basement membrane, 1068-1074
 Tumor necrosis factor- α (TNF- α)
 effects of hemoperfusion with PMX-F on, 953-961
 expression of IL-10 and, in GN, disease activity and, 80-92
 as predictor of hypoalbuminemia, hypocholesterolemia, and mortality in ESRD patients on HD, 107-114
 Twins, identical, bilateral fibromuscular dysplasia in, 6:E4

- TxB₂ (thromboxane B₂), synthesis of, in PB monocytes, as marker of disease activity of lupus nephritis, 778-784
- Type 1 diabetes mellitus, *see* Insulin-dependent diabetes mellitus, CRD with
- Type I membranoproliferative glomerulonephritis, *see* Membranoproliferative glomerulonephritis type I
- Type 2 diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Type III collagen, deposition of mesangial, in IgAN, 146-152
- Type III membranoproliferative glomerulonephritis (MPGN), glomerular deposits with circulating NF-stabilized convertase in, 56-63
- UG (uterglobin), physiological role of, in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120
- Ultrafiltration, *see* Persistent ultrafiltration
- Ultrasound
- Doppler, fistulography or, in diagnosis of chronic HD AVG stenosis, compared, 273-277
 - see also* Echocardiography of ESRD patients and specific conditions
- Ultrasound dilution method of recirculation measurements, 1046-1058, 6:E5
- Unconventional living organ donations, ethical issues in, 682-684
- Unilateral adrenalectomy for adrenal adenoma, reversible renin-aldosterone axis suppression after, 160-163
- Unilateral renal vein thrombosis, rTPA for, 1075-1079
- United Network for Organ Sharing (UNOS) Transplant data, S1:143, S1:146
- United States population, *see* General population
- United States Renal Data System (USRDS)
- committees of, S1:5-6, S1:22
 - database of, *see* Database, USRDS 1998 ADR
 - networks of, and their states, S1:6
 - organizational structure of, S1:21-22
 - products of, *see* Products, USRDS
 - role in continuous quality improvement in ESRD, S4:182-189
 - who's who in, S1:4-6
 - see also* United States Renal Data System, 1993 ADR of; United States Renal Data System, 1997 ADR of; United States Renal Data System, 1998 ADR of
- United States Renal Data System (USRDS), 1993 ADR of, discontinuity in, S1:148
- United States Renal Data System (USRDS), 1997 ADR of, differences between 1998 ADR and, S1:9-11
- errata to, S1:19
- United States Renal Data System (USRDS), 1998 ADR of, common abbreviations used in, S1:7-8
- differences between, and 1993 ADR, S1:9-11
 - executive summary of, S1:9-19
 - introduction to, S1:1-3
 - purposes and goals of, S1:20-21
 - see also* Age of ESRD patients, USRDS 1998 ADR on; Analytical methods used in USRDS 1998 ADR; Costs of ESRD care, USRDS 1998 ADR on; Facilities for ESRD care, USRDS 1998 ADR on; Hospitalization for ESRD, USRDS 1998 ADR on; Incidence and prevalence of treated ESRD, USRDS 1998 ADR on; Mortality of ESRD patients, USRDS 1998 ADR on; Patient survival with ESRD, USRDS 1998 ADR on; Pediatric end-stage renal disease, USRDS 1998 ADR on; Primary disease in ESRD, USRDS 1998 ADR on; Race of ESRD patients, USRDS 1998 ADR on; Renal replacement therapies for ESRD, USRDS 1998 ADR on; Sex of ESRD patients, USRDS 1998 ADR on; United States Renal Data System
- UNOS (United Network for Organ Sharing) Transplant data, S1:143, S1:146
- Urate excretion, 917-933
- hyperuricemia and, 927-929
 - hypouricemia and, 922-926
 - plasma natriuretic factor and, 926-927
 - urate transport and, *see* Urate transport
- Urate transport, 920-922
- effects of extracellular volume changes on, 920-921
 - pyrazinamide effects on, 919-920
- Urea
- kinetics of, *see* Kinetics, urea
 - plasma, AD, AFB, and HCO₃ dialysate effects on, 118
 - serum, reinfusion and concentration of ascitic fluid in ESRD cirrhotic patients on HD, 166
 - see also* Urea clearance; Urea nitrogen; Urea reduction ratio
- Urea clearance
- on CRRTs, 187, 188
 - on PD, catheter-related infections and, 755, 757
- Urea nitrogen
- appearance of, as basis for estimation of protein catabolism in ARF patients on CRRT, 444-453
 - see also* BUN
- Urea reduction ratio (URR)
- and mortality of ESRD patients on HD, 110
 - as outcome-based measure of dialysis dose, S4:16-31
- Uremia
- acute-phase inflammatory process leading to, S4:105-112
 - see also* Chronic renal failure and entries beginning with term: Uremic
- Uremic arteriopathy, calcific, *see* Calciphylaxis, ESRD and
- Uremic cardiomyopathy in ESRD patients on HD, dilated, persistent ultrafiltration for, 664-668
- Uremic syndrome, *see* Hemolytic uremic syndrome
- Uremic toxins, CVD and, research recommendations on, 903-904
- Ureteritis, hemorrhagic, carboplatin-related, 5:E5
- Uric acid
- ADH and renal clearance of, 692-697
 - serum, in malnourished patients on PD, 764
 - see also* Urate excretion
- Urinary bladder, carboplatin toxicity to transitional epithelium of, 5:E5
- Urinary excretion
- adenosine, in contrast nephropathy, 66
 - xanthine, in contrast nephropathy, 64-71
 - see also* Urate excretion; Urinary excretion, Na; Urinary excretion, protein and entries ending with suffix: -uria

- Urinary excretion, Na
 in contrast nephropathy, 66
 K/Na ratio of, mineralocorticoid effects on, 47-51
 pressure natriuresis in aging kidney, renal nerves in, 605-610
- Urinary excretion, protein
 in de novo minimal change disease, 511
 in GN, 82, 594
 in HTN, race and, 35
 see also Proteinuria
- Urinary schistosomiasis, 4:xlili-xlvi
- URR (urea reduction ratio), and mortality of ESRD patients on HD, 110
- USRDS, *see* United States Renal Data System
- Uteroglobin (UG; blastokinin; Clara cell 10-kD), physiological role of, in normal glomerular function, UG gene knockout and discovery of, 1084-1086, 1106-1120
- Vaccination, ID, IM, and SC HBV, in ESRD patients on HD, antibody response to, compared, 1041-1045
- Vancomycin-resistant enterococci (VRE) in ESRD patients on chronic HD, 254-257, 415-418, 521-523
 and cefazolin as alternative to vancomycin, 401-409, 521-523
- Vascular access
 and flawed recirculation measurements due to intradialytic disequilibrium or recirculation at low flow, 1046-1058, 6:E5
 see also Catheters; Arteriovenous grafts, HD, stenosis of; Thrombosis of HD vascular access grafts
- Vascular disease
 renovascular disease as primary disease in ESRD, 279, 709, 755
 see also Peripheral vascular disease
- Vasculitides, pauci-immune, ANCA test in, 344-349
- Vasopressin (antidiuretic hormone), renal clearance of uric acid, 692-697
- VDR, *see* Vitamin D receptor
- Vena cava, inferior, acute thrombosis of, rTPA for, 1075-1079
- Venous pressure-driven protocol, reduction of HD AVG stenosis and thrombosis with, 302-308
- Venovenous hemofiltration, continuous, after OHT, 290-294
- Ventricular angiography, left, effects of allopurinol before, on free radical formation, 64-71
- Ventricular hypertrophy, *see* Left ventricular hypertrophy
- Vitamin(s)
 DMMS on use of, S1:68
 see also specific vitamins
- Vitamin B₆, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
- Vitamin B₁₂, *see* Homocysteine, vitamin B₁₂, vitamin B₆, folate, MTHFR and
- Vitamin D
 bioactivation of, and control of calcitriol homeostasis, S2:14-16; *see also* Calcitriol
 essential role of, S2:13
 see also Vitamin D analogue(s); Vitamin D receptor
- Vitamin D analogue(s), S2:25-39
 for cancer, S2:26-29
 DMMS on use of, S1:65
 for immunologic disorders, S2:29-30
 introduction to, S2:1-2
 for osteoporosis, S2:30
 overview on, S2:35-36
 for psoriasis, S2:27-28
 for secondary HPT, S2:25-27; *see also* Secondary hyperparathyroidism in ESRD patients on HD, vitamin D analogue(s) for
 selectivity of, *see* Selectivity of vitamin D analogues
 see also Paricalcitol for secondary HPT in ESRD patients on HD and *specific vitamin D analogues*
- Vitamin D-binding protein, serum, interaction of vitamin D analogues with, S2:31-33
- Vitamin D 24-hydroxylase, *see* 24-Hydroxylase
- Vitamin D receptor (VDR), S2:3-4
 biological effects of calcitriol on, S2:3-4; *see also* Calcitriol
 characteristics of, S2:13-14
 control of intracellular levels of, S2:19
 interactions between nuclear receptor coactivators and, S2:18
 ligand binding by, *see* Ligand binding by VDR
 posttranslational modifications of, S2:20
 and VDR gene polymorphism in secondary HPT, 461-469, S2:14
 see also RXR-VDR heterodimerization
- Vitamin E (α tocopherol), cardioprotective effects of, S3:59
- VRE, *see* Vancomycin-resistant enterococci in ESRD patients on chronic HD
- Warfarin, calciphylaxis and, 384-391
- Water
 CRRTs and avoidance of fluctuation in, 187-188
 see also Extracellular volume
- Wegener's granulomatosis, 2:E1
 ANCA test in, 344-349
- Weight loss
 in HTN management of patients with normal renal function, S3:69
 in type 2 DM management, S3:161-162
- White Americans, *see* Race
- Who's who in USRDS, S1:4-6
- Withdrawal
 CsA, effects of, on arteriopathy due to, 247-253
 from dialysis by ESRD patients, as cause of mortality, USRDS 1998 ADR on, S1:86-87
- World Wide Web, Internet, 1998 USRDS products on, S1:23, S1:25
- Xanthine, urinary excretion of, in contrast nephropathy, 64-71
- Young adults, normotensive, with ADPKD, LVM and diastolic function in, 970-975